An    O
abdominal    O
ultrasound    O
every    O
3    O
months    O
until    O
at    O
least    O
eight    O
years    O
of    O
age    O
is    O
recommended    O
and    O
a    O
blood    O
test    O
to    O
measure    O
alpha-fetoprotein    B-Glycoprotein114888310
(    O
AFP    O
)    O
every    O
6    O
weeks    O
until    O
at    O
least    O
four    O
years    O
of    O
age    O
.    O

Blood    O
testing    O
is    O
also    O
used    O
to    O
look    O
for    O
abnormal    O
levels    O
of    O
alphafetoprotein    B-Glycoprotein114888310
or    O
hormones    O
.    O

An    O
omphalocele    O
is    O
often    O
detected    O
through    O
AFP    B-Glycoprotein114888310
screening    I-Glycoprotein114888310
or    O
a    O
detailed    O
fetal    O
ultrasound    O
.    O

Approximately    O
95%    O
of    O
people    O
with    O
A    O
-    O
T    O
have    O
elevated    O
serum    O
AFP    B-Glycoprotein114888310
levels    O
after    O
the    O
age    O
of    O
two    O
,    O
and    O
measured    O
levels    O
of    O
AFP    O
appear    O
to    O
increase    O
slowly    O
over    O
time    O
.    O

The    O
diagnosis    O
of    O
A    O
-    O
T    O
is    O
usually    O
suspected    O
by    O
the    O
combination    O
of    O
neurologic    O
clinical    O
features    O
(    O
ataxia    O
,    O
abnormal    O
control    O
of    O
eye    O
movement    O
,    O
and    O
postural    O
instability    O
)    O
with    O
telangiectasia    O
and    O
sometimes    O
increased    O
infections    O
,    O
and    O
confirmed    O
by    O
specific    O
laboratory    O
abnormalities    O
(    O
elevated    O
alpha-fetoprotein    B-Glycoprotein114888310
levels    O
,    O
increased    O
chromosomal    O
breakage    O
or    O
cell    O
death    O
of    O
white    O
blood    O
cells    O
after    O
exposure    O
to    O
X    O
-    O
rays    O
,    O
absence    O
of    O
ATM    O
protein    O
in    O
white    O
blood    O
cells    O
,    O
or    O
mutations    O
in    O
each    O
of    O
the    O
person    O
’s    O
ATM    O
genes    O
)    O
.    O

Elevated    O
and    O
slowly    O
increasing    O
alpha-fetoprotein    B-Glycoprotein114888310
levels    O
in    O
serum    O
after    O
2    O
years    O
of    O
age    O

Most    O
often    O
the    O
ataxia    O
appears    O
between    O
10    O
and    O
15    O
years    O
of    O
age    O
,    O
and    O
differs    O
from    O
A    O
-    O
T    O
by    O
the    O
absence    O
of    O
telangiectasia    O
and    O
oculomotor    O
apraxia    O
,    O
a    O
normal    O
alpha    B-Glycoprotein114888310
fetalprotein    I-Glycoprotein114888310
,    O
and    O
the    O
frequent    O
presence    O
of    O
scoliosis    O
,    O
absent    O
tendon    O
reflexes    O
,    O
and    O
abnormal    O
features    O
on    O
the    O
EKG    O
.    O

Like    O
those    O
with    O
A    O
-    O
T    O
,    O
children    O
with    O
NBS    O
have    O
enhanced    O
sensitivity    O
to    O
radiation    O
,    O
disposition    O
to    O
lymphoma    O
and    O
leukemia    O
,    O
and    O
some    O
laboratory    O
measures    O
of    O
impaired    O
immune    O
function    O
,    O
but    O
do    O
not    O
have    O
ocular    O
telangiectasia    O
or    O
an    O
elevated    O
level    O
of    O
AFP    B-Glycoprotein114888310
.    O

Alpha-1-fetoprotein    B-Glycoprotein114888310
or    O
Alpha    O
-    O
fetoprotein    O
,    O
a    O
protein    O
in    O
humans    O
that    O
is    O
associated    O
with    O
fetal    O
development    O

High    O
levels    O
of    O
alpha-fetoprotein    B-Glycoprotein114888310
(    O
AFP    O
)    O
in    O
the    O
blood    O
can    O
be    O
found    O
in    O
many    O
cases    O
of    O
HCC    O
and    O
intrahepatic    O
cholangiocarcinoma    O
.    O

Furin    O
is    O
one    O
of    O
the    O
proteases    O
responsible    O
for    O
the    O
proteolytic    O
cleavage    O
of    O
HIV    O
envelope    O
polyprotein    O
precursor    O
gp160    O
to    O
gp120    B-Glycoprotein114888310
and    O
gp41    O
prior    O
to    O
viral    O
assembly    O
.    O

By    O
blocking    O
the    O
gp120    B-Glycoprotein114888310
receptor    O
of    O
the    O
virus    O
,    O
it    O
prevents    O
initial    O
viral    O
attachment    O
to    O
the    O
host    O
CD4    O
+    O
T    O
cell    O
and    O
entry    O
into    O
the    O
host    O
immune    O
cell    O
;    O
its    O
method    O
of    O
action    O
is    O
a    O
first    O
for    O
HIV    O
drugs    O
.    O

Epigallocatechin    O
gallate    O
(    O
EGCG    O
)    O
,    O
a    O
catechin    O
in    O
green    O
tea    O
,    O
binds    O
to    O
gp120    B-Glycoprotein114888310
,    O
which    O
works    O
in    O
conjunction    O
with    O
gp41    O
,    O
itself    O
blocked    O
by    O
TF-3    O
(    O
a    O
theaflavin    O
)    O
,    O
both    O
receptors    O
of    O
which    O
HIV    O
hijacks    O
to    O
enter    O
into    O
healthy    O
human    O
immune    O
cells    O
.    O

The    O
virucidal    O
activity    O
of    O
CV    O
-    O
N    O
is    O
mediated    O
through    O
specific    O
high    O
-    O
affinity    O
interactions    O
with    O
the    O
viral    O
surface    O
envelope    O
glycoproteins    O
gp120    B-Glycoprotein114888310
and    O
gp41    O
,    O
as    O
well    O
as    O
to    O
high    O
-    O
mannose    O
oligosaccharides    O
found    O
on    O
the    O
HIV    O
envelope    O
.    O

Their    O
work    O
is    O
not    O
complete    O
,    O
but    O
those    O
in    O
the    O
study    O
who    O
produced    O
IgG    B-Glycoprotein114888310
antibodies    O
that    O
recognise    O
the    O
V2    O
loop    O
in    O
the    O
HIV    O
envelope    O
protein    O
gp120    B-Glycoprotein114888310
were    O
43%    O
less    O
likely    O
to    O
become    O
infected    O
.    O

EP3    O
deficient    O
mice    O
exhibit    O
significant    O
reductions    O
in    O
:    O
hyperalgesic    O
writhing    O
(    O
i.e.    O
squirming    O
)    O
responses    O
to    O
acetic    O
acid    O
administration    O
;    O
acute    O
but    O
not    O
chronic    O
Herpes    O
simplex    O
infection    O
-    O
induced    O
pain    O
;    O
and    O
HIV-1    O
Envelope    B-Glycoprotein114888310
glycoprotein    I-Glycoprotein114888310
GP120    I-Glycoprotein114888310
intrathecal    O
injection    O
-    O
induced    O
tactile    O
allodynia    O
.    O

HIV    O
has    O
an    O
adhesion    O
molecule    O
termed    O
gp120    B-Glycoprotein114888310
that    O
binds    O
to    O
its    O
ligand    O
CD4    B-Glycoprotein114888310
,    O
which    O
is    O
expressed    O
on    O
lymphocytes    O
.    O

D    O
of    O
the    O
University    O
Of    O
Texas    O
Medical    O
School    O
at    O
Houston    O
announced    O
that    O
they    O
have    O
engineered    O
an    O
abzyme    O
that    O
degrades    O
the    O
superantigenic    O
region    O
of    O
the    O
gp120    B-Glycoprotein114888310
CD4    B-Glycoprotein114888310
binding    O
site    O
.    O

By    O
inhibiting    O
activation    O
of    O
p65    O
by    O
transcription    O
coactivator    O
p300    O
,    O
"    O
VCAM1    O
"    O
and    O
"    O
SELE    B-Glycoprotein114888310
"    O
expression    O
is    O
downregulated    O
,    O
genes    O
that    O
encode    O
endothelial    O
cell    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
,    O
causing    O
decreased    O
lymphocyte    O
and    O
leukocyte    O
activation    O
and    O
hence    O
decreasing    O
inflammation    O

E-selectin    B-Glycoprotein114888310
:    O
E    O
-    O
selectin    O
is    O
expressed    O
on    O
activated    O
endothelial    O
cells    O
.    O

:*    O
E-selectin    B-Glycoprotein114888310

E-selectin    B-Glycoprotein114888310
,    O
also    O
known    O
as    O
CD62    B-Glycoprotein114888310
antigen-like    I-Glycoprotein114888310
family    I-Glycoprotein114888310
member    I-Glycoprotein114888310
E    I-Glycoprotein114888310
(    O
CD62E    O
)    O
,    O
endothelial-leukocyte    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
1    I-Glycoprotein114888310
(    O
ELAM-1    O
)    O
,    O
or    O
leukocyte-endothelial    B-Glycoprotein114888310
cell    I-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
2    I-Glycoprotein114888310
(    O
LECAM2    O
)    O
,    O
is    O
a    O
cell    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
expressed    O
only    O
on    O
endothelial    O
cells    O
activated    O
by    O
cytokines    O
.    O

NKG2A    O
dimerizes    O
with    O
CD94    B-Glycoprotein114888310
to    O
make    O
an    O
inhibitory    O
receptor    O
(    O
CD94/NKG2    O
)    O
.    O

NKG2    O
receptors    O
are    O
transmembrane    O
proteins    O
type    O
II    O
which    O
dimerize    O
with    O
CD94    B-Glycoprotein114888310
molecule    O
.    O

"    O
Euryarchaeota    O
"    O
may    O
appear    O
either    O
gram    O
-    O
positive    O
or    O
gram    O
-    O
negative    O
depending    O
on    O
whether    O
pseudomurein    B-Glycoprotein114888310
is    O
present    O
in    O
the    O
cell    O
wall    O
.    O
"    O
Euryarchaeota    O
"    O

Cell    O
-    O
wall    O
-    O
containing    O
Archaea    O
are    O
also    O
lysed    O
by    O
specialized    O
pseudomurein    B-Glycoprotein114888310
-    O
cleaving    O
lysins    O
,    O
while    O
most    O
archaeal    O
viruses    O
employ    O
alternate    O
mechanisms    O
.    O

CLEC5A    B-Glycoprotein114888310
(    O
MDL1    O
)    O

Some    O
lacritin    O
is    O
produced    O
by    O
the    O
meibomian    O
gland    O
,    O
and    O
also    O
by    O
epithelial    O
cells    O
of    O
the    O
conjunctiva    O
and    O
cornea    O
that    O
together    O
with    O
lacrimal    O
gland    O
comprise    O
much    O
of    O
the    O
lacrimal    B-Glycoprotein114888310
functional    I-Glycoprotein114888310
unit    I-Glycoprotein114888310
(    O
LFU    O
)    O
.    O

:*    O
CD164    B-Glycoprotein114888310

Other    O
macroglobulins    O
include    O
alpha-2    B-Glycoprotein114888310
macroglobulin    I-Glycoprotein114888310
,    O
which    O
is    O
elevated    O
in    O
nephrotic    O
syndrome    O
,    O
diabetes    O
,    O
severe    O
burns    O
,    O
and    O
other    O
conditions    O
,    O
while    O
a    O
deficiency    O
is    O
associated    O
with    O
chronic    O
obstructive    O
pulmonary    O
disease    O
.    O

Another    O
example    O
is    O
alpha-2    B-Glycoprotein114888310
macroglobulin    I-Glycoprotein114888310
.    O

α2-macroglobulin    B-Glycoprotein114888310

"    O
alpha-2-Macroglobulin    B-Glycoprotein114888310
(    O
A2    O
M    O
)    O
:    O
"    O
is    O
also    O
a    O
major    O
inhibitor    O
of    O
thrombin    O
.    O

BDCA2    B-Glycoprotein114888310
(    O
CD303    O
)    O

In    O
ideal    O
circumstances    O
,    O
influenza    O
virus    O
neuraminidase    O
(    O
NA    O
)    O
should    O
act    O
on    O
the    O
same    O
type    O
of    O
receptor    O
the    O
virus    O
hemagglutinin    B-Glycoprotein114888310
(    O
HA    O
)    O
binds    O
to    O
,    O
a    O
phenomenon    O
that    O
does    O
not    O
always    O
happen    O
.    O

Hemagglutinin    B-Glycoprotein114888310

Hemagglutinin    B-Glycoprotein114888310
or    O
haemagglutinin    B-Glycoprotein114888310
(    O
British    O
English    O
)    O
refers    O
to    O
a    O
substance    O
that    O
causes    O
red    O
blood    O
cells    O
(    O
RBCs    O
)    O
to    O
agglutinate    O
.    O

Measles    O
hemagglutinin    O
is    O
a    O
hemagglutinin    B-Glycoprotein114888310
produced    O
by    O
measles    O
virus    O
.    O

Hemagglutinin    O
-    O
neuraminidase    O
refers    O
to    O
a    O
single    O
viral    O
protein    O
that    O
has    O
both    O
hemagglutinin    B-Glycoprotein114888310
and    O
neuraminidase    O
activity    O
.    O

FLAG    O
,    O
HA    B-Glycoprotein114888310
,    O
c    O
-    O
myc    O
)    O
or    O
with    O
an    O
antibody    O
to    O
the    O
native    O
protein    O
.    O

To    O
overcome    O
the    O
problem    O
of    O
specificity    O
,    O
the    O
protein    O
of    O
interest    O
can    O
be    O
fused    O
to    O
a    O
tag    O
like    O
FLAG    O
or    O
HA    B-Glycoprotein114888310
that    O
are    O
recognized    O
by    O
antibodies    O
.    O

Soybeans    O
also    O
contain    O
biologically    O
active    O
or    O
metabolic    O
proteins    O
,    O
such    O
as    O
enzymes    O
,    O
trypsin    O
inhibitors    O
,    O
hemagglutinin    B-Glycoprotein114888310
,    O
and    O
cysteine    O
proteases    O
very    O
similar    O
to    O
papain    O
.    O

Science    O
"    O
was    O
sceptical    O
too    O
at    O
first    O
,    O
but    O
eventually    O
published    O
what    O
amounted    O
to    O
about    O
15    O
percent    O
of    O
the    O
haemagglutinin    B-Glycoprotein114888310
gene    O
as    O
well    O
as    O
small    O
fragments    O
of    O
the    O
four    O
other    O
genes    O
on    O
21    O
March    O
1997    O
.    O

The    O
Influenza    O
virus    O
is    O
an    O
RNA    O
virus    O
that    O
is    O
divided    O
into    O
three    O
serological    O
types    O
:    O
A    O
,    O
B    O
and    O
C.    O
Hemagglutinin    B-Glycoprotein114888310
(    O
HA    O
)    O
and    O
neuraminidase    O
(    O
NA    O
)    O
are    O
two    O
important    O
glycoproteins    O
on    O
influenza    O
virus    O
membranes    O
.    O

For    O
example    O
,    O
influenza    O
virus    O
has    O
a    O
hemagglutinin    B-Glycoprotein114888310
on    O
its    O
surface    O
that    O
is    O
required    O
for    O
recognition    O
of    O
the    O
sugar    O
sialic    O
acid    O
on    O
host    O
cell    O
surface    O
molecules    O
.    O

They    O
usually    O
contain    O
whole    O
virus    O
,    O
not    O
just    O
hemagglutinin    B-Glycoprotein114888310
as    O
in    O
most    O
human    O
flu    O
vaccines    O
.    O

HA    O
-    O
tag    O
,    O
a    O
peptide    O
from    O
hemagglutinin    B-Glycoprotein114888310
recognized    O
by    O
an    O
antibody    O
(    O
YPYDVPDYA    O
)    O

Two    O
nidogens    O
have    O
been    O
identified    O
in    O
humans    O
:    O
nidogen-1    B-Glycoprotein114888310
(    O
NID1    O
)    O
and    O
nidogen-2    O
(    O
NID2    O
)    O
.    O

The    O
chief    O
components    O
of    O
Matrigel    O
are    O
structural    O
proteins    O
such    O
as    O
laminin    B-Glycoprotein114888310
,    O
entactin    B-Glycoprotein114888310
,    O
collagen    O
and    O
heparan    O
sulfate    O
proteoglycans    O
which    O
present    O
cultured    O
cells    O
with    O
the    O
adhesive    O
peptide    O
sequences    O
that    O
they    O
would    O
encounter    O
in    O
their    O
natural    O
environment    O
.    O

DEC205    B-Glycoprotein114888310
(    O
CD205    O
)    O

Mucin    B-Glycoprotein114888310
5B    I-Glycoprotein114888310
(    O
MUC5B    O
)    O

In    O
the    O
capable    O
dendritic    O
cells    O
,    O
cytosolic    O
diversion    O
is    O
the    O
name    O
of    O
the    O
process    O
that    O
diverts    O
antigens    O
away    O
from    O
the    O
route    O
in    O
which    O
they    O
are    O
guided    O
for    O
antigen    O
presentation    O
by    O
MHC    B-Glycoprotein114888310
II    I-Glycoprotein114888310
by    O
being    O
transported    O
for    O
release    O
into    O
the    O
cytoplasm    O
following    O
endocytosis    O
for    O
degradation    O
by    O
the    O
proteasomes    O
necessary    O
for    O
MHC    B-Glycoprotein114888310
I    I-Glycoprotein114888310
antigen    O
presentation    O
(    O
cross    O
-    O
presentation    O
)    O
.    O

Thus    O
when    O
an    O
antigen    O
is    O
properly    O
presented    O
to    O
the    O
T    O
lymphocytes    O
by    O
an    O
antigen    O
presenting    O
cell    O
(    O
APC    O
)    O
,    O
which    O
displays    O
the    O
antigen    O
on    O
its    O
MHC    B-Glycoprotein114888310
II    I-Glycoprotein114888310
complex    O
and    O
which    O
activates    O
T    O
cell´s    O
costimulatory    O
receptors    O
,    O
T    O
lymphocytes    O
undergo    O
productive    O
response    O
.    O

Another    O
one    O
of    O
the    O
many    O
ways    O
in    O
which    O
herpes    O
viruses    O
evade    O
the    O
immune    O
system    O
is    O
by    O
down    O
regulation    O
of    O
MHC    B-Glycoprotein114888310
I    I-Glycoprotein114888310
and    O
MHC    B-Glycoprotein114888310
II    I-Glycoprotein114888310
.    O

In    O
addition    O
,    O
histological    O
analysis    O
revealed    O
that    O
the    O
meningeal    O
lymphatics    O
constitutively    O
contain    O
T    O
cells    O
,    O
B    O
cells    O
,    O
and    O
MHC    B-Glycoprotein114888310
class    I-Glycoprotein114888310
II    I-Glycoprotein114888310
-    O
expressing    O
myeloid    O
cells    O
,    O
demonstrating    O
that    O
meningeal    O
lymphatic    O
vessels    O
are    O
capable    O
of    O
carrying    O
immune    O
cells    O
.    O

Current    O
research    O
has    O
shown    O
that    O
there    O
is    O
an    O
association    O
between    O
allergic    O
fungal    O
sinusitis    O
and    O
MHC    B-Glycoprotein114888310
II    I-Glycoprotein114888310
alleles    O
,    O
suggesting    O
a    O
genetic    O
component    O
to    O
this    O
chronic    O
inflammatory    O
respiratory    O
tract    O
disorder    O
.    O

Type    O
2    O
:    O
MHC    B-Glycoprotein114888310
class    I-Glycoprotein114888310
II    I-Glycoprotein114888310
is    O
not    O
expressed    O
on    O
the    O
cell    O
surface    O
of    O
all    O
antigen    O
presenting    O
cells    O
.    O

Function    O
of    O
T    O
helper    O
cells    O
:    O
Antigen    O
-    O
presenting    O
cells    O
(    O
APCs    O
)    O
present    O
antigen    O
on    O
their    O
Class    O
II    O
MHC    O
molecules    O
(    O
MHC2    B-Glycoprotein114888310
)    O
.    O

Another    O
function    O
of    O
interferons    O
is    O
to    O
upregulate    O
major    O
histocompatibility    O
complex    O
molecules    O
,    O
MHC    B-Glycoprotein114888310
I    I-Glycoprotein114888310
and    O
MHC    B-Glycoprotein114888310
II    I-Glycoprotein114888310
,    O
and    O
increase    O
immunoproteasome    O
activity    O
.    O

IP    O
receptor    O
activation    O
of    O
these    O
cells    O
also    O
blocks    O
their    O
lipopolysaccharide    O
-    O
stimulated    O
expression    O
of    O
pro    O
-    O
inflammatory    O
cell    O
surface    O
proteins    O
(    O
i.e.    O
CD86    O
,    O
CD40    O
,    O
and    O
MHC    B-Glycoprotein114888310
class    I-Glycoprotein114888310
II    I-Glycoprotein114888310
molecules    O
)    O
that    O
are    O
critical    O
for    O
developing    O
adaptive    O
immune    O
responses    O
.    O
IL    O
receptor    O
-    O
activated    O
bone    O
marrow    O
-    O
derived    O
dendritic    O
cells    O

These    O
cells    O
have    O
T    O
-    O
cell    O
receptors    O
and    O
CD4    O
molecules    O
that    O
,    O
in    O
combination    O
,    O
bind    O
antigenic    O
peptides    O
presented    O
on    O
major    B-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
complex    I-Glycoprotein114888310
(MHC)    I-Glycoprotein114888310
class    I-Glycoprotein114888310
II    I-Glycoprotein114888310
molecules    O
on    O
antigen    O
-    O
presenting    O
cells    O
.    O

When    O
memory    O
helper    O
T    O
cells    O
'    O
CD4    B-Glycoprotein114888310
receptors    O
bind    O
to    O
the    O
MHC    B-Glycoprotein114888310
class    I-Glycoprotein114888310
II    I-Glycoprotein114888310
molecules    O
which    O
are    O
expressed    O
on    O
the    O
surfaces    O
of    O
the    O
target    O
cells    O
of    O
the    O
graft    O
tissue    O
,    O
the    O
memory    O
helper    O
T    O
cells    O
'    O
T    O
cell    O
receptors    O
(    O
TCRs    O
)    O
can    O
recognize    O
their    O
target    O
antigen    O
that    O
is    O
presented    O
by    O
the    O
MHC    O
class    O
II    O
molecules    O
.    O

EBV    O
that    O
are    O
made    O
in    O
the    O
B    O
cells    O
have    O
low    O
numbers    O
of    O
gHgLgp42    O
complexes    O
,    O
because    O
these    O
three    O
-    O
part    O
complexes    O
interact    O
with    O
Human    O
-    O
leukocyte    O
-    O
antigen    O
class    B-Glycoprotein114888310
II    I-Glycoprotein114888310
molecules    O
present    O
in    O
B    O
cells    O
in    O
the    O
endoplasmic    O
reticulum    O
and    O
are    O
degraded    O
.    O

Then    O
,    O
viral    O
glycoprotein    O
gp42    O
interacts    O
with    O
cellular    O
MHC    B-Glycoprotein114888310
class    I-Glycoprotein114888310
II    I-Glycoprotein114888310
molecules    O
.    O

APCs    O
then    O
present    O
the    O
fragments    O
to    O
T    O
helper    O
cells    O
(    O
CD4    B-Glycoprotein114888310
+    O
)    O
by    O
the    O
use    O
of    O
class    B-Glycoprotein114888310
II    I-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
molecules    O
on    O
their    O
surface    O
.    O

"    O
Tumor    O
antigens    O
"    O
are    O
those    O
antigens    O
that    O
are    O
presented    O
by    O
MHC    B-Glycoprotein114888310
class    I-Glycoprotein114888310
I    I-Glycoprotein114888310
or    O
MHC    B-Glycoprotein114888310
class    I-Glycoprotein114888310
II    I-Glycoprotein114888310
molecules    O
on    O
the    O
surface    O
of    O
tumor    O
cells    O
.    O

There    O
are    O
two    O
types    O
of    O
MHC    O
molecules    O
which    O
differ    O
in    O
the    O
source    O
of    O
the    O
antigens    O
:    O
MHC    B-Glycoprotein114888310
class    I-Glycoprotein114888310
I    I-Glycoprotein114888310
molecules    O
(    O
MHC    O
-    O
I    O
)    O
bind    O
peptides    O
from    O
the    O
cell    O
cytosol    O
,    O
while    O
peptides    O
generated    O
in    O
the    O
endocytic    O
vesicles    O
after    O
internalisation    O
are    O
bound    O
to    O
MHC    B-Glycoprotein114888310
class    I-Glycoprotein114888310
II    I-Glycoprotein114888310
(    O
MHC    O
-    O
II    O
)    O
.    O

CD2    B-Glycoprotein114888310

These    O
additional    O
proteins    O
are    O
:    O
CD2    B-Glycoprotein114888310
and    O
CD16    O
.    O

Siplizumab    O
(    O
MEDI-507    O
)    O
is    O
a    O
novel    O
monoclonal    O
antibody    O
with    O
a    O
human    O
IgG1    B-Glycoprotein114888310
,    O
kappa    O
directed    O
to    O
CD2    B-Glycoprotein114888310
.    O

:    O
:    O
:    O
CD2    B-Glycoprotein114888310

Alefacept    O
inhibits    O
the    O
activation    O
of    O
CD4    B-Glycoprotein114888310
+    O
and    O
CD8    B-Glycoprotein114888310
+    O
T    O
cells    O
by    O
interfering    O
with    O
CD2    B-Glycoprotein114888310
on    O
the    O
T    O
cell    O
membrane    O
thereby    O
blocking    O
the    O
costimulatory    O
molecule    O
LFA-3/CD2    O
interaction    O
.    O

SIGLEC    O
family    O
including    O
Myelin-associated    B-Glycoprotein114888310
glycoprotein    I-Glycoprotein114888310
(    O
MAG    O
,    O
SIGLEC-4    O
)    O
,    O
CD22    B-Glycoprotein114888310
and    O
CD83    O

MAG    O
Myelin-associated    B-Glycoprotein114888310
glycoprotein    I-Glycoprotein114888310
acts    O
via    O
the    O
receptors    O
NgR2    O
,    O
GT1b    O
,    O
NgR1    O
,    O
p75    O
,    O
TROY    O
and    O
LINGO1    O
.    O

Myelin-associated    B-Glycoprotein114888310
glycoprotein    I-Glycoprotein114888310

Versican    O
belongs    O
to    O
the    O
lectican    O
protein    O
family    O
,    O
with    O
aggrecan    B-Glycoprotein114888310
(    O
abundant    O
in    O
cartilage    O
)    O
,    O
brevican    B-Glycoprotein114888310
and    O
neurocan    B-Glycoprotein114888310
(    O
nervous    O
system    O
proteoglycans    O
)    O
as    O
other    O
members    O
.    O

The    O
four    O
mutations    O
of    O
the    O
ACAN    B-Glycoprotein114888310
gene    I-Glycoprotein114888310
are    O
known    O
to    O
cause    O
dwarfism    O
or    O
aborted    O
fetuses    O
in    O
miniature    O
horses    O
.    O

:    O
Glutamyl    O
endopeptidase    O
;    O
bonds    O
cleaved    O
include    O
-Thr    O
-    O
Glu    O
-    O
Gly    O
-    O
Glu373-Ala    O
-    O
Arg    O
-    O
Gly    O
-    O
Ser-    O
in    O
the    O
interglobular    O
domain    O
of    O
mammalian    O
aggrecan    B-Glycoprotein114888310

Depending    O
on    O
the    O
tissue    O
type    O
,    O
cells    O
that    O
bind    O
to    O
this    O
bioscaffold    O
will    O
have    O
significant    O
,    O
measurable    O
increases    O
in    O
select    O
tissue    O
repair    O
factors    O
,    O
including    O
aggrecan    B-Glycoprotein114888310
,    O
connective    O
tissue    O
growth    O
factor    O
(    O
CTGF    O
)    O
,    O
transforming    O
growth    O
factors    O
(    O
TGF-β1    O
and    O
TBF-β3    O
)    O
,    O
bone    O
morphogenic    O
protein    O
(    O
BMP-2    O
)    O
and    O
other    O
repair    O
factors    O
.    O

This    O
coming    O
together    O
was    O
as    O
a    O
result    O
of    O
a    O
much    O
greater    O
understanding    O
of    O
the    O
cellular    O
and    O
molecular    O
biology    O
of    O
glycan    B-Glycoprotein114888310
.    O

Drugs    O
already    O
on    O
the    O
market    O
,    O
such    O
as    O
heparin    O
,    O
erythropoietin    O
and    O
a    O
few    O
anti    O
-    O
flu    O
drugs    O
have    O
proven    O
effective    O
and    O
highlight    O
the    O
importance    O
of    O
glycans    B-Glycoprotein114888310
as    O
a    O
new    O
class    O
of    O
drug    O
.    O

Although    O
these    O
glycans    B-Glycoprotein114888310
are    O
molecules    O
that    O
are    O
difficult    O
to    O
synthesize    O
in    O
a    O
reproducible    O
way    O
,    O
owing    O
to    O
their    O
complex    O
structure    O
,    O
this    O
new    O
field    O
of    O
research    O
is    O
highly    O
encouraging    O
for    O
the    O
future    O
.    O

This    O
enzyme    O
participates    O
in    O
amino    O
sugars    O
metabolism    O
and    O
glycan    B-Glycoprotein114888310
biosynthesis    O
.    O

,    O
Gilbert    O
has    O
been    O
dissecting    O
the    O
mechanisms    O
of    O
glycan    B-Glycoprotein114888310
utilisation    O
by    O
gut    O
bacteria    O
,    O
in    O
the    O
human    O
microbiota    O
.    O

This    O
enzyme    O
participates    O
in    O
the    O
biosynthesis    O
of    O
n    O
-    O
glycan    B-Glycoprotein114888310
and    O
glycan    O
structures    O
.    O

This    O
enzyme    O
participates    O
in    O
the    O
biosynthesis    O
of    O
chondroitin    O
sulfate    O
and    O
glycan    B-Glycoprotein114888310
structures    O
.    O

This    O
enzyme    O
participates    O
in    O
the    O
biosynthesis    O
of    O
n    O
-    O
glycan    B-Glycoprotein114888310
and    O
glycan    O
structures    O
.    O

This    O
enzyme    O
participates    O
in    O
3    O
metabolic    O
pathways    O
:    O
the    O
lactoseries    O
and    O
neolactoseries    O
of    O
glycosphingolipid    O
biosynthesis    O
,    O
as    O
well    O
as    O
the    O
biosynthesis    O
of    O
glycan    B-Glycoprotein114888310
structures    O
.    O

The    O
basic    O
peptidoglycan    O
structure    O
of    O
both    O
Gram    O
-    O
positive    O
and    O
Gram    O
-    O
negative    O
bacteria    O
comprises    O
a    O
sheet    O
of    O
glycan    B-Glycoprotein114888310
chains    O
connected    O
by    O
short    O
cross    O
-    O
linking    O
polypeptides    O
.    O

This    O
enzyme    O
participates    O
in    O
glycosaminoglycan    O
degradation    O
and    O
degradation    O
of    O
glycan    B-Glycoprotein114888310
structures    O
.    O

This    O
enzyme    O
participates    O
in    O
the    O
degradtaion    O
of    O
glycan    B-Glycoprotein114888310
structures    O
.    O

This    O
enzyme    O
is    O
also    O
called    O
almond    O
emulsin    O
fucosidase    O
I.    O
This    O
enzyme    O
participates    O
in    O
the    O
degradation    O
of    O
glycan    B-Glycoprotein114888310
structures    O
.    O

They    O
are    O
used    O
to    O
modify    O
the    O
glycan    B-Glycoprotein114888310
after    O
it    O
has    O
been    O
added    O
onto    O
the    O
lipid    O
to    O
represent    O
the    O
final    O
oligosaccharide    O
structure    O
.    O

The    O
secretion    O
is    O
a    O
clear    O
fluid    O
that    O
is    O
rich    O
in    O
mucoproteins    B-Glycoprotein114888310
.    O

It    O
is    O
the    O
main    O
source    O
of    O
the    O
anti    O
-    O
tumor    O
mucoprotein    B-Glycoprotein114888310
calvacin    O
,    O
which    O
is    O
present    O
only    O
in    O
tiny    O
quantities    O
.    O

properdin    B-Glycoprotein114888310

The    O
complex    O
is    O
believed    O
to    O
be    O
unstable    O
until    O
it    O
binds    O
properdin    B-Glycoprotein114888310
,    O
a    O
serum    O
protein    O
.    O

This    O
C3bBb    O
convertase    O
is    O
stabilized    O
by    O
properdin    B-Glycoprotein114888310
(    O
Factor    O
P    O
)    O
preferentially    O
on    O
microbial    O
surfaces    O
over    O
normal    O
host    O
surfaces    O
,    O
and    O
is    O
now    O
able    O
to    O
cleave    O
many    O
more    O
C3    O
molecules    O
thus    O
amplifying    O
the    O
signal    O
.    O

Different    O
alpha    O
,    O
beta    O
and    O
gamma    O
chain    O
isomers    O
combine    O
to    O
give    O
rise    O
to    O
different    O
heterotrimeric    O
laminin    O
isoforms    O
,    O
which    O
were    O
formerly    O
designated    O
by    O
Arabic    O
numerals    O
in    O
the    O
order    O
of    O
their    O
discovery    O
,    O
e.g.    O
alpha1beta1gamma1    O
heterotrimer    O
was    O
known    O
as    O
laminin    O
1    O
,    O
but    O
the    O
nomenclature    O
now    O
calls    O
for    O
using    O
the    O
numbers    O
of    O
each    O
individual    O
laminin    O
subunit    O
isoform    O
,    O
e.g.    O
what    O
was    O
formerly    O
Laminin    O
1    O
is    O
now    O
Laminin    B-Glycoprotein114888310
111    I-Glycoprotein114888310
,    O
and    O
what    O
was    O
formerly    O
Laminin    O
5    O
is    O
now    O
Laminin    O
332    O
.    O

|    O
pokeweed    B-Glycoprotein114888310
mitogen    I-Glycoprotein114888310
(    O
PWM    O
)    O

Although    O
clinically    O
debated    O
,    O
the    O
Dutch    O
hypothesis    O
remains    O
one    O
of    O
four    O
main    O
plausible    O
explanations    O
which    O
could    O
help    O
explain    O
the    O
complex    O
pathogenesis    O
of    O
COPD    O
,    O
others    O
being    O
the    O
protease    O
-    O
antiprotease    O
hypothesis    O
(    O
involving    O
alpha    B-Glycoprotein114888310
1-antitrypsin    I-Glycoprotein114888310
overexpression    O
and    O
consequent    O
alpha-1    O
proteinase    O
deficiency    O
)    O
,    O
the    O
British    O
hypothesis    O
(    O
regarding    O
a    O
putative    O
aetiological    O
role    O
of    O
acute    O
bronchial    O
infections    O
)    O
,    O
and    O
the    O
autoimmunity    O
hypothesis    O
.    O

α1-antitrypsin    B-Glycoprotein114888310

Patients    O
with    O
alpha    B-Glycoprotein114888310
1-antitrypsin    I-Glycoprotein114888310
deficiency    O
have    O
been    O
found    O
to    O
be    O
particularly    O
susceptible    O
to    O
bronchiectasis    O
,    O
for    O
unknown    O
reasons    O
.    O

|rowspan=2|    O
Alpha    B-Glycoprotein114888310
1-antitrypsin    I-Glycoprotein114888310
(    O
AAT    O
)    O

The    O
designation    O
of    O
uterine    O
serpins    O
as    O
SERPINA14    O
is    O
based    O
on    O
their    O
classification    O
as    O
a    O
highly    O
-    O
divergent    O
group    O
of    O
the    O
α1-antitrypsin    B-Glycoprotein114888310
or    O
A    O
clade    O
.    O

SERPINA1    B-Glycoprotein114888310
:    O
serpin    O
peptidase    O
inhibitor    O
,    O
clade    O
A    O
(    O
alpha-1    O
antiproteinase    O
,    O
antitrypsin    O
)    O
,    O
member    O
1    O

Solid    O
pseudopapillary    O
tumours    O
show    O
positive    O
nuclear    O
staining    O
for    O
beta    O
catenin    O
,    O
as    O
well    O
as    O
positive    O
immunostaining    O
for    O
CD10    B-Glycoprotein114888310
,    O
CD56    O
,    O
vimentin    O
,    O
alpha    B-Glycoprotein114888310
1-antitrypsin    I-Glycoprotein114888310
,    O
and    O
neuron    O
specific    O
enolase    O
;    O
they    O
are    O
negative    O
for    O
chromogranin    O
and    O
pancreatic    O
enzymes    O
.    O

Tracy    O
,    O
born    O
in    O
1990    O
,    O
was    O
the    O
first    O
sheep    O
to    O
produce    O
large    O
quantities    O
of    O
human    O
protein    O
,    O
making    O
35    O
g    O
of    O
the    O
alpha-1-antitrypsin    B-Glycoprotein114888310
(    O
used    O
in    O
treatment    O
of    O
cystic    O
fibrosis    O
)    O
in    O
each    O
litre    O
of    O
her    O
milk    O
.    O

Other    O
less    O
frequent    O
antibodies    O
are    O
found    O
against    O
LRP4    O
,    O
Agrin    B-Glycoprotein114888310
and    O
titin    O
proteins    O
.    O

Agrin    B-Glycoprotein114888310
,    O
a    O
protein    O
linked    O
to    O
heparan    O
sulfate    O

The    O
protein    O
agrin    B-Glycoprotein114888310
,    O
which    O
concentrates    O
acetylcholine    O
receptors    O
during    O
human    O
embryonic    O
development    O
,    O
was    O
first    O
isolated    O
from    O
this    O
species    O
.    O

Furthermore    O
,    O
omigapil    O
was    O
found    O
to    O
be    O
even    O
more    O
effective    O
in    O
improving    O
muscle    O
function    O
and    O
strength    O
when    O
coupled    O
with    O
overexpression    O
of    O
the    O
extracellular    O
martrix    O
molecule    O
mini    O
-    O
agrin    B-Glycoprotein114888310
in    O
MDC1A    O
mice    O
.    O

Ependymin    B-Glycoprotein114888310
is    O
a    O
glycoprotein    O
associated    O
with    O
the    O
consolidation    O
of    O
long    O
-    O
term    O
memory    O
,    O
claims    O
involving    O
protection    O
from    O
strokes    O
,    O
and    O
neuronal    O
regeneration    O
.    O

C-type    B-Glycoprotein114888310
lectin    I-Glycoprotein114888310
domain    I-Glycoprotein114888310
family    I-Glycoprotein114888310
1    I-Glycoprotein114888310
member    I-Glycoprotein114888310
A    I-Glycoprotein114888310
is    O
a    O
protein    O
that    O
in    O
humans    O
is    O
encoded    O
by    O
the    O
"    O
CLEC1A    O
"    O
gene    O
.    O

Protein    B-Glycoprotein114888310
S    I-Glycoprotein114888310
,    O
an    O
anticoagulant    O
,    O
decreases    O
.    O

Protein    B-Glycoprotein114888310
S    I-Glycoprotein114888310
or    O
protein    B-Glycoprotein114888310
C    I-Glycoprotein114888310
deficiency    O

To    O
rule    O
out    O
other    O
causes    O
for    O
hypercoagulation    O
,    O
it    O
may    O
be    O
appropriate    O
to    O
check    O
the    O
antithrombin    B-Glycoprotein114888310
,    O
protein    B-Glycoprotein114888310
C    I-Glycoprotein114888310
,    O
protein    B-Glycoprotein114888310
S    I-Glycoprotein114888310
,    O
factor    O
V    O
Leiden    O
,    O
and    O
prothrombin    O
G20210A.    O

Protein    B-Glycoprotein114888310
S    I-Glycoprotein114888310
,    O
plasma    O
glycoprotein    O

Thrombophilia    O
,    O
a    O
tendency    O
to    O
develop    O
blood    O
clots    O
due    O
to    O
abnormalities    O
in    O
coagulation    O
,    O
e.g.    O
factor    O
V    O
Leiden    O
,    O
deficiency    O
of    O
protein    B-Glycoprotein114888310
C    I-Glycoprotein114888310
,    O
protein    B-Glycoprotein114888310
S    I-Glycoprotein114888310
or    O
antithrombin    B-Glycoprotein114888310
,    O
or    O
related    O
problems    O

The    O
microvilli    O
are    O
covered    O
with    O
glycocalyx    B-Glycoprotein114888310
,    O
consisting    O
of    O
peripheral    O
glycoproteins    O
that    O
can    O
attach    O
themselves    O
to    O
a    O
plasma    O
membrane    O
via    O
transmembrane    O
proteins    O
.    O

"    O
Vannellidae    O
"    O
are    O
surrounded    O
by    O
an    O
outer    O
covering    O
called    O
the    O
glycocalyx    B-Glycoprotein114888310
,    O
which    O
is    O
generally    O
10    O
-    O
20    O
nm    O
across    O
,    O
though    O
the    O
thickness    O
varies    O
among    O
species    O
.    O

In    O
certain    O
organisms    O
,    O
cells    O
are    O
covered    O
with    O
the    O
glycocalyx    B-Glycoprotein114888310
layer    O
,    O
which    O
can    O
be    O
modeled    O
as    O
a    O
polyelectrolyte    O
layer    O
with    O
a    O
volume    O
spread    O
electric    O
charge    O
.    O

Glycocalyx    B-Glycoprotein114888310

Glycocalyx    B-Glycoprotein114888310

Glycocalyx    B-Glycoprotein114888310

:    O
:*    O
Common    B-Glycoprotein114888310
gp130    I-Glycoprotein114888310
subunit    I-Glycoprotein114888310
(    O
gp130    O
,    O
CD130    O
)    O

Glycoprotein    B-Glycoprotein114888310
130    I-Glycoprotein114888310
,    O

Glycoprotein    B-Glycoprotein114888310
130    I-Glycoprotein114888310
(    O
also    O
known    O
as    O
gp130    B-Glycoprotein114888310
,    O
IL6ST    B-Glycoprotein114888310
,    O
IL6-beta    B-Glycoprotein114888310
or    O
CD130    B-Glycoprotein114888310
)    O
is    O
a    O
transmembrane    O
protein    O
which    O
is    O
the    O
founding    O
member    O
of    O
the    O
class    O
of    O
all    O
cytokine    O
receptors    O
.    O

Sweatt    O
and    O
Miller    O
also    O
showed    O
that    O
the    O
gene    O
"    O
reelin    B-Glycoprotein114888310
"    O
,    O
which    O
is    O
involved    O
in    O
long    O
term    O
potentiation    O
induction    O
,    O
had    O
a    O
reduced    O
methylation    O
profile    O
and    O
increased    O
reelin    O
mRNA    O
in    O
fear    O
-    O
conditioned    O
versus    O
control    O
rats    O
.    O

In    O
schizophrenics    O
,    O
it    O
has    O
been    O
shown    O
that    O
"    O
reelin    B-Glycoprotein114888310
"    O
is    O
down    O
-    O
regulated    O
through    O
increased    O
DNA    O
methylation    O
at    O
promoter    O
regions    O
in    O
GABAergic    O
interneurons    O
.    O

Roberts    O
syndrome    O
,    O
is    O
a    O
rare    O
form    O
of    O
lissencephaly    O
caused    O
by    O
a    O
mutation    O
in    O
the    O
reelin    B-Glycoprotein114888310
gene    O
.    O

Norman    O
–    O
Roberts    O
syndrome    O
is    O
one    O
of    O
two    O
known    O
disorders    O
caused    O
by    O
a    O
disruption    O
of    O
the    O
reelin    B-Glycoprotein114888310
-    O
signaling    O
pathway    O
.    O

The    O
"    O
shaking    O
rat    O
Kawasaki    O
"    O
(    O
SRK    O
)    O
is    O
an    O
autosomal    O
recessive    O
mutant    O
rat    O
that    O
has    O
a    O
short    O
deletion    O
in    O
the    O
RELN    B-Glycoprotein114888310
gene    O
.    O

This    O
results    O
in    O
the    O
lowered    O
expression    O
of    O
Reelin    B-Glycoprotein114888310
protein    O
,    O
essential    O
for    O
proper    O
cortex    O
lamination    O
and    O
cerebellum    O
development    O
.    O

In    O
murine    O
liver    O
,    O
Reelin    B-Glycoprotein114888310
expressed    O
by    O
Ito    O
cells    O
has    O
been    O
shown    O
to    O
be    O
a    O
reliable    O
marker    O
in    O
discerning    O
them    O
from    O
other    O
myofibroblasts    O
.    O

Cajal    O
–    O
Retzius    O
cells    O
(    O
CR    O
cells    O
)    O
(    O
also    O
known    O
as    O
Horizontal    O
cell    O
of    O
Cajal    O
)    O
are    O
a    O
heterogeneous    O
population    O
of    O
morphologically    O
and    O
molecularly    O
distinct    O
reelin    B-Glycoprotein114888310
-    O
producing    O
cell    O
types    O
in    O
the    O
marginal    O
zone    O
/    O
layer    O
I    O
of    O
the    O
developmental    O
cerebral    O
cortex    O
and    O
in    O
the    O
immature    O
hippocampus    O
of    O
different    O
species    O
and    O
at    O
different    O
times    O
during    O
embryogenesis    O
and    O
postnatal    O
life    O
.    O

CR    O
cells    O
secrete    O
the    O
extracellular    O
matrix    O
protein    O
"    O
reelin    B-Glycoprotein114888310
"    O
,    O
which    O
is    O
critically    O
involved    O
in    O
the    O
control    O
of    O
radial    O
neuronal    O
migration    O
through    O
a    O
signaling    O
pathway    O
,    O
including    O
the    O
very    O
low    O
density    O
lipoprotein    O
receptor    O
(    O
VLDLR    O
)    O
,    O
the    O
apolipoprotein    O
E    O
receptor    O
type    O
2    O
(    O
ApoER2    O
)    O
,    O
and    O
the    O
cytoplasmic    O
adapter    O
protein    O
disabled    O
1    O
(    O
Dab1    O
)    O
.    O

Mincle    B-Glycoprotein114888310
(    O
CLEC4E    O
)    O

Alvircept    B-Glycoprotein114888310
sudotox    I-Glycoprotein114888310
is    O
a    O
form    O
of    O
recombinant    O
CD4    B-Glycoprotein114888310
derived    O
from    O
"    O
Pneumonas    O
aeruginosa    O
"    O
exotoxin    O
A    O
,    O
or    O
'    O
PE40    O
.    O

The    O
presence    O
of    O
anti    O
-    O
MOG    B-Glycoprotein114888310
,    O
even    O
with    O
CDMS    O
diagnosis    O
,    O
can    O
be    O
considered    O
as    O
a    O
biomarker    O
against    O
MS    O
disease    O
modifying    O
therapies    O
like    O
fingolimod    O

Myelin    O
basic    O
protein    O
(    O
MBP    O
)    O
constitutes    O
~23%    O
of    O
myelin    O
protein    O
,    O
myelin    B-Glycoprotein114888310
oligodendrocyte    I-Glycoprotein114888310
glycoprotein    I-Glycoprotein114888310
,    O
and    O
proteolipid    O
protein    O
(    O
PLP    O
,    O
which    O
makes    O
up    O
~50%    O
of    O
myelin    O
protein    O
)    O
.    O

Like    O
other    O
selectin    B-Glycoprotein114888310
,    O
it    O
plays    O
an    O
important    O
part    O
in    O
inflammation    O
.    O

This    O
is    O
due    O
to    O
lower    O
opsonic    O
activity    O
,    O
as    O
well    O
as    O
diminished    O
up    O
-    O
regulation    O
of    O
integrin    B-Glycoprotein114888310
and    O
selectin    B-Glycoprotein114888310
receptors    O
,    O
which    O
limit    O
the    O
ability    O
of    O
neutrophils    O
to    O
interact    O
with    O
adhesion    B-Glycoprotein114888310
molecule    I-Glycoprotein114888310
in    O
the    O
endothelium    O
.    O

Integrins    O
work    O
alongside    O
other    O
receptors    O
such    O
as    O
cadherin    B-Glycoprotein114888310
,    O
the    O
immunoglobulin    O
superfamily    O
cell    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
,    O
selectin    B-Glycoprotein114888310
and    O
syndecans    O
,    O
to    O
mediate    O
cell    O
–    O
cell    O
and    O
cell    O
–    O
matrix    O
interaction    O
.    O

Examples    O
of    O
these    O
proteins    O
include    O
selectins    B-Glycoprotein114888310
,    O
integrins    B-Glycoprotein114888310
,    O
syndecans    O
,    O
and    O
cadherins    B-Glycoprotein114888310
.    O

The    O
major    O
classes    O
are    O
named    O
integrins    B-Glycoprotein114888310
,    O
Ig    O
superfamily    O
members    O
,    O
cadherins    B-Glycoprotein114888310
,    O
and    O
selectins    B-Glycoprotein114888310
.    O

Diphtheria    B-Glycoprotein114888310
toxin    I-Glycoprotein114888310

The    O
best    O
-    O
known    O
manganese    O
-    O
containing    O
polypeptides    O
may    O
be    O
arginase    O
,    O
the    O
diphtheria    B-Glycoprotein114888310
toxin    I-Glycoprotein114888310
,    O
and    O
Mn    O
-    O
containing    O
superoxide    O
dismutase    O
(    O
Mn    O
-    O
SOD    O
)    O
.    O

However    O
,    O
bacterial    O
toxins    O
,    O
such    O
as    O
diphtheria    B-Glycoprotein114888310
toxin    I-Glycoprotein114888310
,    O
which    O
is    O
used    O
in    O
denileukin    O
diftitox    O
,    O
an    O
FDA    O
-    O
approved    O
treatment    O
for    O
leukemia    O
and    O
lymphoma    O
,    O
have    O
proven    O
to    O
be    O
more    O
practical    O
.    O

In    O
1888    O
Emile    O
Roux    O
and    O
Alexandre    O
Yersin    O
showed    O
that    O
the    O
clinical    O
effects    O
of    O
diphtheria    O
were    O
caused    O
by    O
diphtheria    B-Glycoprotein114888310
toxin    I-Glycoprotein114888310
and    O
,    O
following    O
the    O
1890    O
discovery    O
of    O
an    O
antitoxin    O
-    O
based    O
immunity    O
to    O
diphtheria    O
and    O
tetanus    O
by    O
Emil    O
Adolf    O
von    O
Behring    O
and    O
Kitasato    O
Shibasaburō    O
,    O
antitoxin    O
became    O
the    O
first    O
major    O
success    O
of    O
modern    O
therapeutic    O
immunology    O
.    O

channel    O
-    O
forming    O
toxins    O
,    O
including    O
colicins    O
,    O
diphtheria    B-Glycoprotein114888310
toxin    I-Glycoprotein114888310
,    O
and    O
others    O

The    O
most    O
important    O
is    O
idd1which    O
is    O
the    O
major    B-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
complex    I-Glycoprotein114888310
class    O
II    O
loci    O
I    O
-    O
Ag7    O
.    O

Women    O
who    O
have    O
borne    O
multiple    O
children    O
by    O
the    O
same    O
father    O
typically    O
have    O
antibodies    O
against    O
the    O
father    O
’s    O
red    O
blood    O
cell    O
and    O
major    B-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
complex    I-Glycoprotein114888310
(    O
MHC    O
)    O
proteins    O
.    O

Because    O
no    O
correlation    O
is    O
found    O
between    O
female    O
extra    O
-    O
pair    O
fertilization    O
frequencies    O
and    O
the    O
overall    O
heterozygosity    O
of    O
their    O
social    O
mates    O
,    O
it    O
is    O
suggested    O
that    O
females    O
may    O
choose    O
only    O
a    O
selective    O
set    O
of    O
heterozygous    O
genes    O
,    O
particularly    O
the    O
MHC    B-Glycoprotein114888310
locus    O
,    O
which    O
can    O
affect    O
the    O
immunocompetence    O
of    O
offspring    O
.    O

Major    B-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
complex    I-Glycoprotein114888310
class    B-Glycoprotein114888310
I    I-Glycoprotein114888310
deficiency    O

Major    B-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
complex    I-Glycoprotein114888310
class    O
II    O
deficiency    O

One    O
such    O
way    O
is    O
by    O
encoding    O
a    O
protein    O
mimicking    O
human    O
interleukin    O
10    O
(    O
hIL-10    O
)    O
and    O
another    O
is    O
by    O
downregulation    O
of    O
the    O
major    B-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
complex    I-Glycoprotein114888310
II    O
(    O
MHC    O
II    O
)    O
in    O
infected    O
cells    O
.    O

B7    O
is    O
a    O
type    O
of    O
peripheral    O
membrane    O
protein    O
found    O
on    O
activated    O
antigen    O
presenting    O
cells    O
(    O
APC    O
)    O
that    O
,    O
when    O
paired    O
with    O
either    O
a    O
CD28    O
or    O
CD152    O
(    O
CTLA-4    O
)    O
surface    O
protein    O
on    O
a    O
T    O
cell    O
,    O
can    O
produce    O
a    O
costimulatory    O
signal    O
or    O
a    O
coinhibitory    O
signal    O
to    O
enhance    O
or    O
decrease    O
the    O
activity    O
of    O
a    O
MHC    B-Glycoprotein114888310
-    O
TCR    O
signal    O
between    O
the    O
APC    O
and    O
the    O
T    O
cell    O
,    O
respectively    O
.    O

The    O
T    O
cell    O
receptor    O
must    O
first    O
interact    O
with    O
the    O
Major    B-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
complex    I-Glycoprotein114888310
(    O
MHC    O
)    O
surface    O
protein    O
.    O

The    O
gene    O
is    O
located    O
in    O
the    O
major    B-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
complex    I-Glycoprotein114888310
class    O
III    O
region    O
,    O
in    O
a    O
cluster    O
with    O
two    O
closely    O
related    O
genes    O
which    O
encode    O
similar    O
proteins    O
.    O

Bach    O
's    O
work    O
on    O
transplant    O
compatibility    O
helped    O
in    O
later    O
experiments    O
that    O
identified    O
the    O
major    B-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
complex    I-Glycoprotein114888310
.    O

Kinetic    O
-    O
segregation    O
model    O
was    O
originally    O
used    O
to    O
elucidate    O
how    O
binding    O
of    O
TCR    O
to    O
peptide    O
-    O
MHC    B-Glycoprotein114888310
-    O
complex    O
on    O
APC    O
is    O
communicated    O
across    O
the    O
T    O
-    O
cell    O
membrane    O
resulting    O
in    O
T    O
-    O
cell    O
activation    O
.    O

Major    B-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
complex    I-Glycoprotein114888310
(    O
MHC    O
)    O

Major    B-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
complex    I-Glycoprotein114888310
-    O
a    O
highly    O
polymorphic    O
region    O
on    O
chromosome    O
6    O
with    O
genes    O
particularly    O
involved    O
in    O
immune    O
functions    O

The    O
allergoid    O
sustain    O
the    O
linear    O
epitopes    O
recognized    O
by    O
the    O
MHC    B-Glycoprotein114888310
-    O
TCR    O
cell    O
-    O
present    O
systems    O
(    O
keeps    O
the    O
immunoreactivity    O
)    O
but    O
has    O
less    O
reaginic    O
epitopes    O
(    O
less    O
allergenicity    O
)    O
.    O

To    O
function    O
properly    O
,    O
an    O
immune    O
system    O
must    O
detect    O
a    O
wide    O
variety    O
of    O
agents    O
,    O
known    O
as    O
pathogens    O
,    O
from    O
viruses    O
to    O
parasitic    O
worms    O
,    O
and    O
distinguish    B-Glycoprotein114888310
them    O
from    O
the    O
organism    O
's    O
own    O
healthy    O
tissue    O
.    O

"    O
This    O
term    O
describes    O
cells    O
with    O
low    O
levels    O
of    O
a    O
cell    O
-    O
surface    O
marker    O
called    O
MHC    O
I    O
(    O
major    B-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
complex    I-Glycoprotein114888310
)    O
–    O
a    O
situation    O
that    O
can    O
arise    O
in    O
viral    O
infections    O
of    O
host    O
cells    O
.    O

IFNs    O
also    O
have    O
various    O
other    O
functions    O
:    O
they    O
activate    O
immune    O
cells    O
,    O
such    O
as    O
natural    O
killer    O
cells    O
and    O
macrophages    O
;    O
they    O
increase    O
host    O
defenses    O
by    O
up    O
-    O
regulating    O
antigen    O
presentation    O
by    O
virtue    O
of    O
increasing    O
the    O
expression    O
of    O
major    B-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
complex    I-Glycoprotein114888310
(    O
MHC    O
)    O
antigens    O
.    O

In    O
IBM    O
,    O
muscle    O
fibers    O
are    O
overloaded    O
with    O
these    O
major    B-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
complex    I-Glycoprotein114888310
(    O
MHC    O
)    O
molecules    O
that    O
carry    O
the    O
antigen    O
protein    O
pieces    O
,    O
leading    O
to    O
more    O
ER    O
stress    O
and    O
more    O
protein    O
misfolding    O
.    O

There    O
are    O
some    O
reports    O
suggesting    O
MHC    B-Glycoprotein114888310
molecules    O
and    O
sialic    O
acid    O
residues    O
functioning    O
in    O
this    O
capacity    O
as    O
well    O
.    O

Most    O
of    O
the    O
identified    O
genes    O
relate    O
to    O
the    O
immune    O
system    O
,    O
particularly    O
the    O
major    B-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
complex    I-Glycoprotein114888310
(    O
MHC    O
)    O
and    O
T    O
cells    O
.    O

PSORS1    O
"    O
is    O
located    O
on    O
chromosome    O
6    O
in    O
the    O
major    B-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
complex    I-Glycoprotein114888310
(    O
MHC    O
)    O
,    O
which    O
controls    O
important    O
immune    O
functions    O
.    O

He    O
and    O
his    O
research    O
group    O
have    O
made    O
many    O
subsequent    O
discoveries    O
about    O
this    O
type    O
of    O
molecule    O
,    O
subsequently    O
,    O
specifically    O
concerning    O
its    O
biochemical    O
properties    O
and    O
other    O
characteristics    O
,    O
including    O
the    O
demonstration    O
that    O
T    O
cells    O
are    O
able    O
to    O
detect    O
and    O
respond    O
to    O
even    O
a    O
single    O
molecule    O
of    O
their    O
ligand    O
-    O
fragments    O
of    O
antigens    O
bound    O
to    O
Major    B-Glycoprotein114888310
Histocompatibility    I-Glycoprotein114888310
Complex    I-Glycoprotein114888310
cell    O
surface    O
molecules    O
.    O

The    O
first    O
signal    O
is    O
the    O
major    B-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
complex    I-Glycoprotein114888310
(    O
MHC    O
)    O
,    O
which    O
in    O
humans    O
is    O
also    O
called    O
the    O
human    O
leukocyte    O
antigen    O
(    O
HLA    O
)    O
.    O

Otherwise    O
,    O
the    O
number    O
of    O
mismatched    O
gene    O
variants    O
,    O
namely    O
alleles    O
,    O
encoding    O
cell    O
surface    O
molecules    O
called    O
major    B-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
complex    I-Glycoprotein114888310
(    O
MHC    O
)    O
,    O
classes    O
I    O
and    O
II    O
,    O
correlate    O
with    O
the    O
rapidity    O
and    O
severity    O
of    O
transplant    O
rejection    O
.    O

The    O
recipient    O
's    O
helper    O
T    O
cells    O
coordinate    O
specific    O
immunity    O
directed    O
at    O
the    O
donor    O
's    O
"    O
self    O
"    O
peptides    O
or    O
at    O
the    O
donor    O
's    O
Major    B-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
complex    I-Glycoprotein114888310
molecules    O
,    O
or    O
at    O
both    O
.    O

However    O
,    O
γδ    O
T    O
cells    O
are    O
peculiar    O
in    O
that    O
they    O
do    O
not    O
seem    O
to    O
require    O
antigen    O
processing    O
and    O
major-histocompatibility-complex    B-Glycoprotein114888310
(    O
MHC    O
)    O
presentation    O
of    O
peptide    O
epitopes    O
,    O
although    O
some    O
recognize    O
MHC    B-Glycoprotein114888310
class    I-Glycoprotein114888310
Ib    I-Glycoprotein114888310
molecules    I-Glycoprotein114888310
.    O

However    O
,    O
none    O
of    O
the    O
known    O
antigen    O
-    O
presenting    O
molecules    O
like    O
MHC    B-Glycoprotein114888310
class    O
I    O
and    O
II    O
or    O
CD1    O
are    O
required    O
for    O
γδ    O
T    O
cell    O
activation    O
suggesting    O
the    O
existence    O
of    O
a    O
novel    O
presenting    O
element    O
.    O

The    O
extensive    O
structural    O
diversity    O
of    O
Vδ1    O
and    O
Vδ3    O
TCRs    O
and    O
the    O
existence    O
of    O
Vδ1    O
+    O
clones    O
reactive    O
against    O
MHC    B-Glycoprotein114888310
,    O
MHC    O
-    O
like    O
,    O
or    O
non    O
-    O
MHC    O
molecules    O
suggest    O
recognition    O
of    O
a    O
highly    O
diverse    O
and    O
heterogeneous    O
set    O
of    O
antigens    O
by    O
non    O
-    O
Vδ2    O
cells    O
,    O
although    O
cognate    O
interactions    O
between    O
non    O
-    O
Vδ2    O
TCRs    O
and    O
any    O
of    O
these    O
antigens    O
have    O
not    O
been    O
shown    O
yet    O
.    O

MHC    B-Glycoprotein114888310
class    O
-    O
I    O
-    O
chain    O
-    O
related    O
gene    O
A    O
(    O
MICA    O
)    O
has    O
also    O
been    O
proposed    O
as    O
an    O
important    O
tumor    O
antigen    O
recognized    O
by    O
Vδ1    O
+    O
T    O
cells    O
.    O

Major    B-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
antigen    I-Glycoprotein114888310
testing    O
may    O
be    O
performed    O
to    O
investigate    O
genetic    O
susceptibility    O
to    O
uveitis    O
.    O

This    O
gene    O
localizes    O
to    O
the    O
major    O
histocompatibility    O
complex    O
(    O
MHC    B-Glycoprotein114888310
)    O
class    O
III    O
region    O
on    O
chromosome    O
6    O
.    O

Antigen    O
presenting    O
cells    O
present    O
antigens    O
in    O
the    O
form    O
of    O
peptides    O
on    O
histocompatibility    B-Glycoprotein114888310
molecule    I-Glycoprotein114888310
.    O

For    O
T    O
-    O
Cell    O
Receptor    O
(    O
TCR    O
)    O
recognition    O
,    O
the    O
peptide    O
must    O
be    O
processed    O
into    O
small    O
fragments    O
inside    O
the    O
cell    O
and    O
presented    O
by    O
a    O
major    B-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
complex    I-Glycoprotein114888310
(    O
MHC    O
)    O
.    O

Because    O
T    O
cells    O
recognise    O
only    O
fragmented    O
antigens    O
displayed    O
on    O
cell    O
surfaces    O
,    O
antigen    O
processing    O
must    O
occur    O
before    O
the    O
antigen    O
fragment    O
,    O
now    O
bound    O
to    O
the    O
major    B-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
complex    I-Glycoprotein114888310
(MHC)    I-Glycoprotein114888310
,    O
is    O
transported    O
to    O
the    O
surface    O
of    O
the    O
cell    O
,    O
a    O
process    O
known    O
as    O
presentation    O
,    O
where    O
it    O
can    O
be    O
recognized    O
by    O
a    O
T    O
cell    O
receptor    O
.    O

All    O
nucleated    O
cells    O
in    O
the    O
body    O
(    O
along    O
with    O
platelets    O
)    O
display    O
class    O
I    O
major    B-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
complex    I-Glycoprotein114888310
(    O
MHC    O
-    O
I    O
molecules    O
)    O
.    O

This    O
gene    O
encodes    O
a    O
transmembrane    O
glycoprotein    O
that    O
mediates    O
interaction    O
between    O
newly    O
assembled    O
major    O
histocompatibility    O
complex    O
(    O
MHC    B-Glycoprotein114888310
)    O
class    B-Glycoprotein114888310
I    I-Glycoprotein114888310
molecules    O
and    O
the    O
transporter    O
associated    O
with    O
antigen    O
processing    O
(    O
TAP    O
)    O
,    O
which    O
is    O
required    O
for    O
the    O
transport    O
of    O
antigenic    O
peptides    O
across    O
the    O
endoplasmic    O
reticulum    O
membrane    O
.    O

"    O
HuC242    O
binds    O
to    O
the    O
extracellular    O
domain    O
of    O
the    O
tumor    O
-    O
associated    O
carbohydrate    O
antigen    O
known    O
as    O
CanAg    O
(    O
a    O
novel    O
glycoform    O
of    O
MUC1    B-Glycoprotein114888310
)    O
.    O

These    O
include    O
both    O
unfavorable    O
genes    O
,    O
where    O
high    O
expression    O
is    O
related    O
to    O
poor    O
outcome    O
,    O
for    O
example    O
C    O
-    O
Met    O
and    O
MUC-1    B-Glycoprotein114888310
,    O
and    O
favorable    O
genes    O
where    O
high    O
expression    O
is    O
associated    O
with    O
better    O
survival    O
,    O
for    O
example    O
the    O
transcription    O
factor    O
PELP1    O
.    O

The    O
embryo    O
secretes    O
human    O
chorionic    O
gonadotropin    O
(    O
hCG    O
)    O
,    O
which    O
downregulates    O
anti    O
-    O
adhesion    O
factor    O
,    O
MUC-1    B-Glycoprotein114888310
,    O
located    O
on    O
the    O
uterine    O
epithelium    O
at    O
the    O
site    O
of    O
invasion    O
.    O

The    O
neoplastic    O
cells    O
are    O
reactive    O
with    O
keratin    O
,    O
CK7    O
,    O
and    O
Epithelial    B-Glycoprotein114888310
membrane    I-Glycoprotein114888310
antigen    I-Glycoprotein114888310
,    O
but    O
negative    O
with    O
TTF-1    O
and    O
CK20    O
.    O

MUC1    B-Glycoprotein114888310
,    O

MUC1    B-Glycoprotein114888310
,    O

Lectin    O
pathway    O
,    O
Ficolin    B-Glycoprotein114888310

Bivatuzumab    O
(    O
previously    O
BIWA    O
4    O
)    O
is    O
a    O
humanized    O
monoclonal    O
antibody    O
against    O
CD44    B-Glycoprotein114888310
v6    O
.    O

:*    O
CD44    B-Glycoprotein114888310

:*    O
CD44    B-Glycoprotein114888310

CD44    B-Glycoprotein114888310
antigen    O
,    O
the    O
main    O
cell    O
surface    O
receptor    O
for    O
HA    O
.    O

In    O
cancer    O
cells    O
,    O
CD44    B-Glycoprotein114888310
,    O
death    O
receptor-3    O
(    O
DR3    O
)    O
,    O
LAMP1    O
,    O
and    O
LAMP2    O
were    O
identified    O
as    O
E    O
-    O
selectin    O
ligands    O
present    O
on    O
colon    O
cancer    O
cells    O
.    O
,    O
and    O
CD44v    O
,    O
Mac2-BP    O
,    O
and    O

The    O
CD44    B-Glycoprotein114888310
3’UTR    O
has    O
been    O
shown    O
to    O
regulate    O
expression    O
of    O
the    O
CD44    O
protein    O
and    O
cell    O
cycle    O
regulation    O
protein    O
,    O
CDC42    O
,    O
by    O
antagonizing    O
the    O
function    O
of    O
three    O
microRNAs    O
-    O
miR-216    O
,    O
miR-330    O
and    O
miR-608    O
.    O

Most    O
hyaladherins    O
belong    O
to    O
the    O
Link    O
module    O
superfamily    O
,    O
including    O
its    O
main    O
receptor    O
CD44    B-Glycoprotein114888310
,    O
hyalectans    O
and    O
TSG-6    O
.    O

Lingual    O
taste    O
bud    O
organoids    O
containing    O
taste    O
cells    O
,    O
however    O
,    O
have    O
been    O
created    O
using    O
the    O
LGR5    O
+    O
or    O
CD44    B-Glycoprotein114888310
+    O
stem    O
/    O
progenitor    O
cells    O
of    O
circumvallate    O
(    O
CV    O
)    O
papilla    O
tissue    O
.    O

EFF    O
-    O
AFF    O
is    O
a    O
family    O
of    O
type    O
I    O
membrane    B-Glycoprotein114888310
glycoproteins    I-Glycoprotein114888310
that    O
act    O
as    O
cell    O
–    O
cell    O
fusogens    O
,    O
named    O
from    O
'    O
Anchor    O
cell    O
fusion    O
failure    O
'    O
.    O

It    O
is    O
a    O
member    O
of    O
the    O
tenascin    B-Glycoprotein114888310
(    O
TN    O
)    O
gene    O
family    O
,    O
which    O
includes    O
at    O
least    O
3    O
genes    O
in    O
mammals    O
:    O
TNC    O
(    O
or    O
hexabrachion    O
)    O
,    O
TNX    B-Glycoprotein114888310
(    O
TNXB    O
)    O
,    O
and    O
TNR    O
.    O

A    O
member    O
of    O
the    O
tenascin    B-Glycoprotein114888310
family    O
,    O
tenascin    B-Glycoprotein114888310
X    I-Glycoprotein114888310
(    O
TN    O
-    O
X    O
)    O
also    O
known    O
as    O
hexabrachion-like    B-Glycoprotein114888310
protein    I-Glycoprotein114888310
is    O
a    O
glycoprotein    O
that    O
is    O
expressed    O
in    O
connective    O
tissues    O
including    O
skin    O
,    O
joints    O
and    O
muscles    O
.    O

Abrin    B-Glycoprotein114888310
(    O
similar    O
to    O
ricin    O
but    O
even    O
more    O
toxic    O
)    O

An    O
alignment    O
of    O
the    O
toxic    O
proteins    O
ricin    O
and    O
abrin    B-Glycoprotein114888310
.    O

Jewelry    O
is    O
made    O
from    O
deadly    O
toxic    O
red    O
and    O
black    O
seeds    O
called    O
jumbies    O
,    O
jumbie    O
eyes    O
or    O
jumbie    O
beads    O
(    O
seeds    O
of    O
"    O
Abrus    O
precatorius    O
"    O
containing    O
the    O
lethal    O
AB    O
toxin    O
abrin    B-Glycoprotein114888310
)    O
in    O
the    O
Caribbean    O
and    O
South    O
America    O
.    O

Tumor-associated    B-Glycoprotein114888310
glycoprotein    I-Glycoprotein114888310
72    I-Glycoprotein114888310

NKG2D    O
is    O
a    O
transmembrane    O
protein    O
belonging    O
to    O
the    O
CD94/NKG2    O
family    O
of    O
C-type    B-Glycoprotein114888310
lectin-like    I-Glycoprotein114888310
receptors    I-Glycoprotein114888310
.    O

the    O
low    O
-    O
affinity    O
receptor    O
FcεRII    O
(    O
CD23    O
)    O
is    O
a    O
C-type    B-Glycoprotein114888310
lectin    I-Glycoprotein114888310
.    O

Their    O
life    O
cycle    O
is    O
thought    O
to    O
begin    O
with    O
a    O
virion    O
attaching    O
to    O
specific    O
cell    O
-    O
surface    O
receptors    O
such    O
as    O
C-type    B-Glycoprotein114888310
lectin    I-Glycoprotein114888310
,    O
DC-SIGN    B-Glycoprotein114888310
,    O
or    O
integrin    B-Glycoprotein114888310
,    O
which    O
is    O
followed    O
by    O
fusion    O
of    O
the    O
viral    O
envelope    O
with    O
cellular    O
membranes    O
.    O

the    O
three    O
major    O
classes    O
of    O
mammalian    O
glycan    B-Glycoprotein114888310
-    O
binding    O
proteins    O
(    O
GBPs    O
)    O
:    O
C-type    B-Glycoprotein114888310
lectin    I-Glycoprotein114888310
,    O
galectin    B-Glycoprotein114888310
,    O
and    O
SIGLEC    O

CD94/NKG2    O
is    O
a    O
family    O
of    O
C-type    B-Glycoprotein114888310
lectin    I-Glycoprotein114888310
receptors    O
which    O
are    O
expressed    O
predominantly    O
on    O
the    O
surface    O
of    O
NK    O
cells    O
and    O
a    O
subset    O
of    O
CD8    O
+    O
T    O
-    O
lymphocyte    O
.    O

His    O
dream    O
was    O
to    O
"    O
transfer    O
rice    O
immunity    O
to    O
cereals    O
such    O
as    O
wheat    O
,    O
maize    O
,    O
sorghum    O
and    O
barley    O
,    O
and    O
transfer    O
bread    O
-    O
wheat    O
proteins    O
(    O
gliadin    B-Glycoprotein114888310
and    O
glutenin    B-Glycoprotein114888310
)    O
to    O
other    O
cereals    O
,    O
especially    O
rice    O
and    O
maize    O
"    O
.    O

Like    O
all    O
types    O
of    O
rice    O
,    O
glutinous    O
rice    O
does    O
not    O
contain    O
dietary    O
gluten    O
(    O
i.e.    O
does    O
not    O
contain    O
glutenin    B-Glycoprotein114888310
and    O
gliadin    B-Glycoprotein114888310
)    O
,    O
and    O
should    O
be    O
safe    O
for    O
gluten    O
-    O
free    O
diets    O
.    O

Modifications    O
tested    O
include    O
those    O
to    O
create    O
resistance    O
to    O
herbicides    O
,    O
create    O
resistance    O
to    O
insects    O
and    O
to    O
fungal    O
pathogens    O
(    O
especially    O
fusarium    O
)    O
and    O
viruses    O
,    O
tolerance    O
to    O
drought    O
and    O
resistance    O
to    O
salinity    O
and    O
heat    O
,    O
increased    O
and    O
decreased    O
content    O
of    O
glutenin    B-Glycoprotein114888310
,    O
improved    O
nutrition    O
(    O
higher    O
protein    O
content    O
,    O
increased    O
heat    O
stability    O
of    O
the    O
enzyme    O
phytase    O
,    O
increased    O
content    O
of    O
water    O
-    O
soluble    O
dietary    O
fiber    O
,    O
increased    O
lysine    O
content    O
)    O
,    O
improved    O
qualities    O
for    O
use    O
as    O
biofuel    O
feedstock    O
,    O
production    O
of    O
drugs    O
via    O
pharming    O
and    O
yield    O
increases    O
.    O

Immune    O
regulating    O
proteins    O
found    O
in    O
prostasomes    O
include    O
:    O
amino    O
-    O
peptidase    O
N    O
(    O
CD13    O
)    O
;    O
dipeptidyl    O
-    O
peptidase    O
IV    O
(    O
CD26    O
)    O
;    O
enkephalinase    O
(    O
neutral    O
endopeptidase    O
,    O
CD10    B-Glycoprotein114888310
)    O
;    O
angiotensin    O
converting    O
enzyme    O
(    O
ACE    O
,    O
CD143    O
)    O
;    O
tissue    O
factor    O
TF    O
(    O
CD142    O
,    O
thromboplastin    O
)    O
;    O
decay    O
accelerating    O
factor    O
(    O
CD55    O
)    O
;    O
protectin    O
(    O
CD59    O
,    O
inhibitor    O
of    O
MAC    O
)    O
and    O
complement    O
regulatory    O
membrane    O
cofactor    O
protein    O
(    O
CD46    O
)    O
.    O

Mature    O
AM    O
is    O
degraded    O
by    O
the    O
aminopeptidase    O
neprilysin    B-Glycoprotein114888310
.    O

Neprilysin    B-Glycoprotein114888310
,    O
also    O
known    O
as    O
membrane    B-Glycoprotein114888310
metallo-endopeptidase    I-Glycoprotein114888310
(    O
MME    B-Glycoprotein114888310
)    O
,    O
neutral    B-Glycoprotein114888310
endopeptidase    I-Glycoprotein114888310
(    O
NEP    B-Glycoprotein114888310
)    O
,    O
cluster    B-Glycoprotein114888310
of    I-Glycoprotein114888310
differentiation    I-Glycoprotein114888310
10    I-Glycoprotein114888310
(    O
CD10    B-Glycoprotein114888310
)    O
,    O
and    O
common    B-Glycoprotein114888310
acute    I-Glycoprotein114888310
lymphoblastic    I-Glycoprotein114888310
leukemia    I-Glycoprotein114888310
antigen    I-Glycoprotein114888310
(    O
CALLA    B-Glycoprotein114888310
)    O
is    O
an    O
enzyme    O
that    O
in    O
humans    O
is    O
encoded    O
by    O
the    O
"    O
MME    O
"    O
gene    O
.    O

The    O
immunophenotype    O
profile    O
consists    O
of    O
CD5    O
+    O
(    O
in    O
about    O
80%    O
)    O
,    O
CD10-/+    O
,    O
and    O
it    O
is    O
usually    O
CD5    O
+    O
and    O
CD10    B-Glycoprotein114888310
.    O

Immunohistochemical    O
staining    O
of    O
the    O
convoluted    O
tubules    O
and    O
glomeruli    O
with    O
CD10    B-Glycoprotein114888310
.    O

Solid    O
pseudopapillary    O
tumours    O
show    O
positive    O
nuclear    O
staining    O
for    O
beta    O
catenin    O
,    O
as    O
well    O
as    O
positive    O
immunostaining    O
for    O
CD10    B-Glycoprotein114888310
,    O
CD56    O
,    O
vimentin    O
,    O
alpha    B-Glycoprotein114888310
1-antitrypsin    I-Glycoprotein114888310
,    O
and    O
neuron    O
specific    O
enolase    O
;    O
they    O
are    O
negative    O
for    O
chromogranin    O
and    O
pancreatic    O
enzymes    O
.    O

Diagnosis    O
may    O
be    O
aided    O
by    O
immunostaining    O
;    O
endometrial    O
stromal    O
nodules    O
are    O
positive    O
for    O
CD10    B-Glycoprotein114888310
;    O
leiomyomas    O
are    O
positive    O
for    O
caldesmon    O
and    O
desmin    O
(    O
and    O
sometimes    O
CD10    O
)    O
.    O

Sacubitrilat    O
inhibits    O
the    O
enzyme    O
neprilysin    B-Glycoprotein114888310
,    O
which    O
is    O
responsible    O
for    O
the    O
degradation    O
of    O
atrial    O
and    O
brain    O
natriuretic    O
peptide    O
,    O
two    O
blood    O
pressure    O
-    O
lowering    O
peptides    O
that    O
work    O
mainly    O
by    O
reducing    O
blood    O
volume    O
.    O

As    O
the    O
leader    O
of    O
the    O
Cure    O
Alzheimer    O
's    O
Fund    O
Alzheimer    O
’s    O
Genome    O
Project    O
,    O
Tanzi    O
has    O
carried    O
out    O
multiple    O
genome    O
wide    O
association    O
studies    O
of    O
thousands    O
of    O
Alzheimer    O
’s    O
families    O
leading    O
to    O
the    O
identification    O
of    O
novel    O
AD    O
candidate    O
genes    O
,    O
including    O
CD33    B-Glycoprotein114888310
and    O
the    O
first    O
two    O
rare    O
mutations    O
causing    O
late    O
-    O
onset    O
AD    O
in    O
the    O
ADAM10    O
gene    O
.    O

CD33    B-Glycoprotein114888310
or    O
Siglec-3    O
(    O
sialic    O
acid    O
binding    O
Ig    O
-    O
like    O
lectin    O
3    O
,    O
SIGLEC3    O
,    O
SIGLEC-3    O
,    O
gp67    O
,    O
p67    O
)    O
is    O
a    O
transmembrane    O
receptor    O
expressed    O
on    O
cells    O
of    O
myeloid    O
lineage    O
.    O

Vadastuximab    O
talirine    O
or    O
SGN    O
-    O
CD33A    O
is    O
an    O
antibody    O
-    O
drug    O
conjugate    O
or    O
ADC    O
directed    O
to    O
CD33    B-Glycoprotein114888310
(    O
SIGLEC-3    O
)    O
,    O
which    O
is    O
a    O
transmembrane    O
receptor    O
expressed    O
on    O
cells    O
of    O
myeloid    O
lineage    O
.    O

Jacalin    B-Glycoprotein114888310
is    O
a    O
plant    O
based    O
lectin    O
,    O
but    O
not    O
a    O
legume    B-Glycoprotein114888310
lectin    I-Glycoprotein114888310
,    O
found    O
in    O
jackfruit    O
.    O

Also    O
,    O
intravenous    B-Glycoprotein114888310
immunoglobulin    I-Glycoprotein114888310
(    O
IVIGs    O
)    O
can    O
be    O
used    O
to    O
bind    O
the    O
circulating    O
antibodies    O
.    O

He    O
says    O
it    O
is    O
primary    O
antiphospholipid    O
syndrome    O
and    O
tells    O
him    O
to    O
start    O
Jack    O
on    O
heparin    O
and    O
IV    B-Glycoprotein114888310
immunoglobulin    I-Glycoprotein114888310
.    O

Intravenous    B-Glycoprotein114888310
Immunoglobulin    I-Glycoprotein114888310
may    O
also    O
occasionally    O
be    O
used    O
.    O

In    O
medicine    O
,    O
protective    O
passive    O
immunity    O
can    O
also    O
be    O
transferred    B-Glycoprotein114888310
artificially    I-Glycoprotein114888310
from    O
one    O
individual    O
to    O
another    O
via    O
antibody    O
-    O
rich    O
serum    O
.    O

Corticosteroids    O
or    O
intravenous    B-Glycoprotein114888310
immunoglobulin    I-Glycoprotein114888310
(    O
IVIG    O
)    O
may    O
be    O
useful    O
in    O
certain    O
cases    O
.    O

A    O
2015    O
Cochrane    O
review    O
found    O
no    O
evidence    O
of    O
benefit    O
of    O
using    O
intravenous    B-Glycoprotein114888310
immunoglobulin    I-Glycoprotein114888310
(    O
IVIG    O
)    O
in    O
adults    O
and    O
tentative    O
benefit    O
in    O
certain    O
children    O
.    O

Passive    O
immunity    O
can    O
occur    O
naturally    O
,    O
when    O
maternal    O
antibodies    O
are    O
transferred    O
to    O
the    O
fetus    O
through    O
the    O
placenta    O
,    O
and    O
it    O
can    O
also    O
be    O
induced    O
artificially    O
,    O
when    O
high    O
levels    O
of    O
antibodies    O
specific    O
to    O
a    O
pathogen    O
or    O
toxin    O
(    O
obtained    O
from    O
humans    O
,    O
horses    O
,    O
or    O
other    O
animals    O
)    O
are    O
transferred    O
to    O
non    O
-    O
immune    O
persons    O
through    O
blood    O
products    O
that    O
contain    O
antibodies    O
,    O
such    O
as    O
in    O
immunoglobulin    B-Glycoprotein114888310
therapy    I-Glycoprotein114888310
or    O
antiserum    O
therapy    O
.    O

Artificially    O
acquired    O
passive    O
immunity    O
is    O
a    O
short    O
-    O
term    O
immunization    O
achieved    O
by    O
the    O
transfer    O
of    O
antibodies    O
,    O
which    O
can    O
be    O
administered    O
in    O
several    O
forms    O
;    O
as    O
human    O
or    O
animal    O
blood    O
plasma    O
or    O
serum    O
,    O
as    O
pooled    O
human    O
immunoglobulin    O
for    O
intravenous    O
(    O
IVIG    B-Glycoprotein114888310
)    O
or    O
intramuscular    O
(    O
IG    O
)    O
use    O
,    O
as    O
high    O
-    O
titer    O
human    O
IVIG    O
or    O
IG    O
from    O
immunized    O
donors    O
or    O
from    O
donors    O
recovering    O
from    O
the    O
disease    O
,    O
and    O
as    O
monoclonal    O
antibodies    O
(    O
MAb    O
)    O
.    O

Intravenous    B-Glycoprotein114888310
immunoglobulin    I-Glycoprotein114888310
,    O
if    O
not    O
otherwise    O
noted    O
,    O
consists    O
of    O
polyvalent    O
IgG.    O

Intravenous    B-Glycoprotein114888310
immunoglobulin    I-Glycoprotein114888310
(    O
IVIg    O
)    O

There    O
are    O
three    O
types    O
of    O
prophylactic    O
treatments    O
,    O
namely    O
,    O
the    O
use    O
of    O
medication    O
,    O
sterile    O
environments    O
,    O
and    O
intravenous    B-Glycoprotein114888310
immunoglobulin    I-Glycoprotein114888310
therapy    O
(    O
IVIG    O
)    O
.    O

In    O
addition    O
,    O
the    O
patient    O
can    O
also    O
undergo    O
intravenous    B-Glycoprotein114888310
immunoglobulin    I-Glycoprotein114888310
(    O
IVIG    O
)    O
supplementation    O
.    O

Eltrombopag    O
was    O
initially    O
approved    O
by    O
the    O
U.S.    O
Food    O
and    O
Drug    O
Administration    O
on    O
November    O
20    O
,    O
2008    O
,    O
for    O
the    O
treatment    O
of    O
thrombocytopenia    O
in    O
patients    O
with    O
chronic    O
immune    O
(    O
idiopathic    O
)    O
thrombocytopenic    O
purpura    O
who    O
have    O
had    O
an    O
insufficient    O
response    O
to    O
corticosteroids    O
,    O
immunoglobulin    B-Glycoprotein114888310
therapy    I-Glycoprotein114888310
,    O
or    O
splenectomy    O
.    O

The    O
Alzheimer    O
's    O
drug    O
Gammagard    B-Glycoprotein114888310
fails    O
to    O
produce    O
results    O
in    O
a    O
large    O
-    O
scale    O
clinical    O
trial    O
.    O

The    O
second    O
,    O
more    O
recent    O
approach    O
pioneered    O
in    O
France    O
during    O
the    O
last    O
decade    O
(    O
early    O
2000s    O
)    O
involves    O
monthly    O
intravenous    O
infusions    O
of    O
immunoglobulins    B-Glycoprotein114888310
(    O
IVIG    O
)    O
,    O
with    O
an    O
initial    O
dose    O
of    O
2    O
gr    O
/    O
kg    O
/    O
month    O
of    O
body    O
weight    O
,    O
which    O
has    O
proven    O
very    O
successful    O
as    O
per    O
abundant    O
case    O
-    O
report    O
evidence    O
from    O
around    O
the    O
world    O
.    O

This    O
results    O
in    O
no    O
phosphorylation    O
of    O
the    O
p62    B-Glycoprotein114888310
and    O
optineurin    O
proteins    O
.    O

HSF2    O
has    O
been    O
shown    O
to    O
interact    O
with    O
Nucleoporin    B-Glycoprotein114888310
62    I-Glycoprotein114888310
and    O
HSF1    O
.    O

Oral    O
trehalose    O
shows    O
antidepressant    O
properties    O
in    O
the    O
mouse    O
model    O
of    O
depression    O
,    O
possibly    O
through    O
reducing    O
p62    B-Glycoprotein114888310
ratio    O
and    O
increasing    O
autophagy    O
in    O
the    O
frontal    O
cortex    O
.    O

δ    O
-    O
IgD    B-Glycoprotein114888310

Immunoglobulin    B-Glycoprotein114888310
D    I-Glycoprotein114888310
(    O
IgD    O
)    O

δ    O
–    O
IgD    B-Glycoprotein114888310

A    O
mature    O
,    O
naive    O
B    O
cell    O
expresses    O
both    O
the    O
IgM    B-Glycoprotein114888310
and    O
IgD    B-Glycoprotein114888310
classes    O
.    O

|    O
IgD    B-Glycoprotein114888310

the    O
hyalectans    O
(    O
a    O
family    O
of    O
proteoglycan    B-Glycoprotein114888310
)    O
:    O
aggrecan    B-Glycoprotein114888310
,    O
brevican    B-Glycoprotein114888310
,    O
neurocan    B-Glycoprotein114888310
and    O
versican    B-Glycoprotein114888310
,    O
which    O
are    O
expressed    O
in    O
the    O
CNS    O
;    O

Versican    O
belongs    O
to    O
the    O
lectican    O
protein    O
family    O
,    O
with    O
aggrecan    B-Glycoprotein114888310
(    O
abundant    O
in    O
cartilage    O
)    O
,    O
brevican    B-Glycoprotein114888310
and    O
neurocan    B-Glycoprotein114888310
(    O
nervous    O
system    O
proteoglycans    O
)    O
as    O
other    O
members    O
.    O

This    O
mutant    O
gene    O
is    O
transcribed    O
as    O
a    O
messenger    O
RNA    O
with    O
a    O
continuous    O
open    O
reading    O
frame    O
extending    O
over    O
300    O
nucleotides    O
and    O
is    O
translated    O
into    O
the    O
sialoglycoprotein    B-Glycoprotein114888310
found    O
on    O
Ge-2,-3    O
red    O
cells    O
.    O

The    O
gene    O
product    O
is    O
a    O
cell    O
surface    O
sialoglycoprotein    B-Glycoprotein114888310
,    O
a    O
type    O
I    O
membrane    O
protein    O
that    O
is    O
a    O
member    O
of    O
the    O
Ig    O
superfamily    O
.    O

screening    O
for    O
the    O
toxin    O
of    O
"    O
Escherichia    O
coli    O
"    O
,    O
first    O
named    O
"    O
Vero    O
toxin    O
"    O
after    O
this    O
cell    O
line    O
,    O
and    O
later    O
called    O
"    O
Shiga-like    B-Glycoprotein114888310
toxin    I-Glycoprotein114888310
"    O
due    O
to    O
its    O
similarity    O
to    O
Shiga    B-Glycoprotein114888310
toxin    I-Glycoprotein114888310
isolated    O
from    O
"    O
Shigella    O
dysenteriae    O
"    O

Shiga-like    B-Glycoprotein114888310
toxin    I-Glycoprotein114888310

Glycophorin    O
D    O
(    O
GPD    O
)    O
is    O
generated    O
from    O
the    O
glycophorin    O
C    O
messenger    O
RNA    O
by    O
leaky    O
translation    O
at    O
an    O
in    O
frame    O
AUG    O
at    O
codon    O
30    O
:    O
glycophorin    O
D    O
=    O
glycophorin    B-Glycoprotein114888310
C    O
residues    O
30    O
to    O
128    O
.    O

Only    O
mature    O
blood    O
cells    O
contain    O
the    O
membrane    O
proteins    O
,    O
such    O
as    O
aquaporin    O
and    O
glycophorin    B-Glycoprotein114888310
,    O
that    O
are    O
required    O
to    O
attach    O
to    O
and    O
pass    O
the    O
blood    O
vessel    O
endothelium    O
.    O

Laboratory    O
tests    O
include    O
blood    O
tests    O
for    O
vitamin    O
B-12    O
levels    O
,    O
a    O
complete    O
blood    O
count    O
,    O
measurement    O
of    O
thyroid    O
stimulating    O
hormone    O
levels    O
,    O
a    O
comprehensive    O
metabolic    O
panel    O
screening    O
for    O
diabetes    O
and    O
pre    O
-    O
diabetes    O
,    O
and    O
a    O
serum    B-Glycoprotein114888310
immunofixation    I-Glycoprotein114888310
test    I-Glycoprotein114888310
,    O
which    O
tests    O
for    O
antibodies    O
in    O
the    O
blood    O
.    O

In    O
the    O
macrophage    O
,    O
the    O
primary    O
signal    O
for    O
activation    O
is    O
IFN-γ    O
from    O
Th1    O
type    O
CD4    B-Glycoprotein114888310
T    O
cells    O
.    O

IL-17    O
function    O
is    O
also    O
essential    O
to    O
a    O
subset    O
of    O
CD4    B-Glycoprotein114888310
+    O
T    O
-    O
Cells    O
called    O
T    O
helper    O
17    O
(    O
Th17    O
)    O
cells    O
.    O

In    O
the    O
final    O
phase    O
of    O
elimination    O
,    O
tumor    O
-    O
specific    O
CD4+    B-Glycoprotein114888310
and    O
CD8    O
+    O
T    O
cells    O
home    O
to    O
the    O
tumor    O
site    O
and    O
the    O
cytotoxic    O
T    O
lymphocytes    O
then    O
destroy    O
the    O
antigen    O
-    O
bearing    O
tumor    O
cells    O
which    O
remain    O
at    O
the    O
site    O
.    O

HIV    O
testing    O
and    O
CD4    B-Glycoprotein114888310
count    O

A    O
midwife    O
draws    O
blood    O
to    O
measure    O
patients    O
'    O
CD4    B-Glycoprotein114888310
count    O
within    O
20    O
minutes    O
using    O
the    O
Pima    O
point    O
-    O
of    O
-    O
care    O
CD4    O
analyzer    O
,    O
in    O
Uganda    O
.    O

The    O
tyrosine    O
kinase    O
Lck    O
functions    O
either    O
in    O
conjunction    O
with    O
a    O
co    O
-    O
receptor    O
molecule    O
(    O
CD4    B-Glycoprotein114888310
or    O
CD8    B-Glycoprotein114888310
)    O
or    O
as    O
a    O
free    O
Lck    O
kinase    O
.    O

The    O
Vpu    O
protein    O
acts    O
in    O
the    O
degradation    O
of    O
CD4    B-Glycoprotein114888310
in    O
the    O
endoplasmic    O
reticulum    O
and    O
in    O
the    O
enhancement    O
of    O
virion    O
release    O
from    O
the    O
plasma    O
membrane    O
of    O
infected    O
cells    O
.    O

In    O
2008    O
RTI    O
worked    O
with    O
CIDRZ    O
to    O
implement    O
an    O
interface    O
with    O
the    O
Laboratory    O
Information    O
Management    O
System    O
(    O
LMIS    O
)    O
at    O
Kalingalinga    O
Clinic    O
,    O
enabling    O
lab    O
test    O
results    O
such    O
as    O
CD4    B-Glycoprotein114888310
counts    O
to    O
be    O
transferred    O
to    O
patient    O
records    O
automatically    O
twice    O
daily    O
.    O

The    O
MHC    O
:    O
antigen    O
complex    O
is    O
also    O
recognized    O
by    O
the    O
helper    O
cell    O
's    O
CD4    B-Glycoprotein114888310
co    O
-    O
receptor    O
,    O
which    O
recruits    O
molecules    O
inside    O
the    O
T    O
cell    O
(    O
e.g.    O
,    O
Lck    O
)    O
that    O
are    O
responsible    O
for    O
the    O
T    O
cell    O
's    O
activation    O
.    O

Helper    O
T    O
cells    O
recognize    O
these    O
,    O
with    O
the    O
help    O
of    O
their    O
expression    O
of    O
CD4    O
co    O
-    O
receptor    O
(    O
CD4+    B-Glycoprotein114888310
)    O
.    O

Triggering    O
monocytes    O
-    O
expressed    O
PD-1    O
by    O
its    O
ligand    O
PD    O
-    O
L1    O
induces    O
IL-10    O
production    O
which    O
activates    O
CD4    B-Glycoprotein114888310
Th2    O
cells    O
and    O
inhibits    O
CD4    B-Glycoprotein114888310
Th1    O
cell    O
function    O
.    O

A    O
CD4    B-Glycoprotein114888310
+    O
T    O
lymphocyte    O

|    O
CD4+    B-Glycoprotein114888310
T    I-Glycoprotein114888310
cells    I-Glycoprotein114888310

Interleukin    O
16    O
(    O
IL-16    O
)    O
is    O
a    O
cytokine    O
that    O
is    O
released    O
by    O
a    O
variety    O
of    O
cells    O
(    O
including    O
lymphocytes    O
and    O
some    O
epithelial    O
cells    O
)    O
that    O
has    O
been    O
characterized    O
as    O
a    O
chemoattractant    O
for    O
certain    O
immune    O
cells    O
expressing    O
the    O
cell    O
surface    O
molecule    O
CD4    B-Glycoprotein114888310
.    O

IL-21    O
is    O
expressed    O
in    O
activated    O
human    O
CD4    B-Glycoprotein114888310
+    O
T    O
cells    O
but    O
not    O
in    O
most    O
other    O
tissues    O
.    O

Arsenic    O
exposure    O
in    O
small    O
children    O
distorts    O
the    O
ratio    O
of    O
T    O
helper    O
cells    O
(    O
CD4    B-Glycoprotein114888310
)    O
to    O
cytotoxic    O
T    O
cells    O
(    O
CD8    B-Glycoprotein114888310
)    O
,    O
which    O
are    O
responsible    O
for    O
immunodepression    O
.    O

CD4    B-Glycoprotein114888310
+    O
Th    O
(    O
T    O
helper    O
)    O
cells    O
:    O
activate    O
and    O
regulate    O
T    O
and    O
B    O
cells    O

CD4+    B-Glycoprotein114888310
helper    O
T    O
cells    O
:    O
T    O
cells    O
displaying    O
co    O
-    O
receptor    O
CD4    B-Glycoprotein114888310
are    O
known    O
as    O
CD4    O
+    O
T    O
cells    O
.    O

T    O
-    O
cell    O
changes    O
(    O
increased    O
CD4    B-Glycoprotein114888310
CD8    B-Glycoprotein114888310
ratio    O
)    O

When    O
memory    O
helper    O
T    O
cells    O
'    O
CD4    B-Glycoprotein114888310
receptors    O
bind    O
to    O
the    O
MHC    B-Glycoprotein114888310
class    I-Glycoprotein114888310
II    I-Glycoprotein114888310
molecules    O
which    O
are    O
expressed    O
on    O
the    O
surfaces    O
of    O
the    O
target    O
cells    O
of    O
the    O
graft    O
tissue    O
,    O
the    O
memory    O
helper    O
T    O
cells    O
'    O
T    O
cell    O
receptors    O
(    O
TCRs    O
)    O
can    O
recognize    O
their    O
target    O
antigen    O
that    O
is    O
presented    O
by    O
the    O
MHC    O
class    O
II    O
molecules    O
.    O

HIV    O
has    O
an    O
adhesion    O
molecule    O
termed    O
gp120    B-Glycoprotein114888310
that    O
binds    O
to    O
its    O
ligand    O
CD4    B-Glycoprotein114888310
,    O
which    O
is    O
expressed    O
on    O
lymphocytes    O
.    O

It    O
is    O
described    O
as    O
CD4    B-Glycoprotein114888310
CD8    B-Glycoprotein114888310
+    O
,    O
with    O
CD30    O
and    O
CD56    O
usually    O
negative    O
.    O

Another    O
criticism    O
of    O
the    O
McDonald    O
criteria    O
is    O
that    O
the    O
definition    O
of    O
"    O
lesions    O
typical    O
of    O
MS    O
"    O
is    O
unclear    O
;    O
a    O
2013    O
review    O
identified    O
the    O
following    O
characteristics    O
:    O
specific    O
cell    O
morphology    O
shown    O
by    O
hematoxylin    O
,    O
demyelination    O
shown    O
by    O
Luxol    O
fast    O
blue    O
,    O
macrophage    O
appearance    O
by    O
KiM1P    O
or    O
CD68    O
,    O
damage    O
to    O
the    O
axons    O
shown    O
by    O
Bielschowsky    O
stain    O
,    O
astrocytopathy    O
shown    O
by    O
glial    O
fibrillary    O
acidic    O
protein    O
,    O
and    O
different    O
lymphocyte    O
subtypes    O
,    O
reacting    O
to    O
CD3    O
,    O
CD4    B-Glycoprotein114888310
,    O
CD8    B-Glycoprotein114888310
,    O
CD20    O
and    O
CD138    O
.    O

D    O
of    O
the    O
University    O
Of    O
Texas    O
Medical    O
School    O
at    O
Houston    O
announced    O
that    O
they    O
have    O
engineered    O
an    O
abzyme    O
that    O
degrades    O
the    O
superantigenic    O
region    O
of    O
the    O
gp120    B-Glycoprotein114888310
CD4    B-Glycoprotein114888310
binding    O
site    O
.    O

APCs    O
then    O
present    O
the    O
fragments    O
to    O
T    O
helper    O
cells    O
(    O
CD4    B-Glycoprotein114888310
+    O
)    O
by    O
the    O
use    O
of    O
class    B-Glycoprotein114888310
II    I-Glycoprotein114888310
histocompatibility    I-Glycoprotein114888310
molecules    O
on    O
their    O
surface    O
.    O

Antigens    O
from    O
the    O
extracellular    O
space    O
and    O
sometimes    O
also    O
endogenous    O
ones    O
,    O
are    O
enclosed    O
into    O
endocytic    O
vesicles    O
and    O
presented    O
on    O
the    O
cell    O
surface    O
by    O
MHC    O
-    O
II    O
molecules    O
to    O
the    O
helper    O
T    O
cells    O
expressing    O
CD4    B-Glycoprotein114888310
molecule    I-Glycoprotein114888310
.    O

Elevated    O
expression    O
levels    O
of    O
CCL2/MCP-1    O
,    O
CCL5/RANTES    O
and    O
CCL17/TARC    O
which    O
result    O
in    O
chemoattracted    O
CD4+    B-Glycoprotein114888310
and    O
CD8    O
+    O
T    O
cell    O
populations    O
to    O
the    O
surrounding    O
area    O
may    O
be    O
responsible    O
for    O
exerting    O
a    O
downmodulatory    O
effect    O
on    O
the    O
AchE    O
and    O
CHRM3    O
expressions    O
.    O

CD137    O
can    O
be    O
expressed    O
by    O
activated    O
T    O
cells    O
,    O
but    O
to    O
a    O
larger    O
extent    O
on    O
CD8    B-Glycoprotein114888310
than    O
on    O
CD4    B-Glycoprotein114888310
T    O
cells    O
.    O

Ophthalmic    O
screening    O
frequency    O
is    O
based    O
on    O
CD4    B-Glycoprotein114888310
count    I-Glycoprotein114888310
<    O
50    O
cells    O
/    O
mL    O
,    O
0-    O
35%    O
possibility    O
of    O
CMV    O
retinitis    O
)    O

CD1d    B-Glycoprotein114888310
(    O
group    O
2    O
CD1    O
)    O
is    O
expressed    O
in    O
a    O
wider    O
variety    O
of    O
cells    O
.    O

Mice    O
lack    O
the    O
group    O
1    O
CD1    O
molecules    O
,    O
and    O
instead    O
have    O
2    O
copies    O
of    O
CD1d    B-Glycoprotein114888310
.    O

For    O
example    O
,    O
astrotactin-1    B-Glycoprotein114888310
(    O
TC    O
#    O
9.B.87.3.1    O
)    O
is    O
involved    O
in    O
neural    O
cell    O
migration    O
in    O
mammals    O
and    O
apextrin    O
(    O
TC    O
#    O
1.C.39.7.4    O
)    O
is    O
involved    O
in    O
sea    O
urchin    O
(    O
"    O
Heliocidaris    O
erythrogramma    O
"    O
)    O
development    O
.    O
"    O
Drosophila    O
"    O
Torso    O
-    O
like    O
protein    O
(    O
TC    O
#    O
1.C.39.15.1    O
)    O
,    O
which    O
controls    O
embryonic    O
patterning    O
,    O
also    O
contains    O
a    O
MACPF    O
domain    O
.    O

The    O
smallest    O
variable    B-Glycoprotein114888310
surface    I-Glycoprotein114888310
glycoprotein    I-Glycoprotein114888310
(    O
40    O
kDa    O
in    O
size    O
)    O
to    O
date    O
has    O
been    O
found    O
in    O
"    O
T.    O
vivax    O
"    O
,    O
which    O
bears    O
little    O
carbohydrate    O
.    O

Expression    B-Glycoprotein114888310
site    I-Glycoprotein114888310
associated    I-Glycoprotein114888310
gene    I-Glycoprotein114888310
,    O
a    O
gene    O
found    O
in    O
the    O
bloodstream    O
expression    O
site    O
of    O
the    O
variable    O
surface    O
glycoproteins    O
of    O
the    O
sleeping    O
sickness    O
parasite    O
,    O
"    O
Trypanosoma    O
brucei    O
"    O

Osteonectin    B-Glycoprotein114888310

Some    O
of    O
the    O
regulatory    O
proteins    O
in    O
mineralized    O
tissues    O
are    O
osteonectin    B-Glycoprotein114888310
,    O
osteopontin    B-Glycoprotein114888310
,    O
osteocalcin    O
,    O
bone    O
sialoprotein    O
and    O
dentin    O
phosphophoryn    O
.    O

Peanut    B-Glycoprotein114888310
agglutinin    I-Glycoprotein114888310
(    O
PNA    B-Glycoprotein114888310
)    O
is    O
plant    O
lectin    O
protein    O
derived    O
from    O
the    O
fruits    O
of    O
"    O
Arachis    O
hypogaea    O
"    O
.    O

Von    B-Glycoprotein114888310
Willebrand    I-Glycoprotein114888310
factor    I-Glycoprotein114888310
(    O
vWF    B-Glycoprotein114888310
)    O
is    O
a    O
blood    O
glycoprotein    O
involved    O
in    O
hemostasis    O
.    O

Ristocetin    O
forms    O
complexes    O
with    O
von    B-Glycoprotein114888310
Willebrand    I-Glycoprotein114888310
Factor    I-Glycoprotein114888310
(    O
vWF    O
)    O
that    O
bind    O
to    O
the    O
glycoprotein    O
Ib    O
(    O
GP1b    O
)    O
receptors    O
on    O
platelets    O
,    O
causing    O
platelet    O
activation    O
and    O
aggregation    O
.    O

It    O
measures    O
platelet    O
aggregation    O
with    O
the    O
help    O
of    O
von    B-Glycoprotein114888310
Willebrand    I-Glycoprotein114888310
factor    I-Glycoprotein114888310
(    O
vWF    O
)    O
and    O
exogenous    O
antibiotic    O
ristocetin    O
added    O
in    O
a    O
graded    O
fashion    O
.    O

For    O
example    O
,    O
some    O
α    O
chains    O
have    O
an    O
additional    O
structural    O
element    O
(    O
or    O
"    O
domain    O
"    O
)    O
inserted    O
toward    O
the    O
N    O
-    O
terminal    O
,    O
the    O
alpha    O
-    O
A    O
domain    O
(    O
so    O
called    O
because    O
it    O
has    O
a    O
similar    O
structure    O
to    O
the    O
A    O
-    O
domains    O
found    O
in    O
the    O
protein    O
von    B-Glycoprotein114888310
Willebrand    I-Glycoprotein114888310
factor    I-Glycoprotein114888310
;    O
it    O
is    O
also    O
termed    O
the    O
α-I    O
domain    O
)    O
.    O

:    O
The    O
enzyme    O
cleaves    O
the    O
von    B-Glycoprotein114888310
Willebrand    I-Glycoprotein114888310
factor    I-Glycoprotein114888310
at    O
bond    O
Tyr842-Met843    O
within    O
the    O
A2    O
domain    O

The    O
domain    O
is    O
named    O
after    O
the    O
von    B-Glycoprotein114888310
Willebrand    I-Glycoprotein114888310
factor    I-Glycoprotein114888310
(    O
VWF    O
)    O
type    O
C    O
repeat    O
which    O
is    O
found    O
in    O
multidomain    O
protein    O
/    O
multifunctional    O
proteins    O
involved    O
in    O
maintaining    O
homeostasis    O
.    O

Von    B-Glycoprotein114888310
Willebrand    I-Glycoprotein114888310
factor    I-Glycoprotein114888310
(    O
VWF    O
)    O

von    B-Glycoprotein114888310
Willebrand    I-Glycoprotein114888310
factor    I-Glycoprotein114888310
(    O
vWF    O
)    O
:    O
0.252(0.051    O
)    O

Endothelial    O
cells    O
are    O
attached    O
to    O
the    O
subendothelial    O
collagen    O
by    O
von    B-Glycoprotein114888310
Willebrand    I-Glycoprotein114888310
factor    I-Glycoprotein114888310
(    O
VWF    O
)    O
which    O
these    O
cells    O
produce    O
.    O

α    O
granules    O
(    O
alpha    O
granules    O
)    O
–    O
containing    O
P    O
-    O
selectin    O
,    O
platelet    O
factor    O
4    O
,    O
transforming    O
growth    O
factor-β1    O
,    O
platelet    O
-    O
derived    O
growth    O
factor    O
,    O
fibronectin    B-Glycoprotein114888310
,    O
B    O
-    O
thromboglobulin    O
,    O
vWF    B-Glycoprotein114888310
,    O
fibrinogen    O
,    O
and    O
coagulation    O
factors    O
V    B-Glycoprotein114888310
and    O
XIII    O
.    O

Aggregation    O
begins    O
minutes    O
after    O
activation    O
,    O
and    O
occurs    O
as    O
a    O
result    O
of    O
turning    O
on    O
the    O
GPIIb    O
/    O
IIIa    O
receptor    O
,    O
allowing    O
these    O
receptors    O
to    O
bind    O
with    O
vWF    B-Glycoprotein114888310
or    O
fibrinogen    O
.    O

It    O
primarily    O
functions    O
to    O
mediate    O
the    O
first    O
critical    O
step    O
in    O
platelet    O
adhesion    O
,    O
by    O
facilitating    O
binding    O
to    O
von    B-Glycoprotein114888310
Willebrand    I-Glycoprotein114888310
factor    I-Glycoprotein114888310
(    O
VWF    O
)    O
on    O
damaged    O
sub    O
-    O
endothelium    O
under    O
conditions    O
of    O
high    O
fluid    O
shear    O
stress    O
.    O

The    O
GPIb    O
-    O
V    O
-    O
IX    O
complex    O
binds    O
von    B-Glycoprotein114888310
Willebrand    I-Glycoprotein114888310
factor    I-Glycoprotein114888310
,    O
allowing    O
platelet    O
adhesion    O
and    O
platelet    O
plug    O
formation    O
at    O
sites    O
of    O
vascular    O
injury    O
.    O

Concanavalin    B-Glycoprotein114888310
A    I-Glycoprotein114888310
,    O
Phytohaemagglutinin    B-Glycoprotein114888310

The    O
Rowett    O
institute    O
mistakenly    O
assumed    O
the    O
media    O
was    O
talking    O
about    O
a    O
second    O
line    O
transformed    O
with    O
concanavalin    B-Glycoprotein114888310
A    I-Glycoprotein114888310
(    O
ConA    O
)    O
,    O
a    O
Jack    O
Bean    O
lectin    O
that    O
is    O
toxic    O
to    O
mammals    O
.    O

They    O
also    O
reported    O
stress    O
-    O
related    O
decreases    O
in    O
NK    O
and    O
T    O
cell    O
function    O
,    O
and    O
T    O
cell    O
proliferative    O
responses    O
to    O
phytohaemagglutinin    B-Glycoprotein114888310
[    O
PHA    O
]    O
and    O
concanavalin    B-Glycoprotein114888310
A    I-Glycoprotein114888310
[    O
Con    O
A    O
]    O
.    O

They    O
also    O
replicated    O
Herbert    O
and    O
Cohen    O
's    O
finding    O
of    O
stress    O
-    O
related    O
decreases    O
in    O
NKCC    O
and    O
T    O
cell    O
mitogen    O
proliferation    O
to    O
Phytohaemagglutinin    B-Glycoprotein114888310
(    O
PHA    O
)    O
and    O
Concanavalin    B-Glycoprotein114888310
A    I-Glycoprotein114888310
(    O
Con    O
A    O
)    O
.    O

They    O
can    O
restore    O
the    O
response    O
of    O
purified    O
T    O
lymphocytes    O
to    O
Con    B-Glycoprotein114888310
A    I-Glycoprotein114888310

Integrins    B-Glycoprotein114888310
act    O
as    O
adhesion    O
receptors    O
,    O
transporting    O
signals    O
across    O
the    O
plasma    O
membrane    O
in    O
multiple    O
directions    O
.    O

The    O
six    O
Ig    O
motif    O
of    O
the    O
L1    O
protein    O
contains    O
a    O
Arg    O
-    O
Gly    O
-    O
Asp    O
sequence    O
which    O
allows    O
binding    O
with    O
diverse    O
surface    O
cell    O
integrin    B-Glycoprotein114888310
.    O

In    O
the    O
infected    O
cell    O
system    O
of    O
a    O
human    O
immunodeficiency    O
virus    O
(    O
HIV    O
)    O
,    O
it    O
is    O
shown    O
to    O
block    O
the    O
integrin    B-Glycoprotein114888310
-    O
dependent    O
processes    O
.    O

Tie-2/Ang-1    O
signaling    O
activates    O
integrin    B-Glycoprotein114888310
and    O
N    O
-    O
cadherin    B-Glycoprotein114888310
in    O
LSK    O
-    O
Tie2    O
+    O
cells    O
and    O
promotes    O
hematopoietic    O
stem    O
cell    O
(    O
HSC    O
)    O
interactions    O
with    O
extracellular    O
matrix    O
and    O
its    O
cellular    O
components    O
.    O
Ang-1    O

Integrin    B-Glycoprotein114888310

integrin    B-Glycoprotein114888310

Considering    O
the    O
large    O
size    O
(    O
>    O
1000    O
kDa    O
)    O
and    O
hydration    O
capability    O
of    O
versican    O
,    O
it    O
is    O
possible    O
that    O
the    O
interaction    O
of    O
integrins    B-Glycoprotein114888310
(    O
large    O
family    O
of    O
cell    O
adhesion    O
molecules    O
)    O
with    O
their    O
cell    O
surface    O
receptors    O
is    O
sterically    O
hindered    O
.    O

the    O
C1    O
domain    O
,    O
in    O
which    O
the    O
RGD    O
motif    O
binds    O
to    O
platelet    O
integrin    B-Glycoprotein114888310
αIIbβ3    O
when    O
this    O
is    O
activated    O
(    O
Von    O
Willebrand    O
factor    O
type    O
C    O
domain    O
)    O

The    O
classes    O
of    O
enzymes    O
that    O
have    O
manganese    O
cofactors    O
is    O
large    O
and    O
includes    O
oxidoreductases    O
,    O
transferases    O
,    O
hydrolases    O
,    O
lyases    O
,    O
isomerases    O
,    O
ligases    O
,    O
lectins    O
,    O
and    O
integrin    B-Glycoprotein114888310
.    O

In    O
hemidesmosomes    O
plectin    O
has    O
been    O
shown    O
to    O
interact    O
with    O
the    O
integrin    B-Glycoprotein114888310
β4    O
subunits    O
of    O
the    O
hemidesmosome    O
plaque    O
and    O
function    O
in    O
a    O
clamp    O
-    O
like    O
manner    O
to    O
link    O
the    O
intermediate    O
filament    O
cytokeratin    O
to    O
the    O
junction    O
.    O

This    O
triggers    O
the    O
activation    O
of    O
integrin    B-Glycoprotein114888310
from    O
the    O
cancer    O
cells    O
allowing    O
their    O
firmer    O
adhesion    O
to    O
members    O
of    O
the    O
Ig    O
-    O
CAM    O
family    O
such    O
as    O
ICAM    O
,    O
initiating    O
the    O
transendothelial    O
migration    O
and    O
extravasation    O
processes    O
.    O

Cell    O
-    O
ECM    O
interactions    O
induce    O
changes    O
in    O
differentiation    O
and    O
self    O
-    O
renewal    O
by    O
the    O
stiffness    O
of    O
the    O
substrate    O
via    O
mechanotransduction    O
,    O
and    O
different    O
integrin    B-Glycoprotein114888310
interacting    O
with    O
ECM    O
molecules    O
.    O

Abituzumab    O
is    O
a    O
humanized    O
IgG2    O
monoclonal    O
antibody    O
(    O
mAb    O
)    O
targeted    O
at    O
CD51    O
(    O
an    O
integrin    B-Glycoprotein114888310
)    O
currently    O
in    O
development    O
by    O
Merck    O
KGaA    O
Darmstadt    O
,    O
Germany    O
in    O
an    O
attempt    O
to    O
prevent    O
bone    O
lesion    O
metastases    O
in    O
castration    O
-    O
resistant    O
prostate    O
cancer    O
.    O

In    O
mature    O
cardiomyocytes    O
and    O
skeletal    O
muscle    O
,    O
talin-2    O
is    O
expressed    O
at    O
costameres    O
and    O
intercalated    O
discs    O
,    O
thus    O
demonstrating    O
that    O
talin2    O
links    O
integrins    B-Glycoprotein114888310
and    O
the    O
actin    O
cytoskeleton    O
in    O
stable    O
adhesion    O
complexes    O
involving    O
mature    O
sarcomeres    O
.    O

Ablation    O
of    O
both    O
talin    O
isoforms    O
,    O
talin-2    O
and    O
talin-1    O
prevented    O
normal    O
myoblast    O
fusion    O
and    O
sarcomere    O
assembly    O
,    O
as    O
well    O
as    O
assembly    O
of    O
integrin    O
adhesion    O
complexes    O
,    O
which    O
was    O
attributed    O
to    O
disrupted    O
interactions    O
between    O
integrins    B-Glycoprotein114888310
and    O
the    O
actin    O
cytoskeleton    O
.    O

Talin-2    O
,    O
like    O
talin-1    O
appears    O
to    O
join    O
ligand    O
-    O
bound    O
integrin    B-Glycoprotein114888310
and    O
the    O
actin    O
cytoskeleton    O
,    O
which    O
enhances    O
the    O
affinity    O
of    O
integrin    B-Glycoprotein114888310
for    O
the    O
extracellular    O
matrix    O
and    O
catalyzes    O
focal    O
adhesion    O
-    O
dependent    O
signaling    O
pathways    O
,    O
as    O
well    O
as    O
reinforces    O
the    O
cytoskeletal    O
-    O
integrin    B-Glycoprotein114888310
structure    O
in    O
response    O
to    O
an    O
applied    O
force    O
.    O

Interestingly    O
,    O
the    O
strength    O
of    O
the    O
interaction    O
between    O
talin    O
and    O
integrin    B-Glycoprotein114888310
appears    O
to    O
be    O
fine    O
-    O
tuned    O
through    O
differential    O
expression    O
of    O
isoforms    O
in    O
different    O
tissues    O
.    O

Stretch    O
-    O
activated    O
ion    O
channels    O
,    O
caveolae    O
,    O
integrins    B-Glycoprotein114888310
,    O
cadherins    B-Glycoprotein114888310
,    O
growth    O
factor    O
receptors    O
,    O
myosin    O
motors    O
,    O
cytoskeletal    O
filaments    O
,    O
nuclei    O
,    O
extracellular    O
matrix    O
,    O
and    O
numerous    O
other    O
molecular    O
structures    O
and    O
signaling    O
molecules    O
have    O
been    O
shown    O
to    O
contribute    O
to    O
cellular    O
mechanotransduction    O
.    O

Globular    O
domains    O
(    O
G    O
-    O
Domain    O
)    O
of    O
the    O
α    O
chain    O
are    O
the    O
regions    O
on    O
laminin-111    O
that    O
allow    O
the    O
binding    O
of    O
integrin    B-Glycoprotein114888310
,    O
glycoproteins    O
,    O
sulfated    O
glycolipids    O
and    O
dystroglycan    B-Glycoprotein114888310
.    O

Their    O
life    O
cycle    O
is    O
thought    O
to    O
begin    O
with    O
a    O
virion    O
attaching    O
to    O
specific    O
cell    O
-    O
surface    O
receptors    O
such    O
as    O
C-type    B-Glycoprotein114888310
lectin    I-Glycoprotein114888310
,    O
DC-SIGN    B-Glycoprotein114888310
,    O
or    O
integrin    B-Glycoprotein114888310
,    O
which    O
is    O
followed    O
by    O
fusion    O
of    O
the    O
viral    O
envelope    O
with    O
cellular    O
membranes    O
.    O

This    O
damage    O
occurs    O
due    O
to    O
the    O
synthesis    O
of    O
Ebola    O
virus    O
glycoprotein    O
(    O
GP    O
)    O
,    O
which    O
reduces    O
the    O
availability    O
of    O
specific    O
integrin    B-Glycoprotein114888310
responsible    O
for    O
cell    O
adhesion    O
to    O
the    O
intercellular    O
structure    O
and    O
causes    O
liver    O
damage    O
,    O
leading    O
to    O
improper    O
clotting    O
.    O

Collagen    O
XXIII    O
interacts    O
in    O
an    O
ion    O
-    O
and    O
conformation    O
-    O
dependent    O
manner    O
with    O
integrin    B-Glycoprotein114888310
α2β1    I-Glycoprotein114888310
.    O

Phagocytosis    O
.    O
Phagocytes    O
are    O
immune    O
cells    O
that    O
can    O
recognize    O
and    O
"    O
eat    O
"    O
bacteria    O
.    O
Phagocytes    O
recognize    O
bacteria    O
directly    O
[    O
e.g.    O
,    O
through    O
the    O
so    O
-    O
called    O
scavenger    O
receptor    O
A    O
which    O
recognizes    O
bacterial    O
lipopolysaccharide    O
(    O
LPS    O
)    O
]    O
or    O
indirectly    O
through    O
antibodies    O
(    O
IgG    O
)    O
and    O
complement    O
proteins    O
(    O
C3bi    O
)    O
which    O
coat    O
the    O
bacteria    O
and    O
are    O
recognized    O
by    O
the    O
Fcγ    O
receptors    O
and    O
integrin    B-Glycoprotein114888310
(    O
complement    O
receptor    O
3    O
)    O
.    O

This    O
is    O
due    O
to    O
lower    O
opsonic    O
activity    O
,    O
as    O
well    O
as    O
diminished    O
up    O
-    O
regulation    O
of    O
integrin    B-Glycoprotein114888310
and    O
selectin    B-Glycoprotein114888310
receptors    O
,    O
which    O
limit    O
the    O
ability    O
of    O
neutrophils    O
to    O
interact    O
with    O
adhesion    B-Glycoprotein114888310
molecule    I-Glycoprotein114888310
in    O
the    O
endothelium    O
.    O

Integrins    B-Glycoprotein114888310
are    O
transmembrane    O
receptors    O
that    O
facilitate    O
cell    O
-    O
extracellular    O
matrix    O
(    O
ECM    O
)    O
adhesion    O
.    O

This    O
is    O
followed    O
by    O
a    O
secondary    O
interaction    O
,    O
where    O
a    O
motif    O
in    O
the    O
penton    O
base    O
protein    O
interacts    O
with    O
an    O
integrin    B-Glycoprotein114888310
molecule    O
.    O

Von    O
Willebrand    O
factor    O
,    O
type    O
C    O
(    O
VWFC    O
or    O
VWC)is    O
a    O
protein    O
domain    O
is    O
found    O
in    O
various    O
blood    O
plasma    O
proteins    O
:    O
complement    O
factors    O
B    O
,    O
C2    O
,    O
CR3    O
and    O
CR4    O
;    O
the    O
integrins    B-Glycoprotein114888310
(    O
I    O
-    O
domains    O
)    O
;    O
collagen    O
types    O
VI    O
,    O
VII    O
,    O
XII    O
and    O
XIV    O
;    O
and    O
other    O
extracellular    O
proteins    O
.    O

Caveolin-1    O
has    O
also    O
been    O
shown    O
to    O
play    O
a    O
role    O
in    O
the    O
integrin    B-Glycoprotein114888310
signaling    O
.    O

In    O
1984    O
she    O
moved    O
,    O
as    O
a    O
post    O
doctoral    O
fellow    O
(    O
1984    O
-    O
1987    O
)    O
,    O
to    O
the    O
Laboratory    O
of    O
Molecular    O
Biology    O
(    O
LMB    O
)    O
,    O
Cambridge    O
,    O
UK    O
,    O
where    O
she    O
started    O
her    O
research    O
on    O
position    O
-    O
specific    O
(    O
PS    O
)    O
integrins    B-Glycoprotein114888310
involved    O
in    O
the    O
embryonic    O
development    O
of    O
Drosophila    O
,    O
joining    O
the    O
laboratory    O
of    O
Michael    O
Wilcox    O
.    O

Examples    O
of    O
these    O
proteins    O
include    O
selectins    B-Glycoprotein114888310
,    O
integrins    B-Glycoprotein114888310
,    O
syndecans    O
,    O
and    O
cadherins    B-Glycoprotein114888310
.    O

The    O
major    O
classes    O
are    O
named    O
integrins    B-Glycoprotein114888310
,    O
Ig    O
superfamily    O
members    O
,    O
cadherins    B-Glycoprotein114888310
,    O
and    O
selectins    B-Glycoprotein114888310
.    O

To    O
enter    O
epithelial    O
cells    O
,    O
viral    O
protein    O
BMRF-2    O
interacts    O
with    O
cellular    O
β1    O
integrins    B-Glycoprotein114888310
.    O

At    O
the    O
hemidesmosome    O
,    O
plectin    O
and    O
BPAG1    O
associate    O
with    O
transmembrane    O
proteins    O
α6β4    O
integrin    B-Glycoprotein114888310
,    O
a    O
type    O
of    O
cell    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
,    O
and    O
BP180/collagen    O
XVII    O
,    O
linking    O
K5/K14    O
filaments    O
in    O
the    O
basal    O
cells    O
to    O
the    O
basal    O
lamina    O
.    O

Integrin    B-Glycoprotein114888310
α6    O
anchors    O
the    O
neuroepithelial    O
cells    O
to    O
the    O
basal    O
lamina    O
.    O

Primarily    O
,    O
the    O
VCAM-1    O
protein    O
is    O
an    O
endothelial    O
ligand    O
for    O
VLA-4    O
(    O
Very    O
Late    O
Antigen-4    O
or    O
integrin    O
α4β1    O
)    O
of    O
the    O
β1    O
subfamily    O
of    O
integrin    B-Glycoprotein114888310
.    O

This    O
is    O
the    O
initial    O
binding    O
mechanism    O
,    O
after    O
which    O
it    O
is    O
followed    O
by    O
expression    O
of    O
integrins    B-Glycoprotein114888310
which    O
form    O
stronger    O
bonds    O
and    O
allow    O
leukocytes    O
to    O
migrate    O
toward    O
the    O
specific    O
site    O
of    O
inflammation    O
.    O

Binding    O
of    O
chemokines    O
to    O
CXCR3    O
induces    O
various    O
cellular    O
responses    O
,    O
most    O
notably    O
integrin    B-Glycoprotein114888310
activation    O
,    O
cytoskeletal    O
changes    O
and    O
chemotactic    O
migration    O
.    O

Other    O
receptors    O
also    O
show    O
this    O
functional    O
profile    O
,    O
including    O
p75NTR    O
,    O
the    O
androgen    O
receptor    O
,    O
RET    O
,    O
several    O
integrins    B-Glycoprotein114888310
and    O
Patched    O
.    O

CLEC2    B-Glycoprotein114888310

Synaptophysin    B-Glycoprotein114888310
→    O
-    O

With    O
immunohistochemistry    O
,    O
the    O
chief    O
cells    O
located    O
in    O
the    O
cell    O
balls    O
are    O
positive    O
for    O
chromogranin    O
,    O
synaptophysin    B-Glycoprotein114888310
,    O
neuron    O
specific    O
enolase    O
,    O
serotonin    O
,    O
neurofilament    O
and    O
Neural    O
cell    O
adhesion    O
molecule    O
;    O
they    O
are    O
S-100    O
protein    O
negative    O
.    O

SYP    O
,    O
the    O
HGNC    O
symbol    O
for    O
the    O
protein    O
synaptophysin    B-Glycoprotein114888310

Synaptophysin    B-Glycoprotein114888310

Secretoglobin,    B-Glycoprotein114888310
family    I-Glycoprotein114888310
1A,    I-Glycoprotein114888310
member    I-Glycoprotein114888310
1    I-Glycoprotein114888310
(uteroglobin)    I-Glycoprotein114888310
,    O
a    O
human    O
gene    O

At    O
least    O
20    O
human    O
mucin    O
genes    O
have    O
been    O
distinguished    O
by    O
cDNA    O
cloning    O
—    O
MUC1    B-Glycoprotein114888310
,    O
MUC2    B-Glycoprotein114888310
,    O
MUC3A    B-Glycoprotein114888310
,    O
MUC3B    O
,    O
MUC4    B-Glycoprotein114888310
,    O
MUC5AC    B-Glycoprotein114888310
,    O
MUC5B    B-Glycoprotein114888310
,    O
MUC6    B-Glycoprotein114888310
,    O
MUC7    B-Glycoprotein114888310
,    O
MUC8    O
,    O
MUC12    O
,    O
MUC13    O
,    O
MUC15    O
,    O
MUC16    B-Glycoprotein114888310
,    O
MUC17    B-Glycoprotein114888310
,    O
MUC19    O
,    O
and    O
MUC20    B-Glycoprotein114888310
.    O

Globotriaosylceramide    O
is    O
also    O
one    O
of    O
the    O
targets    O
of    O
Shiga    B-Glycoprotein114888310
toxin    I-Glycoprotein114888310
,    O
which    O
is    O
responsible    O
for    O
pathogenicity    O
of    O
enterohemorrhagic    O
"    O
Escherichia    O
coli    O
"    O
(    O
EHEC    O
)    O
.    O

Shiga    B-Glycoprotein114888310
toxin    I-Glycoprotein114888310

FSL    O
-    O
GB3    O
as    O
a    O
solution    O
/    O
gel    O
has    O
been    O
used    O
to    O
inhibit    O
HIV    O
infection    O
and    O
to    O
neutralise    O
Shiga    B-Glycoprotein114888310
toxin    I-Glycoprotein114888310
.    O

Use    O
in    O
EHEC    O
infections    O
may    O
lead    O
to    O
an    O
increase    O
in    O
expression    O
of    O
Shiga    B-Glycoprotein114888310
toxin    I-Glycoprotein114888310
.    O

The    O
bacterium    O
"    O
Shigella    O
"    O
was    O
thus    O
named    O
after    O
him    O
,    O
as    O
well    O
as    O
the    O
Shiga    B-Glycoprotein114888310
toxin    I-Glycoprotein114888310
,    O
which    O
is    O
produced    O
by    O
the    O
bacterium    O
.    O

Pk    O
antigen    O
is    O
a    O
receptor    O
for    O
shiga    B-Glycoprotein114888310
toxins    I-Glycoprotein114888310
and    O
"    O
Escherichia    O
coli    O
"-    O
associated    O
hemolytic    O
uremic    O
syndrome    O
(    O
HUS    O
)    O
.    O

Maternal    O
antibodies    O
such    O
as    O
immunoglobulin    B-Glycoprotein114888310
G    I-Glycoprotein114888310
(    O
IgG    O
)    O
,    O
which    O
are    O
readily    O
transmitted    O
to    O
the    O
young    O
across    O
the    O
placenta    O
,    O
may    O
explain    O
why    O
very    O
young    O
rabbits    O
are    O
resistant    O
to    O
RHD    O
.    O

The    O
simplest    O
form    O
is    O
the    O
hinge    O
region    O
from    O
IgG1    B-Glycoprotein114888310
.    O

Second    O
,    O
they    O
isolated    O
the    O
DNA    O
sequence    O
that    O
codes    O
the    O
human    O
gene    O
for    O
the    O
Fc    O
end    O
of    O
immunoglobulin    B-Glycoprotein114888310
G1    I-Glycoprotein114888310
(    O
IgG1    O
)    O
.    O

Colostrum    O
is    O
known    O
to    O
contain    O
immune    O
cells    O
(    O
as    O
lymphocytes    O
)    O
and    O
many    O
antibodies    O
such    O
as    O
IgA    B-Glycoprotein114888310
,    O
IgG    B-Glycoprotein114888310
,    O
and    O
IgM    B-Glycoprotein114888310
These    O
are    O
some    O
of    O
the    O
components    O
of    O
the    O
adaptive    O
immune    O
system    O
.    O

In    O
the    O
dairy    O
industry    O
,    O
the    O
quality    O
of    O
colostrum    O
is    O
measured    O
as    O
the    O
amount    O
of    O
IgG    O
(    O
Immunoglobulin    B-Glycoprotein114888310
G    I-Glycoprotein114888310
)    O
per    O
liter    O
.    O

In    O
2012    O
,    O
OncoMed    O
sponsored    O
the    O
USAN    O
nonproprietary    O
name    O
vantictumab    O
for    O
a    O
human    O
IgG2    B-Glycoprotein114888310
anti    O
-    O
Frizzled    O
antibody    O
,    O
an    O
anti    O
-    O
cancer    O
therapeutic    O
.    O

This    O
induces    O
the    O
B    O
-    O
lymphocytes    O
to    O
produce    O
IgG    B-Glycoprotein114888310
immunoglobulins    O
specific    O
for    O
the    O
antigen    O
.    O

This    O
polyclonal    O
IgG    B-Glycoprotein114888310
is    O
purified    O
from    O
the    O
mammal    O
’s    O
serum    O
.    O

Selective    O
deficiency    O
of    O
immunoglobulin    O
G    O
(    O
IgG    B-Glycoprotein114888310
)    O
subclasses    O

Their    O
work    O
is    O
not    O
complete    O
,    O
but    O
those    O
in    O
the    O
study    O
who    O
produced    O
IgG    B-Glycoprotein114888310
antibodies    O
that    O
recognise    O
the    O
V2    O
loop    O
in    O
the    O
HIV    O
envelope    O
protein    O
gp120    B-Glycoprotein114888310
were    O
43%    O
less    O
likely    O
to    O
become    O
infected    O
.    O

Several    O
serological    O
tests    O
can    O
be    O
performed    O
to    O
assess    O
total    O
IgE    O
and    O
allergen    O
specific    O
IgE    B-Glycoprotein114888310
and    O
IgG    B-Glycoprotein114888310
:    O
ELISA    O
,    O
MAST    O
,    O
HIA    O
,    O
and    O
CAP    O
RAST    O
.    O

Thirdly    O
,    O
her    O
group    O
is    O
interested    O
in    O
micro    O
-    O
sized    O
striped    O
patterns    O
of    O
protein    O
(    O
such    O
as    O
serum    O
albumin    O
,    O
immunoglobulin    B-Glycoprotein114888310
G    I-Glycoprotein114888310
,    O
laminin    O
and    O
other    O
growth    O
factors    O
)    O
on    O
biocompatible    O
polymeric    O
substrates    O
(    O
such    O
as    O
poly(methylmethacrylate    O
)    O
or    O
PMMA    O
)    O
.    O

It    O
is    O
a    O
human    O
IgG4    B-Glycoprotein114888310
anti    O
-    O
PD-1    O
monoclonal    O
antibody    O
.    O

Nivolumab    O
is    O
a    O
fully    O
human    O
monoclonal    O
immunoglobulin    B-Glycoprotein114888310
G    I-Glycoprotein114888310
antibody    O
to    O
PD-1    O
.    O

Defective    O
T    O
and    O
B    O
cells    O
as    O
well    O
as    O
markedly    O
decreased    O
IgG1    B-Glycoprotein114888310
responses    O
were    O
observed    O
in    O
miR-155-deficient    O
mice    O
,    O
IgG1    O
is    O
reduced    O
whereas    O
the    O
expression    O
of    O
the    O
IgM    B-Glycoprotein114888310
immunoglobulin    O
remains    O
normal    O
in    O
these    O
mice    O
.    O

For    O
example    O
,    O
those    O
that    O
bind    O
the    O
most    O
common    O
class    O
of    O
antibody    O
,    O
IgG    B-Glycoprotein114888310
,    O
are    O
called    O
"    O
Fc    O
-    O
gamma    O
receptors    O
"    O
(    O
FcγR    O
)    O
,    O
those    O
that    O
bind    O
IgA    B-Glycoprotein114888310
are    O
called    O
"    O
Fc    O
-    O
alpha    O
receptors    O
"    O
(    O
FcαR    O
)    O
and    O
those    O
that    O
bind    O
IgE    B-Glycoprotein114888310
are    O
called    O
"    O
Fc    O
-    O
epsilon    O
receptors    O
"    O
(    O
FcεR    O
)    O
.    O

For    O
example    O
,    O
macrophages    O
begin    O
to    O
ingest    O
and    O
kill    O
an    O
IgG    B-Glycoprotein114888310
-    O
coated    O
pathogen    O
by    O
phagocytosis    O
following    O
engagement    O
of    O
their    O
Fcγ    O
receptors    O
.    O

When    O
IgG    B-Glycoprotein114888310
molecules    O
,    O
specific    O
for    O
a    O
certain    O
antigen    O
or    O
surface    O
component    O
,    O
bind    O
to    O
the    O
pathogen    O
with    O
their    O
Fab    O
region    O
(    O
fragment    O
antigen    O
binding    O
region    O
)    O
,    O
their    O
Fc    O
regions    O
point    O
outwards    O
,    O
in    O
direct    O
reach    O
of    O
phagocytes    O
.    O

Atezolizumab    O
(    O
trade    O
name    O
Tecentriq    O
)    O
is    O
a    O
fully    O
humanized    O
,    O
engineered    O
monoclonal    O
antibody    O
of    O
IgG1    B-Glycoprotein114888310
isotype    O
against    O
the    O
protein    O
programmed    O
cell    O
death    O
-    O
ligand    O
1    O
(    O
PD    O
-    O
L1    O
)    O
.    O

a    O
decrease    O
in    O
levels    O
of    O
immunoglobulin    B-Glycoprotein114888310
G3    I-Glycoprotein114888310

IgM    B-Glycoprotein114888310
antibodies    I-Glycoprotein114888310
are    O
detectable    O
two    O
days    O
after    O
symptom    O
onset    O
and    O
IgG    B-Glycoprotein114888310
antibodies    I-Glycoprotein114888310
can    O
be    O
detected    O
6    O
to    O
18    O
days    O
after    O
symptom    O
onset    O
.    O

During    O
pregnancy    O
,    O
a    O
particular    O
type    O
of    O
antibody    O
,    O
called    O
IgG    B-Glycoprotein114888310
,    O
is    O
transported    O
from    O
mother    O
to    O
baby    O
directly    O
through    O
the    O
placenta    O
,    O
so    O
human    O
babies    O
have    O
high    O
levels    O
of    O
antibodies    O
even    O
at    O
birth    O
,    O
with    O
the    O
same    O
range    O
of    O
antigen    O
specificities    O
as    O
their    O
mother    O
.    O
Breast    O
milk    O
or    O
colostrum    O
also    O
contains    O
antibodies    O
that    O
are    O
transferred    O
to    O
the    O
gut    O
of    O
the    O
infant    O
and    O
protect    O
against    O
bacterial    O
infections    O
until    O
the    O
newborn    O
can    O
synthesize    O
its    O
own    O
antibodies    O
.    O

This    O
is    O
also    O
called    O
antibody    O
-    O
dependent    O
(    O
or    O
cytotoxic    O
)    O
hypersensitivity    O
,    O
and    O
is    O
mediated    O
by    O
IgG    B-Glycoprotein114888310
and    O
IgM    B-Glycoprotein114888310
antibodies    O
.    O

In    O
the    O
original    O
version    O
of    O
the    O
technique    O
,    O
the    O
protein    O
of    O
interest    O
with    O
the    O
TAP    O
tag    O
first    O
binds    O
to    O
beads    O
coated    O
with    O
IgG    B-Glycoprotein114888310
,    O
the    O
TAP    O
tag    O
is    O
then    O
broken    O
apart    O
by    O
an    O
enzyme    O
,    O
and    O
finally    O
a    O
different    O
part    O
of    O
the    O
TAP    O
tag    O
binds    O
reversibly    O
to    O
beads    O
of    O
a    O
different    O
type    O
.    O

The    O
TAP    O
tag    O
consists    O
of    O
calmodulin    O
binding    O
peptide    O
(    O
CBP    O
)    O
from    O
the    O
N    O
-    O
terminal    O
,    O
followed    O
by    O
tobacco    O
etch    O
virus    O
protease    O
(    O
TEV    O
protease    O
)    O
cleavage    O
site    O
and    O
Protein    O
A    O
,    O
which    O
binds    O
tightly    O
to    O
IgG    B-Glycoprotein114888310
The    O
relative    O
order    O
of    O
the    O
modules    O
of    O
the    O
tag    O
is    O
important    O
because    O
Protein    O
A    O
needs    O
to    O
be    O
at    O
the    O
extreme    O
end    O
of    O
the    O
fusion    O
protein    O
so    O
that    O
the    O
entire    O
complex    O
can    O
be    O
retrieved    O
using    O
an    O
IgG    O
matrix    O
.    O

|    O
IgG    B-Glycoprotein114888310

The    O
combination    O
of    O
this    O
cytokine    O
and    O
IL12    O
has    O
been    O
shown    O
to    O
inhibit    O
IL-4    O
dependent    O
IgE    B-Glycoprotein114888310
and    O
IgG1    B-Glycoprotein114888310
production    O
,    O
and    O
enhance    O
IgG2a    O
production    O
in    O
B    O
cells    O
.    O

Immunoglobulin    B-Glycoprotein114888310
G    I-Glycoprotein114888310
(    O
IgG    O
)    O
is    O
the    O
only    O
antibody    O
isotype    O
that    O
can    O
pass    O
through    O
the    O
human    O
placenta    O
,    O
and    O
is    O
the    O
most    O
common    O
antibody    O
of    O
the    O
five    O
types    O
of    O
antibodies    O
found    O
in    O
the    O
body    O
.    O

For    O
allergy    O
testing    O
,    O
Hycor    O
has    O
developed    O
specific    O
and    O
total    O
IgE    B-Glycoprotein114888310
,    O
specific    O
IgG    B-Glycoprotein114888310
,    O
specific    O
IgG4    B-Glycoprotein114888310
,    O
and    O
specific    O
IgE    O
EIA    O
tests    O
.    O

This    O
is    O
an    O
IgG1    B-Glycoprotein114888310
heterodimeric    O
antibody    O
scaffold    O
that    O
consists    O
of    O
two    O
different    O
heavy    O
chains    O
engineered    O
to    O
exclusively    O
assemble    O
into    O
a    O
single    O
molecule    O
,    O
allowing    O
bi    O
-    O
specific    O
binding    O
to    O
two    O
different    O
antigens    O
or    O
drug    O
targets    O
.    O

Immunofluorescence    O
demonstrates    O
diffuse    O
granular    O
uptake    O
of    O
IgG    B-Glycoprotein114888310
The    O
basement    O
membrane    O
may    O
completely    O
surround    O
the    O
granular    O
deposits    O
,    O
forming    O
a    O
"    O
spike    O
and    O
dome    O
"    O
pattern    O
.    O

In    O
Goodpasture    O
syndrome    O
,    O
IgG    B-Glycoprotein114888310
antibodies    O
directed    O
against    O
the    O
glomerular    O
basement    O
membrane    O
trigger    O
an    O
inflammatory    O
reaction    O
,    O
causing    O
a    O
nephritic    O
syndrome    O
and    O
the    O
coughing    O
up    O
of    O
blood    O
.    O

#    O
Immunoglobulin    B-Glycoprotein114888310
G    I-Glycoprotein114888310
(    O
IgG    O
)    O
binds    O
specifically    O
to    O
the    O
target    O
antigen    O
presented    O
on    O
the    O
pathogen    O
extracellularly    O

Alemtuzumab    O
is    O
a    O
recombinant    O
DNA    O
-    O
derived    O
humanized    O
IgG1    B-Glycoprotein114888310
kappa    O
monoclonal    O
antibody    O
that    O
is    O
directed    O
against    O
the    O
21–28    O
kDa    O
cell    O
surface    O
glycoprotein    O
CD52    O
.    O

Peptoids    O
have    O
been    O
developed    O
as    O
candidates    O
for    O
a    O
range    O
of    O
different    O
biomedical    O
applications    O
,    O
including    O
antimicrobial    O
agents    O
and    O
synthetic    O
lung    O
surfactants    O
,    O
as    O
well    O
as    O
ligands    O
for    O
various    O
proteins    O
including    O
Src    O
Homology    O
3    O
(    O
SH3    O
domain    O
)    O
,    O
Vascular    O
Endothelial    O
Growth    O
Factor    O
(    O
VEGF    O
)    O
receptor    O
2    O
,    O
and    O
antibody    O
Immunoglobulin    B-Glycoprotein114888310
G    I-Glycoprotein114888310
biomarkers    O
for    O
the    O
identification    O
of    O
Alzheimer    O
's    O
disease    O
.    O

Hemolytic    O
disease    O
of    O
the    O
newborn    O
,    O
also    O
known    O
as    O
hemolytic    O
disease    O
of    O
the    O
fetus    O
and    O
newborn    O
,    O
HDN    O
,    O
HDFN    O
,    O
or    O
erythroblastosis    O
fetalis    O
,    O
is    O
an    O
alloimmune    O
condition    O
that    O
develops    O
in    O
a    O
fetus    O
,    O
when    O
the    O
IgG    B-Glycoprotein114888310
molecules    O
(    O
one    O
of    O
the    O
five    O
main    O
types    O
of    O
antibodies    O
)    O
produced    O
by    O
the    O
mother    O
pass    O
through    O
the    O
placenta    O
.    O

This    O
occurs    O
due    O
to    O
the    O
decreased    O
amount    O
of    O
immunoglobulin    B-Glycoprotein114888310
G    I-Glycoprotein114888310
(    O
IgG    O
)    O
levels    O
in    O
the    O
infant    O
during    O
the    O
three    O
-    O
month    O
stage    O
.    O

The    O
classical    O
complement    O
pathway    O
is    O
initiated    O
by    O
antigen    O
-    O
antibody    O
complexes    O
with    O
the    O
antibody    O
isotypes    O
IgG    B-Glycoprotein114888310
and    O
IgM    B-Glycoprotein114888310

The    O
IFA    O
will    O
detect    O
an    O
increase    O
in    O
IgG    B-Glycoprotein114888310
or    O
IgM    B-Glycoprotein114888310
antibodies    O
in    O
the    O
bloodstream    O
.    O

For    O
example    O
the    O
total    O
levels    O
of    O
antibodies    O
isotypes    O
or    O
classes    O
:    O
Immunoglobulin    B-Glycoprotein114888310
M    I-Glycoprotein114888310
,    O
Immunoglobulin    B-Glycoprotein114888310
G    I-Glycoprotein114888310
,    O
and    O
Immunoglobulin    B-Glycoprotein114888310
A    I-Glycoprotein114888310
It    O
is    O
important    O
in    O
quantification    O
of    O
free    O
light    O
chains    O
in    O
diseases    O
such    O
as    O
multiple    O
myeloma    O
.    O

In    O
the    O
classical    O
pathway    O
,    O
the    O
microbial    O
pathogen    O
is    O
coated    O
in    O
antibodies    O
(    O
IgG    B-Glycoprotein114888310
and    O
IgM    B-Glycoprotein114888310
)    O
released    O
by    O
B    O
cells    O
.    O

The    O
IgG    B-Glycoprotein114888310
antibody    O
is    O
similar    O
to    O
AGA    O
IgA    B-Glycoprotein114888310
,    O
but    O
is    O
found    O
at    O
higher    O
levels    O
in    O
patients    O
with    O
the    O
IgA    O
-    O
less    O
phenotype    O
.    O

Many    O
other    O
molecules    O
involved    O
in    O
cell    O
-    O
cell    O
contact    O
are    O
implicated    O
in    O
zebrafish    O
epiboly    O
,    O
including    O
G    O
alpha    O
(    O
12/13    O
)    O
which    O
interacts    O
with    O
E    O
-    O
Cadherin    B-Glycoprotein114888310
and    O
actin    O
,    O
as    O
well    O
as    O
the    O
cell    O
adhesion    O
molecule    O
EpCam    O
in    O
the    O
EVL    O
,    O
which    O
may    O
modulate    O
adhesion    O
with    O
the    O
underlying    O
deep    O
cells    O
.    O

Stretch    O
-    O
activated    O
ion    O
channels    O
,    O
caveolae    O
,    O
integrins    B-Glycoprotein114888310
,    O
cadherins    B-Glycoprotein114888310
,    O
growth    O
factor    O
receptors    O
,    O
myosin    O
motors    O
,    O
cytoskeletal    O
filaments    O
,    O
nuclei    O
,    O
extracellular    O
matrix    O
,    O
and    O
numerous    O
other    O
molecular    O
structures    O
and    O
signaling    O
molecules    O
have    O
been    O
shown    O
to    O
contribute    O
to    O
cellular    O
mechanotransduction    O
.    O

They    O
exist    O
in    O
two    O
known    O
forms    O
,    O
InlA    O
and    O
InlB.    O
They    O
are    O
used    O
by    O
the    O
bacteria    O
to    O
invade    O
mammalian    O
cells    O
via    O
cadherin    B-Glycoprotein114888310
transmembrane    O
proteins    O
and    O
Met    O
receptors    O
respectively    O
.    O

Cadherin    B-Glycoprotein114888310

These    O
junctions    O
are    O
formed    O
by    O
transmembrane    O
proteins    O
called    O
cadherins    B-Glycoprotein114888310
.    O

Integrins    O
work    O
alongside    O
other    O
receptors    O
such    O
as    O
cadherin    B-Glycoprotein114888310
,    O
the    O
immunoglobulin    O
superfamily    O
cell    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
,    O
selectin    B-Glycoprotein114888310
and    O
syndecans    O
,    O
to    O
mediate    O
cell    O
–    O
cell    O
and    O
cell    O
–    O
matrix    O
interaction    O
.    O

Protocadherins    O
(    O
Pcdhs    O
)    O
are    O
the    O
largest    O
mammalian    O
subgroup    O
of    O
the    O
cadherin    B-Glycoprotein114888310
superfamily    O
of    O
homophilic    O
cell    O
-    O
adhesion    O
proteins    O
.    O

The    O
PCR    O
fragments    O
that    O
corresponded    O
to    O
Protocadherins    O
were    O
found    O
in    O
vertebrate    O
and    O
invertebrate    O
species    O
This    O
prevalence    O
in    O
a    O
wide    O
range    O
of    O
species    O
suggested    O
that    O
the    O
fragments    O
were    O
part    O
of    O
an    O
ancient    O
cadherin    B-Glycoprotein114888310
and    O
were    O
thus    O
termed    O
"    O
Protocadherins    O
"    O
as    O
the    O
"    O
first    O
cadherins    O
"    O
;    O
although    O
,    O
of    O
the    O
approximately    O
70    O
Pcdh    O
genes    O
identified    O
in    O
mammalian    O
genomes    O
,    O
over    O
50    O
are    O
located    O
in    O
tightly    O
linked    O
gene    O
clusters    O
on    O
the    O
same    O
chromosome    O
,    O
and    O
this    O
kind    O
of    O
organization    O
can    O
only    O
be    O
found    O
in    O
vertebrates    O
.    O

Cadherin    B-Glycoprotein114888310

The    O
protein    O
encoded    O
by    O
this    O
gene    O
is    O
a    O
member    O
of    O
the    O
flamingo    O
subfamily    O
,    O
part    O
of    O
the    O
cadherin    B-Glycoprotein114888310
superfamily    O
.    O

Catenins    O
are    O
proteins    O
that    O
associate    O
with    O
the    O
cytoplasmic    O
domain    O
of    O
a    O
variety    O
of    O
cadherin    B-Glycoprotein114888310
.    O

Examples    O
of    O
these    O
proteins    O
include    O
selectins    B-Glycoprotein114888310
,    O
integrins    B-Glycoprotein114888310
,    O
syndecans    O
,    O
and    O
cadherins    B-Glycoprotein114888310
.    O

The    O
major    O
classes    O
are    O
named    O
integrins    B-Glycoprotein114888310
,    O
Ig    O
superfamily    O
members    O
,    O
cadherins    B-Glycoprotein114888310
,    O
and    O
selectins    B-Glycoprotein114888310
.    O

Cadherins    B-Glycoprotein114888310
(    O
named    O
for    O
"    O
calcium    O
-    O
dependent    O
adhesion    O
"    O
)    O
are    O
a    O
type    O
of    O
cell    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
(CAM)    I-Glycoprotein114888310
that    O
is    O
important    O
in    O
cell    O
adhesion    O
by    O
forming    O
adherens    O
junctions    O
to    O
bind    O
cells    O
with    O
each    O
other    O
.    O

Currently    O
,    O
four    O
desmoglein    O
subfamily    O
members    O
have    O
been    O
identified    O
and    O
all    O
are    O
members    O
of    O
the    O
cadherin    B-Glycoprotein114888310
cell    O
adhesion    O
molecule    O
superfamily    O
.    O

Following    O
the    O
migration    O
of    O
lymphocytes    O
into    O
the    O
glands    O
in    O
response    O
to    O
chemokines    O
and    O
specific    O
adhesion    B-Glycoprotein114888310
molecule    I-Glycoprotein114888310
,    O
T    O
cells    O
interact    O
with    O
epithelial    O
cells    O
.    O

CHL1    O
is    O
a    O
cell    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
closely    O
related    O
to    O
the    O
L1    O
.    O

Cell    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecules    I-Glycoprotein114888310

The    O
molecules    O
responsible    O
for    O
creating    O
cell    O
junctions    O
include    O
various    O
cell    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
.    O

The    O
L1    O
family    O
is    O
a    O
family    O
of    O
cell    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
that    O
includes    O
four    O
different    O
L1-like    O
proteins    O
.    O

This    O
protein    O
,    O
of    O
200    O
-    O
220    O
kDa    O
,    O
is    O
a    O
neuronal    O
cell    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
with    O
a    O
strong    O
implication    O
in    O
cell    O
migration    O
,    O
adhesion    O
,    O
neurite    O
outgrowth    O
,    O
myelination    O
and    O
neuronal    O
differentiation    O
.    O

L1    O
has    O
a    O
static    O
function    O
as    O
a    O
cell    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
which    O
connects    O
different    O
cells    O
.    O

Cell    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
,    O
proteins    O
on    O
cell    O
surfaces    O

In    O
addition    O
to    O
neuronal    O
death    O
,    O
there    O
is    O
evidence    O
suggesting    O
that    O
an    O
improper    O
formation    O
of    O
interneuronal    O
connections    O
and    O
cell    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
malformation    O
are    O
also    O
associated    O
with    O
FASD    O
.    O

L    O
-    O
selectin    O
,    O
also    O
known    O
as    O
CD62L    O
,    O
is    O
a    O
cell    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
found    O
on    O
lymphocytes    O
and    O
the    O
preimplantation    O
embryo    O
.    O

E-selectin    B-Glycoprotein114888310
,    O
also    O
known    O
as    O
CD62    B-Glycoprotein114888310
antigen-like    I-Glycoprotein114888310
family    I-Glycoprotein114888310
member    I-Glycoprotein114888310
E    I-Glycoprotein114888310
(    O
CD62E    O
)    O
,    O
endothelial-leukocyte    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
1    I-Glycoprotein114888310
(    O
ELAM-1    O
)    O
,    O
or    O
leukocyte-endothelial    B-Glycoprotein114888310
cell    I-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
2    I-Glycoprotein114888310
(    O
LECAM2    O
)    O
,    O
is    O
a    O
cell    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
expressed    O
only    O
on    O
endothelial    O
cells    O
activated    O
by    O
cytokines    O
.    O

For    O
example    O
,    O
instead    O
of    O
just    O
making    O
a    O
fluorescent    O
protein    O
,    O
a    O
gene    O
network    O
may    O
switch    O
on    O
an    O
adhesion    B-Glycoprotein114888310
molecule    I-Glycoprotein114888310
so    O
that    O
cells    O
stick    O
to    O
each    O
other    O
,    O
or    O
activate    O
a    O
motility    O
system    O
so    O
that    O
cells    O
move    O
.    O

Activation    O
and    O
deactivation    O
results    O
from    O
a    O
variety    O
of    O
factors    O
,    O
including    O
cytokines    O
,    O
soluble    O
receptors    O
,    O
arachidonic    O
acid    O
metabolites    O
,    O
steroids    O
,    O
receptor    O
antagonists    O
,    O
adhesion    B-Glycoprotein114888310
molecules    I-Glycoprotein114888310
,    O
bacterial    O
products    O
and    O
viral    O
products    O
.    O

This    O
is    O
due    O
to    O
lower    O
opsonic    O
activity    O
,    O
as    O
well    O
as    O
diminished    O
up    O
-    O
regulation    O
of    O
integrin    B-Glycoprotein114888310
and    O
selectin    B-Glycoprotein114888310
receptors    O
,    O
which    O
limit    O
the    O
ability    O
of    O
neutrophils    O
to    O
interact    O
with    O
adhesion    B-Glycoprotein114888310
molecule    I-Glycoprotein114888310
in    O
the    O
endothelium    O
.    O

Integrins    O
work    O
alongside    O
other    O
receptors    O
such    O
as    O
cadherin    B-Glycoprotein114888310
,    O
the    O
immunoglobulin    O
superfamily    O
cell    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
,    O
selectin    B-Glycoprotein114888310
and    O
syndecans    O
,    O
to    O
mediate    O
cell    O
–    O
cell    O
and    O
cell    O
–    O
matrix    O
interaction    O
.    O

Cell    O
adhesion    O
occurs    O
from    O
the    O
action    O
of    O
transmembrane    O
glycoproteins    O
,    O
called    O
cell    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecules    I-Glycoprotein114888310
.    O

Cadherins    B-Glycoprotein114888310
(    O
named    O
for    O
"    O
calcium    O
-    O
dependent    O
adhesion    O
"    O
)    O
are    O
a    O
type    O
of    O
cell    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
(CAM)    I-Glycoprotein114888310
that    O
is    O
important    O
in    O
cell    O
adhesion    O
by    O
forming    O
adherens    O
junctions    O
to    O
bind    O
cells    O
with    O
each    O
other    O
.    O

It    O
also    O
functions    O
as    O
an    O
adhesion    B-Glycoprotein114888310
protein    I-Glycoprotein114888310
,    O
involved    O
in    O
cell    O
attachment    O
and    O
wound    O
healing    O
.    O

Another    O
of    O
Ashwood    O
's    O
studies    O
,    O
published    O
in    O
2011    O
,    O
was    O
,    O
along    O
with    O
two    O
other    O
MIND    O
Institute    O
studies    O
,    O
named    O
among    O
the    O
top    O
10    O
autism    O
research    O
achievements    O
of    O
that    O
year    O
by    O
Autism    O
Speaks    O
,    O
and    O
yet    O
another    O
study    O
provided    O
evidence    O
that    O
levels    O
of    O
cellular    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
in    O
the    O
blood    O
are    O
lower    O
in    O
patients    O
with    O
autism    O
than    O
in    O
controls    O
.    O

At    O
the    O
hemidesmosome    O
,    O
plectin    O
and    O
BPAG1    O
associate    O
with    O
transmembrane    O
proteins    O
α6β4    O
integrin    B-Glycoprotein114888310
,    O
a    O
type    O
of    O
cell    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
,    O
and    O
BP180/collagen    O
XVII    O
,    O
linking    O
K5/K14    O
filaments    O
in    O
the    O
basal    O
cells    O
to    O
the    O
basal    O
lamina    O
.    O

VCAM-1    O
functions    O
as    O
a    O
cell    B-Glycoprotein114888310
adhesion    I-Glycoprotein114888310
molecule    I-Glycoprotein114888310
.    O

Polyclonal    B-Glycoprotein114888310
hypergammaglobulinaemia    O

The    O
nontoxic    O
recombinant    O
protein    O
can    O
induce    O
a    O
level    O
of    O
circulating    O
antibodies    O
sufficient    O
to    O
neutralize    O
the    O
toxic    O
effects    O
of    O
Tityus    O
toxins    O
and    O
is    O
a    O
good    O
candidate    O
for    O
use    O
in    O
the    O
production    O
of    O
a    O
new    O
generation    O
of    O
neutralizing    O
polyclonal    B-Glycoprotein114888310
antibodies    I-Glycoprotein114888310
for    O
clinical    O
use    O
.    O

Synthetic    O
antibodies    O
can    O
be    O
used    O
in    O
all    O
applications    O
where    O
traditional    O
monoclonal    O
or    O
polyclonal    B-Glycoprotein114888310
antibodies    I-Glycoprotein114888310
are    O
used    O
and    O
offer    O
many    O
inherent    O
advantages    O
over    O
animal    O
-    O
derived    O
antibodies    O
,    O
including    O
comparatively    O
low    O
production    O
costs    O
,    O
reagent    O
reproducibility    O
and    O
increased    O
affinity    O
,    O
specificity    O
and    O
stability    O
across    O
a    O
range    O
of    O
experimental    O
conditions    O
.    O

Blood    O
isolated    O
from    O
these    O
animals    O
contains    O
"    O
polyclonal    B-Glycoprotein114888310
antibodies    I-Glycoprotein114888310
"—    O
multiple    O
antibodies    O
that    O
bind    O
to    O
the    O
same    O
antigen    O
—    O
in    O
the    O
serum    O
,    O
which    O
can    O
now    O
be    O
called    O
antiserum    O
.    O

p53    O
-    O
package    O
-    O
palindromic    O
sequence    O
-    O
Parkinson    O
's    O
disease    O
-    O
pBR322    O
-    O
PCR    O
-    O
pedigree    O
-    O
peptide    O
-    O
peptide    O
bond    O
-    O
phage    O
-    O
phagemid    O
-    O
phenotype    O
-    O
phosphatase    O
,    O
alkaline    O
-    O
phosphodiester    O
bond    O
-    O
phosphorylation    O
-    O
physical    O
map    O
-    O
plasmid    O
-    O
point    O
mutation    O
-    O
poly    O
-    O
A    O
track    O
-    O
polyA    O
tail    O
-    O
polyacrylamide    O
gel    O
-    O
polyclonal    B-Glycoprotein114888310
antibodies    I-Glycoprotein114888310
-    O
polydactyly    O
-    O
polymerase    O
-    O
polymerase    O
chain    O
reaction    O
-    O
polymorphism    O
-    O
polynucleotide    O
kinase    O
-    O
polypeptide    O
-    O
positional    O
cloning    O
-    O
post    O
-    O
transcriptional    O
regulation    O
-    O
post    O
-    O
translational    O
modification    O
-    O
post    O
-    O
translational    O
processing    O
-    O
post    O
-    O
translational    O
regulation    O
-    O
PRE    O
-    O
Precursor    O
mRNA    O
-    O
primary    O
immunodeficiency    O
-    O
primary    O
transcript    O
-    O
primer    O
-    O
primer    O
extension    O
-    O
probe    O
-    O
processivity    O
-    O
promoter    O
-    O
pronucleus    O
-    O
prostate    O
cancer    O
-    O
protease    O
-    O
protein    O
-    O
Protein    O
translocation    O
-    O
proto    O
-    O
oncogene    O
-    O
pseudogene    O
-    O
pseudoknot    O
-    O
pseudorevertant    O
-    O
pulse    O
sequence    O
database    O
-    O
pulsed    O
field    O
gel    O
electrophoresis    O
-    O
purine    O
-    O
pyrimidine    O

Polyclonal    B-Glycoprotein114888310
antibodies    I-Glycoprotein114888310
,    O
esp    O
.    O
section    O
on    O
Titermax    O

MRC2    B-Glycoprotein114888310

In    O
addition    O
,    O
the    O
mannose    O
-    O
type    O
glycan    B-Glycoprotein114888310
of    O
ricin    O
are    O
able    O
to    O
bind    O
cells    O
that    O
express    O
mannose    B-Glycoprotein114888310
receptor    I-Glycoprotein114888310
.    O

Extensins    B-Glycoprotein114888310
are    O
a    O
family    O
of    O
flexuous    O
,    O
rodlike    O
,    O
hydroxyproline    O
-    O
rich    O
glycoproteins    O
(    O
HRGPs    O
)    O
of    O
the    O
plant    O
cell    O
wall    O
,    O
discovered    O
by    O
Derek    O
T.A.    O
Lamport    O
at    O
the    O
University    O
of    O
Cambridge    O
.    O

Bovine    B-Glycoprotein114888310
submaxillary    I-Glycoprotein114888310
mucin    I-Glycoprotein114888310
(    O
BSM    O
)    O
coatings    O
are    O
a    O
surface    O
treatment    O
provided    O
to    O
biomaterials    O
intended    O
to    O
reduce    O
the    O
growth    O
of    O
disadvantageous    O
bacteria    O
and    O
fungi    O
such    O
as    O
"    O
S.    O
epidermidis    O
"    O
,    O
"    O
E.    O
coli    O
"    O
,    O
and    O
"    O
Candida    O
albicans    O
"    O
.    O

StemGen    O
(    O
Ancestim    O
)    O
(    O
for    O
use    O
in    O
combination    O
with    O
filgrastim    B-Glycoprotein114888310
for    O
mobilizing    O
peripheral    O
hematopoietic    O
stem    O
cells    O
)    O
(    O
sold    O
to    O
Biovitrium    O
,    O
now    O
Swedish    O
Orphan    O
Biovitrum    O
,    O
in    O
December    O
2008    O
)    O

filgrastim    B-Glycoprotein114888310
(    O
INN    O
)    O

Granulocyte    O
colony    O
-    O
stimulating    O
factor    O
(    O
G    O
-    O
CSF    O
)    O
:    O
filgrastim    B-Glycoprotein114888310
sold    O
as    O
Neupogen    O
from    O
Amgen    O
;    O
pegfilgrastim    O
sold    O
as    O
Neulasta    O

In    O
the    O
five    O
days    O
leading    O
up    O
to    O
the    O
procedure    O
,    O
Worrilow    O
underwent    O
a    O
series    O
of    O
injections    O
of    O
a    O
drug    O
called    O
filgrastim    B-Glycoprotein114888310
to    O
increase    O
the    O
number    O
of    O
blood    O
-    O
forming    O
cells    O
in    O
his    O
bloodstream    O
.    O

Filgrastim    B-Glycoprotein114888310

Ancestim    O
is    O
supplied    O
as    O
a    O
sterile    O
,    O
white    O
,    O
preservative    O
-    O
free    O
,    O
lyophilised    O
powder    O
for    O
reconstitution    O
and    O
administration    O
as    O
a    O
subcutaneous    O
(    O
SC    O
)    O
injection    O
and    O
is    O
indicated    O
for    O
use    O
in    O
combination    O
with    O
filgrastim    B-Glycoprotein114888310
for    O
mobilizing    O
peripheral    O
hematopoietic    O
stem    O
cells    O
for    O
later    O
transplanation    O
in    O
certain    O
cancer    O
patients    O
.    O

NUP205    O
,    O
NUP210    B-Glycoprotein114888310
,    O
NUP214    O

"    O
Griffonia    O
simplicifolia    O
"    O
also    O
has    O
a    O
legume    B-Glycoprotein114888310
lectin    I-Glycoprotein114888310
called    O
GS    O
Isolectin    O
B4    O
,    O
which    O
binds    O
to    O
alpha    O
-    O
D    O
-    O
galactosyl    O
residues    O
of    O
polysaccharides    O
and    O
glycoproteins    O
.    O

Smaller    O
doses    O
may    O
be    O
used    O
to    O
induce    O
salivation    O
in    O
order    O
to    O
collect    O
samples    O
of    O
saliva    O
,    O
for    O
instance    O
,    O
to    O
obtain    O
information    O
about    O
IgA    B-Glycoprotein114888310
antibodies    O
.    O

Selective    O
deficiency    O
of    O
immunoglobulin    O
A    O
(    O
IgA    B-Glycoprotein114888310
)    O

Systemic    O
vasculitis    O
due    O
to    O
tissue    O
deposition    O
of    O
IgA    B-Glycoprotein114888310
-    O
containing    O
immune    O
complexes    O
.    O

Those    O
who    O
produced    O
envelope    O
specific    O
IgA    B-Glycoprotein114888310
were    O
54%    O
more    O
likely    O
to    O
become    O
infected    O
,    O
but    O
no    O
more    O
susceptible    O
than    O
trial    O
subjects    O
receiving    O
the    O
placebo    O
.    O

For    O
example    O
,    O
those    O
that    O
bind    O
the    O
most    O
common    O
class    O
of    O
antibody    O
,    O
IgG    B-Glycoprotein114888310
,    O
are    O
called    O
"    O
Fc    O
-    O
gamma    O
receptors    O
"    O
(    O
FcγR    O
)    O
,    O
those    O
that    O
bind    O
IgA    B-Glycoprotein114888310
are    O
called    O
"    O
Fc    O
-    O
alpha    O
receptors    O
"    O
(    O
FcαR    O
)    O
and    O
those    O
that    O
bind    O
IgE    B-Glycoprotein114888310
are    O
called    O
"    O
Fc    O
-    O
epsilon    O
receptors    O
"    O
(    O
FcεR    O
)    O
.    O

Most    O
Immunoglobulin    B-Glycoprotein114888310
A    I-Glycoprotein114888310
produced    O
by    O
tonsillar    O
B    O
cells    O
in    O
vitro    O
appears    O
to    O
be    O
7S    O
monomers    O
,    O
although    O
a    O
significant    O
proportion    O
may    O
be    O
l0S    O
dimeric    O
IgA.    O

Diets    O
lacking    O
sufficient    O
protein    O
are    O
associated    O
with    O
impaired    O
cell    O
-    O
mediated    O
immunity    O
,    O
complement    O
activity    O
,    O
phagocyte    O
function    O
,    O
IgA    B-Glycoprotein114888310
antibody    O
concentrations    O
,    O
and    O
cytokine    O
production    O
.    O

It    O
has    O
been    O
studied    O
for    O
capturing    O
O    O
-    O
glycoproteins    O
such    O
as    O
mucins    B-Glycoprotein114888310
and    O
IgA    B-Glycoprotein114888310
,    O
for    O
potential    O
applications    O
in    O
human    O
immunology    O
.    O

|    O
IgA    B-Glycoprotein114888310

Passive    O
immunity    O
is    O
also    O
provided    O
through    O
colostrum    O
and    O
breast    O
milk    O
,    O
which    O
contain    O
IgA    B-Glycoprotein114888310
antibodies    O
that    O
are    O
transferred    O
to    O
the    O
gut    O
of    O
the    O
infant    O
,    O
providing    O
local    O
protection    O
against    O
disease    O
causing    O
bacteria    O
and    O
viruses    O
until    O
the    O
newborn    O
can    O
synthesize    O
its    O
own    O
antibodies    O
.    O

Ovine    O
uterine    O
serpin    O
also    O
binds    O
to    O
activin    O
,    O
IgM    B-Glycoprotein114888310
and    O
IgA    B-Glycoprotein114888310

Immunoglobulin    B-Glycoprotein114888310
A    I-Glycoprotein114888310
:    O
0.24(0.061    O
)    O

It    O
is    O
characterised    O
by    O
deposits    O
of    O
IgA    B-Glycoprotein114888310
in    O
the    O
space    O
between    O
glomerular    O
capillaries    O
.    O

These    O
include    O
deficiency    O
in    O
CD27    O
+    O
B    O
memory    O
cells    O
,    O
overrepresentation    O
of    O
CD10    O
+    O
transitional    O
B    O
cells    O
,    O
expanded    O
effector    O
(    O
CCR7-    O
)    O
T    O
cells    O
,    O
expanded    O
CD57    O
+    O
senescent    O
CD8    O
+    O
T    O
cells    O
,    O
and    O
alterations    O
in    O
serum    O
immunoglobulin    O
concentrations    O
,    O
most    O
with    O
normal    O
to    O
elevated    O
concentrations    O
of    O
IgM    B-Glycoprotein114888310
and    O
reduced    O
concentrations    O
of    O
IgA    B-Glycoprotein114888310

CCL28    O
has    O
also    O
been    O
implicated    O
in    O
the    O
migration    O
of    O
IgA    B-Glycoprotein114888310
-    O
expressing    O
cells    O
to    O
the    O
mammary    O
gland    O
,    O
salivary    O
gland    O
,    O
intestine    O
and    O
other    O
mucosal    O
tissues    O
.    O

While    O
most    O
of    O
these    O
early    O
studies    O
focused    O
on    O
IgM    O
and    O
IgG    O
,    O
other    O
immunoglobulin    O
isotypes    O
were    O
identified    O
in    O
the    O
1960s    O
:    O
Thomas    O
Tomasi    O
discovered    O
secretory    O
antibody    O
(    O
IgA    B-Glycoprotein114888310
)    O
;    O
David    O
S.    O
Rowe    O
and    O
John    O
L.    O
Fahey    O
discovered    O
IgD    O
;    O
and    O
Kimishige    O
Ishizaka    O
and    O
Teruko    O
Ishizaka    O
discovered    O
IgE    B-Glycoprotein114888310
and    O
showed    O
it    O
was    O
a    O
class    O
of    O
antibodies    O
involved    O
in    O
allergic    O
reactions    O
.    O

Finally    O
,    O
increased    O
biliary    O
pressure    O
decreases    O
production    O
of    O
IgA    B-Glycoprotein114888310
immunoglobulins    O
in    O
the    O
bile    O
.    O

For    O
example    O
the    O
total    O
levels    O
of    O
antibodies    O
isotypes    O
or    O
classes    O
:    O
Immunoglobulin    B-Glycoprotein114888310
M    I-Glycoprotein114888310
,    O
Immunoglobulin    B-Glycoprotein114888310
G    I-Glycoprotein114888310
,    O
and    O
Immunoglobulin    B-Glycoprotein114888310
A    I-Glycoprotein114888310
It    O
is    O
important    O
in    O
quantification    O
of    O
free    O
light    O
chains    O
in    O
diseases    O
such    O
as    O
multiple    O
myeloma    O
.    O

The    O
IgG    B-Glycoprotein114888310
antibody    O
is    O
similar    O
to    O
AGA    O
IgA    B-Glycoprotein114888310
,    O
but    O
is    O
found    O
at    O
higher    O
levels    O
in    O
patients    O
with    O
the    O
IgA    O
-    O
less    O
phenotype    O
.    O

Fibronectin    B-Glycoprotein114888310
-    O
like    O
(    O
FN    O
-    O
like    O
)    O
repeats    O
of    O
Tenascin    B-Glycoprotein114888310
-    O
C    O
and    O
Tenascin    B-Glycoprotein114888310
-    O
R    O
bind    O
with    O
beta    O
2    O
in    O
contrast    O
to    O
the    O
Epidermal    O
growth    O
factor    O
-    O
like    O
(    O
EGF    O
-    O
like    O
)    O
repeats    O
that    O
repel    O
beta2    O
.    O

A    O
member    O
of    O
the    O
tenascin    B-Glycoprotein114888310
family    O
,    O
tenascin    B-Glycoprotein114888310
X    I-Glycoprotein114888310
(    O
TN    O
-    O
X    O
)    O
also    O
known    O
as    O
hexabrachion-like    B-Glycoprotein114888310
protein    I-Glycoprotein114888310
is    O
a    O
glycoprotein    O
that    O
is    O
expressed    O
in    O
connective    O
tissues    O
including    O
skin    O
,    O
joints    O
and    O
muscles    O
.    O

The    O
same    O
pattern    O
can    O
be    O
seen    O
in    O
the    O
deposition    O
of    O
tenascin    B-Glycoprotein114888310
.    O

androgen    B-Glycoprotein114888310
binding    I-Glycoprotein114888310
protein    I-Glycoprotein114888310
(    O
also    O
called    O
testosterone    O
binding    O
globulin    O
)    O
—    O
increases    O
testosterone    O
concentration    O
in    O
the    O
seminiferous    O
tubules    O
to    O
stimulate    O
spermatogenesis    O

Androgen-binding    B-Glycoprotein114888310
protein    I-Glycoprotein114888310

Mucin    B-Glycoprotein114888310
2    I-Glycoprotein114888310
(    O
MUC2    O
)    O

The    O
extremely    O
strong    O
complexation    O
between    O
avidin    B-Glycoprotein114888310
and    O
biotin    O
is    O
instrumental    O
in    O
blood    O
clotting    O
,    O
and    O
has    O
been    O
used    O
as    O
the    O
recognition    O
motif    O
to    O
construct    O
synthetic    O
systems    O
.    O

acrylamide    O
gels    O
-    O
adenine    O
-    O
adenosine    O
deaminase    O
deficiency    O
-    O
adenovirus    O
-    O
agarose    O
gel    O
electrophoresis    O
-    O
agarose    O
gel    O
-    O
Alagille    O
syndrome    O
-    O
alkaline    O
lysis    O
-    O
allele    O
-    O
amino    O
acids    O
-    O
amino    O
terminus    O
-    O
amp    O
resistance    O
-    O
amplification    O
-    O
amplicon    O
-    O
anchor    O
sequence    O
-    O
animal    O
model    O
-    O
anneal    O
-    O
anti    O
-    O
sense    O
strand    O
-    O
antibiotic    O
resistance    O
-    O
antibody    O
-    O
antisense    O
-    O
antisense    O
strand    O
-    O
AP-1    O
site    O
-    O
apoptosis    O
-    O
assembled    O
epitope    O
-    O
ataxia    O
-    O
telangiectasia    O
-    O
ATG    O
or    O
AUG    O
-    O
autoimmune    O
lymphoproliferative    O
syndrome    O
-    O
autoradiography    O
-    O
autosomal    O
dominant    O
-    O
autosome    O
-    O
avidin    B-Glycoprotein114888310
-    O

In    O
addition    O
to    O
the    O
protein    O
crystallography    O
and    O
biochemistry    O
of    O
ribonuclease    O
S    O
,    O
these    O
included    O
solvent    O
accessibility    O
and    O
internal    O
packing    O
of    O
proteins    O
,    O
the    O
first    O
side    O
-    O
chain    O
rotamer    O
library    O
,    O
high    O
-    O
pressure    O
crystallography    O
,    O
new    O
types    O
of    O
chemical    O
tags    O
such    O
as    O
biotin    O
/    O
avidin    B-Glycoprotein114888310
,    O
the    O
nuclear    O
magnetic    O
resonance    O
(    O
NMR    O
)    O
chemical    O
shift    O
index    O
,    O
and    O
structural    O
and    O
biophysical    O
characterization    O
of    O
the    O
effects    O
of    O
mutations    O
.    O

In    O
the    O
1970s    O
,    O
with    O
a    O
succession    O
of    O
students    O
and    O
postdocs    O
,    O
the    O
lab    O
developed    O
a    O
series    O
of    O
chemical    O
,    O
photochemical    O
,    O
and    O
cross    O
-    O
link    O
labels    O
for    O
determining    O
the    O
position    O
and    O
relationships    O
of    O
proteins    O
in    O
biological    O
membranes    O
,    O
including    O
glutaraldehyde    O
and    O
what    O
was    O
one    O
of    O
the    O
two    O
first    O
general    O
uses    O
of    O
the    O
exceptionally    O
tight    O
interaction    O
of    O
biotin    O
with    O
avidin    B-Glycoprotein114888310
,    O
anchored    O
to    O
ferritin    O
for    O
use    O
in    O
electron    O
microscopy    O
.    O

A    O
lectin    O
(    O
BanLec    B-Glycoprotein114888310
)    O
from    O
bananas    O
inhibits    O
HIV-1    O
in    O
vitro    O
.    O

is    O
a    O
component    O
of    O
the    O
GPIb-V-IX    B-Glycoprotein114888310
complex    I-Glycoprotein114888310
on    O
platelets    O
.    O

This    O
toxin    O
belongs    O
to    O
the    O
cysteine-rich    B-Glycoprotein114888310
secretory    I-Glycoprotein114888310
protein    I-Glycoprotein114888310
(    O
CRISP    O
)    O
family    O
.    O

The    O
function    O
of    O
"    O
Na    O
"-    O
ASP-2    O
is    O
not    O
currently    O
known    O
(    O
though    O
it    O
may    O
function    O
as    O
a    O
chemotaxin    O
mimic    O
)    O
,    O
but    O
it    O
is    O
a    O
cysteine-rich    B-Glycoprotein114888310
secretory    I-Glycoprotein114888310
protein    I-Glycoprotein114888310
that    O
is    O
released    O
during    O
parasite    O
entry    O
into    O
the    O
host    O
.    O

The    O
name    O
"    O
biglycan    O
"    O
was    O
proposed    O
in    O
an    O
article    O
by    O
Fisher    O
,    O
Termine    O
and    O
Young    O
in    O
an    O
article    O
in    O
the    O
Journal    O
of    O
Biological    O
Chemistry    O
in    O
1989    O
because    O
the    O
proteoglycan    B-Glycoprotein114888310
contained    O
two    O
GAG    O
chains    O
;    O
formerly    O
it    O
was    O
known    O
as    O
proteoglycan    O
-    O
I    O
(    O
PG    O
-    O
I    O
)    O
.    O

Aggrecanases    O
act    O
on    O
large    O
proteoglycan    B-Glycoprotein114888310
known    O
as    O
aggrecan    B-Glycoprotein114888310
,    O
which    O
are    O
components    O
of    O
connective    O
tissues    O
such    O
as    O
cartilage    O
.    O

His    O
research    O
has    O
focuses    O
on    O
understanding    O
the    O
structure    O
,    O
biosynthesis    O
and    O
biological    O
roles    O
of    O
proteoglycans    B-Glycoprotein114888310
in    O
mammalian    O
cells    O
and    O
model    O
organisms    O
.    O

The    O
nucleus    O
pulposus    O
consists    O
of    O
large    O
vacuolated    O
notochord    O
cells    O
,    O
small    O
chondrocyte    O
-    O
like    O
cells    O
,    O
collagen    O
fibrils    O
,    O
and    O
aggrecan    B-Glycoprotein114888310
,    O
a    O
proteoglycan    B-Glycoprotein114888310
that    O
aggregates    O
by    O
binding    O
to    O
hyaluronan    O
.    O

Versican    B-Glycoprotein114888310
is    O
a    O
large    O
extracellular    O
matrix    O
proteoglycan    B-Glycoprotein114888310
that    O
is    O
present    O
in    O
a    O
variety    O
of    O
human    O
tissues    O
.    O

TGFB    O
is    O
a    O
regulatory    O
molecule    O
involved    O
in    O
proteoglycan    B-Glycoprotein114888310
production    O
.    O

Oligodendrocyte    O
precursor    O
cells    O
and    O
C6    O
glioma    O
cells    O
produce    O
metalloproteinase    O
,    O
which    O
is    O
shown    O
to    O
inactivate    O
a    O
type    O
of    O
inhibitory    O
proteoglycan    B-Glycoprotein114888310
secreted    O
by    O
Schwann    O
cells    O
.    O

Often    O
,    O
proteins    O
present    O
in    O
the    O
extracellular    O
space    O
are    O
stored    O
outside    O
the    O
cells    O
by    O
attaching    O
to    O
various    O
extracellular    O
matrix    O
components    O
(    O
Collagens    O
,    O
Proteoglycan    B-Glycoprotein114888310
,    O
etc    O
.    O
)    O
.    O

Homocysteine    O
degrades    O
and    O
inhibits    O
the    O
formation    O
of    O
the    O
three    O
main    O
structural    O
components    O
of    O
arteries    O
:    O
collagen    O
,    O
elastin    O
and    O
proteoglycans    B-Glycoprotein114888310
.    O

Activation    O
of    O
mast    O
cells    O
following    O
engagement    O
of    O
FcεRI    O
results    O
in    O
a    O
process    O
called    O
degranulation    O
,    O
whereby    O
the    O
mast    O
cell    O
releases    O
preformed    O
molecules    O
from    O
its    O
cytoplasmic    O
granules    O
;    O
these    O
are    O
a    O
mixture    O
of    O
compounds    O
including    O
histamine    O
,    O
proteoglycan    B-Glycoprotein114888310
,    O
and    O
serine    O
proteases    O
.    O

Lacritin    O
cell    O
targeting    O
is    O
dependent    O
on    O
the    O
cell    O
surface    O
heparan    O
sulfate    O
proteoglycan    B-Glycoprotein114888310
syndecan-1    O
(    O
SDC1    O
)    O
.    O

Histologically    O
,    O
keloids    O
are    O
fibrotic    O
tumors    O
characterized    O
by    O
a    O
collection    O
of    O
atypical    O
fibroblasts    O
with    O
excessive    O
deposition    O
of    O
extracellular    O
matrix    O
components    O
,    O
especially    O
collagen    O
,    O
fibronectin    B-Glycoprotein114888310
,    O
elastin    O
,    O
and    O
proteoglycan    B-Glycoprotein114888310
.    O

FACIT    O
collagen    O
(    O
Fibril    O
Associated    O
Collagens    O
with    O
Interrupted    O
Triple    O
helices    O
)    O
is    O
a    O
type    O
of    O
collagen    O
which    O
is    O
also    O
a    O
proteoglycan    B-Glycoprotein114888310
.    O

Glycoproteins    O
,    O
proteoglycan    B-Glycoprotein114888310
and    O
glycolipids    O
are    O
the    O
most    O
abundant    O
glycoconjugates    O
found    O
in    O
mammalian    O
cells    O
.    O

Nonmineralized    O
organic    O
component    O
(    O
i.e.    O
type    O
1    O
collagen    O
)    O
,    O
mineralized    O
inorganic    O
component    O
(    O
i.e.    O
hydroxyapatite    O
)    O
,    O
and    O
many    O
other    O
noncollagenous    O
matrix    O
proteins    O
(    O
i.e.    O
glycoproteins    O
and    O
proteoglycan    B-Glycoprotein114888310
)    O
make    O
up    O
the    O
nanocomposite    O
structure    O
of    O
the    O
bone    O
ECM    O
.    O

In    O
the    O
case    O
of    O
Alzheimer    O
's    O
disease    O
,    O
inflammatory    O
processes    O
lead    O
to    O
neuron    O
death    O
by    O
inhibiting    O
growth    O
at    O
axons    O
and    O
activating    O
astrocytes    O
that    O
produce    O
proteoglycans    B-Glycoprotein114888310
.    O

Chondroitinase    O
treatment    O
is    O
a    O
treatment    O
of    O
proteoglycan    B-Glycoprotein114888310
,    O
a    O
protein    O
in    O
the    O
fluid    O
among    O
cells    O
where    O
(    O
among    O
other    O
things    O
)    O
they    O
affect    O
neural    O
activity    O
(    O
communication    O
,    O
plasticity    O
)    O
.    O

Proteoglycan    B-Glycoprotein114888310

Cartilage    O
is    O
composed    O
of    O
cells    O
embedded    O
in    O
an    O
extracellular    O
matrix    O
of    O
collagen    O
fibers    O
and    O
proteoglycans    B-Glycoprotein114888310
.    O

The    O
end    O
-    O
product    O
of    O
this    O
pathway    O
is    O
UDP    O
-    O
GlcNAc    O
,    O
which    O
is    O
then    O
used    O
for    O
making    O
glycosaminoglycans    O
,    O
proteoglycans    B-Glycoprotein114888310
,    O
and    O
glycolipids    O
.    O

The    O
elastic    O
matrix    O
forms    O
lamellae    O
,    O
consisting    O
of    O
elastic    O
fibers    O
,    O
collagens    O
(    O
predominately    O
type    O
III    O
)    O
,    O
proteoglycan    B-Glycoprotein114888310
,    O
and    O
glycoaminoglycans    O
.    O

Its    O
dry    O
weight    O
is    O
composed    O
of    O
collagen    O
(    O
50%    O
)    O
,    O
non    O
-    O
collagenous    O
glycoproteins    O
(    O
25%    O
)    O
and    O
proteoglycan    B-Glycoprotein114888310
(    O
25%    O
)    O
.    O

His    O
dream    O
was    O
to    O
"    O
transfer    O
rice    O
immunity    O
to    O
cereals    O
such    O
as    O
wheat    O
,    O
maize    O
,    O
sorghum    O
and    O
barley    O
,    O
and    O
transfer    O
bread    O
-    O
wheat    O
proteins    O
(    O
gliadin    B-Glycoprotein114888310
and    O
glutenin    B-Glycoprotein114888310
)    O
to    O
other    O
cereals    O
,    O
especially    O
rice    O
and    O
maize    O
"    O
.    O

"    O
Triticum    O
"    O
(    O
true    O
wheats    O
)    O
–    O
gliadin    B-Glycoprotein114888310

Like    O
all    O
types    O
of    O
rice    O
,    O
glutinous    O
rice    O
does    O
not    O
contain    O
dietary    O
gluten    O
(    O
i.e.    O
does    O
not    O
contain    O
glutenin    B-Glycoprotein114888310
and    O
gliadin    B-Glycoprotein114888310
)    O
,    O
and    O
should    O
be    O
safe    O
for    O
gluten    O
-    O
free    O
diets    O
.    O

The    O
cause    O
of    O
coeliac    O
disease    O
was    O
eventually    O
discovered    O
to    O
be    O
an    O
autoimmune    O
reaction    O
to    O
gliadin    B-Glycoprotein114888310
,    O
a    O
gluten    O
protein    O
found    O
in    O
wheat    O
,    O
plus    O
Secalin    O
in    O
rye    O
and    O
Hordien    O
in    O
barley    O
.    O

that    O
gliadin    B-Glycoprotein114888310
can    O
cross    O
-    O
link    O
to    O
gangliosides    O
in    O
a    O
transglutaminase    O
independent    O
manner    O
,    O
indicating    O
that    O
gliadin    O
specific    O
T    O
-    O
cell    O
could    O
present    O
these    O
antigens    O
to    O
the    O
immune    O
system    O
.    O

Anti    O
-    O
transglutaminase    O
antibodies    O
are    O
found    O
in    O
celiac    O
disease    O
and    O
may    O
play    O
a    O
role    O
in    O
the    O
small    O
bowel    O
damage    O
in    O
response    O
to    O
dietary    O
gliadin    B-Glycoprotein114888310
that    O
characterises    O
this    O
condition    O
.    O

Anti    O
-    O
gliadin    O
antibodies    O
are    O
produced    O
in    O
response    O
to    O
gliadin    B-Glycoprotein114888310
,    O
a    O
prolamin    B-Glycoprotein114888310
found    O
in    O
wheat    O
.    O

However    O
,    O
a    O
follow    O
-    O
up    O
study    O
showed    O
that    O
the    O
antibody    O
used    O
previously    O
to    O
identify    O
OMgp    O
at    O
nodes    O
crossreacts    O
with    O
another    O
node    O
-    O
enriched    O
component    O
versican    B-Glycoprotein114888310
V2    O
and    O
that    O
OMgp    O
is    O
not    O
required    O
for    O
the    O
integrity    O
of    O
nodes    O
and    O
paranodes    O
,    O
arguing    O
against    O
the    O
previously    O
reported    O
localization    O
and    O
proposed    O
functions    O
of    O
OMgp    O
at    O
nodes    O
.    O

the    O
hyalectans    O
(    O
a    O
family    O
of    O
proteoglycan    B-Glycoprotein114888310
)    O
:    O
aggrecan    B-Glycoprotein114888310
,    O
brevican    B-Glycoprotein114888310
,    O
neurocan    B-Glycoprotein114888310
and    O
versican    B-Glycoprotein114888310
,    O
which    O
are    O
expressed    O
in    O
the    O
CNS    O
;    O

Versican    B-Glycoprotein114888310
is    O
a    O
large    O
extracellular    O
matrix    O
proteoglycan    B-Glycoprotein114888310
that    O
is    O
present    O
in    O
a    O
variety    O
of    O
human    O
tissues    O
.    O

The    O
versican    B-Glycoprotein114888310
3’UTR    O
has    O
been    O
shown    O
to    O
regulate    O
expression    O
of    O
the    O
matrix    O
protein    O
fibronectin    B-Glycoprotein114888310
via    O
antagonizing    O
miR-199a    O
function    O
.    O

Rye    O
(    O
"    O
Secalin    B-Glycoprotein114888310
"    O
)    O
has    O
one    O
glutelin    O

It    O
is    O
thought    O
that    O
fukutin    O
modifies    O
the    O
alpha-dystroglycan    B-Glycoprotein114888310
protein    I-Glycoprotein114888310
,    O
which    O
is    O
important    O
in    O
anchoring    O
cells    O
to    O
certain    O
molecules    O
,    O
specifically    O
including    O
some    O
proteins    O
.    O

GNE    O
knockout    O
mice    O
show    O
problems    O
similar    O
to    O
people    O
with    O
IBM    O
and    O
in    O
people    O
with    O
IBM    O
dystroglycan    B-Glycoprotein114888310
has    O
been    O
found    O
to    O
lack    O
sialic    O
acid    O
.    O

Globular    O
domains    O
(    O
G    O
-    O
Domain    O
)    O
of    O
the    O
α    O
chain    O
are    O
the    O
regions    O
on    O
laminin-111    O
that    O
allow    O
the    O
binding    O
of    O
integrin    B-Glycoprotein114888310
,    O
glycoproteins    O
,    O
sulfated    O
glycolipids    O
and    O
dystroglycan    B-Glycoprotein114888310
.    O

Dystroglycan    B-Glycoprotein114888310
,    O

DAG1    B-Glycoprotein114888310
,    O

Fasciclin    B-Glycoprotein114888310
2    I-Glycoprotein114888310

Genzyme    O
–    O
antithrombin    B-Glycoprotein114888310
III    I-Glycoprotein114888310
in    O
goat    O
milk    O

To    O
rule    O
out    O
other    O
causes    O
for    O
hypercoagulation    O
,    O
it    O
may    O
be    O
appropriate    O
to    O
check    O
the    O
antithrombin    B-Glycoprotein114888310
,    O
protein    B-Glycoprotein114888310
C    I-Glycoprotein114888310
,    O
protein    B-Glycoprotein114888310
S    I-Glycoprotein114888310
,    O
factor    O
V    O
Leiden    O
,    O
and    O
prothrombin    O
G20210A.    O

Direct    O
factor    O
Xa    O
inhibitors    O
(    O
'    O
'    O
'    O
xabans    O
)    O
are    O
a    O
class    O
of    O
anticoagulant    O
drugs    O
which    O
act    O
directly    O
upon    O
Factor    O
X    O
in    O
the    O
coagulation    O
cascade    O
,    O
without    O
using    O
antithrombin    B-Glycoprotein114888310
as    O
a    O
mediator    O
.    O

Factor    O
Xa    O
can    O
help    O
to    O
prevent    O
the    O
inactivation    O
of    O
Factor    O
Va    O
by    O
protecting    O
Factor    O
Va    O
from    O
activated    O
protein    O
C.    O
It    O
is    O
likely    O
that    O
Factor    O
Xa    O
and    O
activated    O
protein    O
C    O
compete    O
for    O
similar    O
sites    O
on    O
Factor    O
Va.    O
Factor    O
Xa    O
is    O
inhibited    O
by    O
the    O
antithrombin    B-Glycoprotein114888310
III    O
/    O
heparin    O
system    O
,    O
which    O
also    O
acts    O
to    O
inhibit    O
thrombin    O
.    O

specific    O
factor    O
inhibitor    O
assays    O
,    O
like    O
Protein    B-Glycoprotein114888310
C    I-Glycoprotein114888310
,    O
TFPI    O
,    O
Antithrombin    B-Glycoprotein114888310
etc    O
.    O

Unlike    O
thrombin    O
,    O
reptilase    O
is    O
resistant    O
to    O
inhibition    O
by    O
antithrombin    B-Glycoprotein114888310
III    I-Glycoprotein114888310
.    O

"    O
Antithrombin    B-Glycoprotein114888310
"    O
is    O
an    O
anticoagulant    O
protein    O
and    O
is    O
important    O
in    O
preventing    O
blood    O
clotting    O
.    O

|rowspan=2|    O
Antithrombin    B-Glycoprotein114888310

Thrombophilia    O
,    O
a    O
tendency    O
to    O
develop    O
blood    O
clots    O
due    O
to    O
abnormalities    O
in    O
coagulation    O
,    O
e.g.    O
factor    O
V    O
Leiden    O
,    O
deficiency    O
of    O
protein    B-Glycoprotein114888310
C    I-Glycoprotein114888310
,    O
protein    B-Glycoprotein114888310
S    I-Glycoprotein114888310
or    O
antithrombin    B-Glycoprotein114888310
,    O
or    O
related    O
problems    O

The    O
principal    O
inhibitor    O
of    O
thrombin    O
in    O
normal    O
blood    O
circulation    O
is    O
antithrombin    B-Glycoprotein114888310
.    O

Sex    B-Glycoprotein114888310
hormone-binding    I-Glycoprotein114888310
globulin    I-Glycoprotein114888310
levels    O
were    O
mildly    O
elevated    O
(    O
6.0–10.0    O
nmol    O
/    O
L    O
)    O
,    O
while    O
thyroxine    O
-    O
binding    O
globulin    O
,    O
corticosteroid-binding    B-Glycoprotein114888310
globulin    I-Glycoprotein114888310
,    O
and    O
prolactin    O
levels    O
were    O
all    O
normal    O
.    O

Sex    B-Glycoprotein114888310
hormone-binding    I-Glycoprotein114888310
globulin    I-Glycoprotein114888310
,    O
corticosteroid-binding    B-Glycoprotein114888310
globulin    I-Glycoprotein114888310
,    O
thyroxine    O
-    O
binding    O
globulin    O
,    O
prolactin    O
,    O
and    O
triglycerides    O
,    O
which    O
are    O
known    O
to    O
be    O
elevated    O
by    O
estrogen    O
,    O
were    O
all    O
within    O
normal    O
ranges    O
in    O
spite    O
of    O
the    O
extremely    O
high    O
levels    O
of    O
estrogen    O
,    O
and    O
inhibin    O
B    O
levels    O
were    O
also    O
normal    O
.    O

It    O
is    O
97.5    O
to    O
98%    O
protein    O
-    O
bound    O
,    O
to    O
albumin    O
,    O
and    O
does    O
not    O
bind    O
to    O
sex    B-Glycoprotein114888310
hormone-binding    I-Glycoprotein114888310
globulin    I-Glycoprotein114888310
or    O
corticosteroid-binding    B-Glycoprotein114888310
globulin    I-Glycoprotein114888310
.    O

Most    O
serum    O
cortisol    O
(    O
all    O
but    O
about    O
4%    O
)    O
is    O
bound    O
to    O
proteins    O
,    O
including    O
corticosteroid    B-Glycoprotein114888310
binding    I-Glycoprotein114888310
globulin    I-Glycoprotein114888310
(    O
CBG    O
)    O
and    O
serum    O
albumin    O
.    O

Endogenous    O
glucocorticoids    O
and    O
some    O
synthetic    O
corticoids    O
have    O
high    O
affinity    O
to    O
the    O
protein    O
transcortin    B-Glycoprotein114888310
(    O
also    O
called    O
corticosteroid    O
-    O
binding    O
globulin    O
)    O
,    O
whereas    O
all    O
of    O
them    O
bind    O
albumin    O
.    O

At    O
least    O
20    O
human    O
mucin    O
genes    O
have    O
been    O
distinguished    O
by    O
cDNA    O
cloning    O
—    O
MUC1    B-Glycoprotein114888310
,    O
MUC2    B-Glycoprotein114888310
,    O
MUC3A    B-Glycoprotein114888310
,    O
MUC3B    O
,    O
MUC4    B-Glycoprotein114888310
,    O
MUC5AC    B-Glycoprotein114888310
,    O
MUC5B    B-Glycoprotein114888310
,    O
MUC6    B-Glycoprotein114888310
,    O
MUC7    B-Glycoprotein114888310
,    O
MUC8    O
,    O
MUC12    O
,    O
MUC13    O
,    O
MUC15    O
,    O
MUC16    B-Glycoprotein114888310
,    O
MUC17    B-Glycoprotein114888310
,    O
MUC19    O
,    O
and    O
MUC20    B-Glycoprotein114888310
.    O

The    O
majority    O
of    O
CMD    O
cases    O
result    O
from    O
a    O
genetic    O
mutation    O
in    O
laminin-α2    O
,    O
a    O
subunit    O
of    O
the    O
laminin    B-Glycoprotein114888310
protein    O
,    O
which    O
serves    O
as    O
an    O
essential    O
mechanical    O
link    O
between    O
basement    O
membrane    O
and    O
muscle    O
fiber    O
in    O
skeletal    O
and    O
heart    O
muscle    O
.    O

Ligands    O
for    O
integrins    O
include    O
fibronectin    B-Glycoprotein114888310
,    O
vitronectin    O
,    O
collagen    O
and    O
laminin    B-Glycoprotein114888310
.    O

Among    O
the    O
ligands    O
of    O
integrins    O
are    O
fibronectin    B-Glycoprotein114888310
,    O
vitronectin    O
,    O
collagen    O
,    O
and    O
laminin    B-Glycoprotein114888310
.    O

The    O
chief    O
components    O
of    O
Matrigel    O
are    O
structural    O
proteins    O
such    O
as    O
laminin    B-Glycoprotein114888310
,    O
entactin    B-Glycoprotein114888310
,    O
collagen    O
and    O
heparan    O
sulfate    O
proteoglycans    O
which    O
present    O
cultured    O
cells    O
with    O
the    O
adhesive    O
peptide    O
sequences    O
that    O
they    O
would    O
encounter    O
in    O
their    O
natural    O
environment    O
.    O

The    O
flamingo    O
cadherins    O
are    O
located    O
at    O
the    O
plasma    O
membrane    O
and    O
have    O
nine    O
cadherin    O
domains    O
,    O
seven    O
epidermal    O
growth    O
factor    O
-    O
like    O
repeats    O
and    O
two    O
laminin    B-Glycoprotein114888310
G    O
-    O
like    O
domains    O
in    O
their    O
ectodomain    O
.    O

Some    O
of    O
these    O
known    O
proteins    O
that    O
induce    O
axon    O
growth    O
of    O
RGCs    O
include    O
laminin    B-Glycoprotein114888310
,    O
Gap-43    O
protein    O
,    O
fatty    O
acid    O
binding    O
protein    O
,    O
calmodulin    O
,    O
Alpha    O
crystallin    O
,    O
IFN    O
-    O
gamma    O
,    O
cyclin    O
-    O
dependent    O
kinase    O
inhibitor    O
protein    O
,    O
beta    O
-    O
hemoglobin    O
,    O
60s    O
-    O
ribosomal    O
protein    O
,    O
GAP    O
-    O
DH    O
,    O
and    O
ADP    O
-    O
ribosylation    O
factor    O
.    O

BAF    O
binds    O
directly    O
to    O
double    O
-    O
stranded    O
DNA    O
,    O
to    O
transcription    O
activators    O
,    O
and    O
to    O
inner    O
nuclear    O
membrane    O
proteins    O
,    O
including    O
lamin    O
A    O
filaments    O
that    O
anchor    O
nuclear    O
pore    O
complexes    O
in    O
place    O
,    O
and    O
nuclear    O
LEM    O
-    O
domain    O
proteins    O
that    O
bind    O
to    O
laminin    B-Glycoprotein114888310
filaments    O
and    O
chromatin    O
.    O

The    O
cells    O
at    O
the    O
exterior    O
then    O
deposit    O
extracellular    O
matrix    O
(    O
ECM    O
)    O
,    O
containing    O
collagen    O
IV    O
and    O
laminin    B-Glycoprotein114888310
,    O
similar    O
to    O
the    O
composition    O
and    O
structure    O
of    O
basement    O
membrane    O
.    O

Netrins    O
share    O
the    O
same    O
terminal    O
structure    O
with    O
vertebrate    O
laminins    B-Glycoprotein114888310
but    O
appear    O
minimally    O
related    O
.    O

During    O
the    O
basement    O
assembly    O
process    O
laminins    B-Glycoprotein114888310
anchor    O
to    O
the    O
cell    O
surface    O
through    O
their    O
G    O
domains    O
after    O
polymerizing    O
through    O
their    O
LN    O
domains    O
.    O

Lander    O
's    O
research    O
is    O
focused    O
on    O
the    O
Systems    O
Biology    O
of    O
Development    O
,    O
and    O
deals    O
with    O
topics    O
in    O
Developmental    O
Biology    O
,    O
Cell    O
Biology    O
,    O
Mathematical    O
&    O
Computational    O
Biology    O
,    O
Glycobiology    O
,    O
Neurobiology    O
,    O
and    O
Engineering    O
for    O
example    O
,    O
of    O
Laminin    B-Glycoprotein114888310
.    O

The    O
3D    O
media    O
can    O
be    O
made    O
using    O
an    O
extracellular    O
matrix    O
hydrogel    O
Matrigel    O
,    O
which    O
is    O
a    O
laminin    B-Glycoprotein114888310
-    O
rich    O
extracellular    O
matrix    O
that    O
is    O
secreted    O
by    O
the    O
Engelbreth    O
-    O
Holm    O
-    O
Swarm    O
tumor    O
line    O
.    O

Laminin    B-Glycoprotein114888310

These    O
LRRs    O
are    O
followed    O
by    O
six    O
repeats    O
similar    O
to    O
epidermal    O
growth    O
factors    O
(    O
EGF    O
)    O
as    O
well    O
as    O
a    O
β-sandwich    O
domain    O
similar    O
to    O
laminin    B-Glycoprotein114888310
G    I-Glycoprotein114888310
Directly    O
after    O
these    O
sequences    O
,    O
invertebrates    O
have    O
one    O
EGF    O
repeat    O
,    O
whereas    O
vertebrates    O
have    O
three    O
EGF    O
repeats    O
.    O

In    O
response    O
to    O
scar    O
-    O
inducing    O
factors    O
,    O
like    O
those    O
discussed    O
above    O
,    O
astrocytes    O
up    O
regulate    O
the    O
production    O
of    O
chondroitin    B-Glycoprotein114888310
sulfate    I-Glycoprotein114888310
proteoglycan    I-Glycoprotein114888310
.    O

Versican    O
is    O
a    O
large    O
chondroitin    B-Glycoprotein114888310
sulfate    I-Glycoprotein114888310
proteoglycan    I-Glycoprotein114888310
with    O
an    O
apparent    O
molecular    O
mass    O
of    O
more    O
than    O
1000kDa    O
.    O

It    O
is    O
the    O
target    O
of    O
diphtheria    B-Glycoprotein114888310
toxin    I-Glycoprotein114888310
(    O
from    O
"    O
Corynebacterium    O
diphtheriae    O
"    O
)    O
,    O
and    O
exotoxin    B-Glycoprotein114888310
A    I-Glycoprotein114888310
(    O
from    O
"    O
Pseudomonas    O
aeruginosa    O
"    O
)    O
.    O

"    O
P.    O
aeruginosa    O
"    O
uses    O
the    O
virulence    O
factor    O
exotoxin    B-Glycoprotein114888310
A    I-Glycoprotein114888310
to    O
inactivate    O
eukaryotic    O
elongation    O
factor    O
2    O
via    O
ADP    O
-    O
ribosylation    O
in    O
the    O
host    O
cell    O
,    O
much    O
as    O
the    O
diphtheria    B-Glycoprotein114888310
toxin    I-Glycoprotein114888310
does    O
.    O

N    O
-    O
Linked    O
glycans    O
are    O
attached    O
in    O
the    O
endoplasmic    O
reticulum    O
to    O
the    O
nitrogen    O
(    O
N    O
)    O
in    O
the    O
side    O
chain    O
of    O
asparagine    O
in    O
the    O
sequon    B-Glycoprotein114888310
.    O

Genetic    O
associations    O
include    O
mutations    O
in    O
pulmonary    O
surfactant    O
proteins    O
A1    O
,    O
A2    O
,    O
C    O
(    O
SFTPA1    O
,    O
SFTPA2B    O
)    O
and    O
mucin    B-Glycoprotein114888310
(    O
MUC5B    B-Glycoprotein114888310
)    O
.    O

In    O
immunocompetent    O
atopic    O
individuals    O
,    O
17%    O
of    O
those    O
affected    O
with    O
allergic    O
fungal    O
sinusitis    O
can    O
develop    O
orbital    O
mycotic    O
symptoms    O
,    O
where    O
the    O
fungus    O
acts    O
as    O
an    O
allergen    O
causing    O
allergic    O
mucin    B-Glycoprotein114888310
.    O

However    O
,    O
it    O
is    O
the    O
mucin    B-Glycoprotein114888310
from    O
bovine    O
and    O
porcine    O
sources    O
that    O
have    O
been    O
used    O
in    O
several    O
biomaterial    O
applications    O
.    O

Mucin    B-Glycoprotein114888310
originates    O
from    O
the    O
mucus    O
secretions    O
from    O
submaxillary    O
glands    O
,    O
which    O
are    O
salivary    O
glands    O
that    O
are    O
located    O
under    O
the    O
floor    O
of    O
the    O
mouth    O
.    O

They    O
are    O
mucin    B-Glycoprotein114888310
-    O
like    O
molecules    O
with    O
a    O
molar    O
mass    O
of    O
over    O
1000    O
kDa    O
.    O

They    O
also    O
secrete    O
mucin    B-Glycoprotein114888310
.    O

Larger    O
than    O
other    O
chemokines    O
(    O
with    O
254    O
amino    O
acids    O
)    O
,    O
CXCL16    O
is    O
composed    O
of    O
a    O
CXC    O
chemokine    O
domain    O
,    O
a    O
mucin    B-Glycoprotein114888310
-    O
like    O
stalk    O
,    O
a    O
transmembrane    O
domain    O
and    O
a    O
cytoplasmic    O
tail    O
containing    O
a    O
potential    O
tyrosine    O
phosphorylation    O
site    O
that    O
may    O
bind    O
SH2    O
.    O

It    O
has    O
been    O
studied    O
for    O
capturing    O
O    O
-    O
glycoproteins    O
such    O
as    O
mucins    B-Glycoprotein114888310
and    O
IgA    B-Glycoprotein114888310
,    O
for    O
potential    O
applications    O
in    O
human    O
immunology    O
.    O

=    O
=    O
=    O
Mucin    B-Glycoprotein114888310
family===    O

This    O
helps    O
the    O
spread    O
of    O
the    O
infection    O
by    O
preventing    O
self    O
-    O
aggregation    O
of    O
new    O
viruses    O
at    O
the    O
cell    O
surface    O
and    O
possible    O
immobilisation    O
in    O
the    O
mucin    B-Glycoprotein114888310
by    O
hemagglutinin    O
(    O
HA    O
)    O
during    O
virus    O
replication    O
.    O

Small    O
tumor    O
nests    O
may    O
be    O
camouflaged    O
amongst    O
the    O
muscle    O
or    O
in    O
periappendiceal    O
fat    O
;    O
cytokeratin    O
preparations    O
best    O
demonstrate    O
the    O
tumor    O
cells    O
;    O
mucin    B-Glycoprotein114888310
stains    O
are    O
also    O
helpful    O
in    O
identifying    O
them    O
.    O

Mucocele    O
—    O
these    O
are    O
common    O
and    O
are    O
caused    O
by    O
rupture    O
of    O
a    O
salivary    O
gland    O
duct    O
and    O
mucin    B-Glycoprotein114888310
spillage    O
into    O
the    O
surrounding    O
tissues    O
.    O

Hunter    O
syndrome    O
can    O
include    O
metachromin    O
granules    O
and    O
mucin    B-Glycoprotein114888310
in    O
the    O
cytoplasm    O
of    O
the    O
eccrine    O
sweat    O
gland    O
cells    O
.    O

Mucin    B-Glycoprotein114888310
:    O
The    O
stomach    O
has    O
a    O
priority    O
to    O
destroy    O
the    O
bacteria    O
and    O
viruses    O
using    O
its    O
highly    O
acidic    O
environment    O
but    O
also    O
has    O
a    O
duty    O
to    O
protect    O
its    O
own    O
lining    O
from    O
its    O
acid    O
.    O

At    O
least    O
20    O
human    O
mucin    O
genes    O
have    O
been    O
distinguished    O
by    O
cDNA    O
cloning    O
—    O
MUC1    B-Glycoprotein114888310
,    O
MUC2    B-Glycoprotein114888310
,    O
MUC3A    B-Glycoprotein114888310
,    O
MUC3B    O
,    O
MUC4    B-Glycoprotein114888310
,    O
MUC5AC    B-Glycoprotein114888310
,    O
MUC5B    B-Glycoprotein114888310
,    O
MUC6    B-Glycoprotein114888310
,    O
MUC7    B-Glycoprotein114888310
,    O
MUC8    O
,    O
MUC12    O
,    O
MUC13    O
,    O
MUC15    O
,    O
MUC16    B-Glycoprotein114888310
,    O
MUC17    B-Glycoprotein114888310
,    O
MUC19    O
,    O
and    O
MUC20    B-Glycoprotein114888310
.    O

At    O
least    O
20    O
human    O
mucin    O
genes    O
have    O
been    O
distinguished    O
by    O
cDNA    O
cloning    O
—    O
MUC1    B-Glycoprotein114888310
,    O
MUC2    B-Glycoprotein114888310
,    O
MUC3A    B-Glycoprotein114888310
,    O
MUC3B    O
,    O
MUC4    B-Glycoprotein114888310
,    O
MUC5AC    B-Glycoprotein114888310
,    O
MUC5B    B-Glycoprotein114888310
,    O
MUC6    B-Glycoprotein114888310
,    O
MUC7    B-Glycoprotein114888310
,    O
MUC8    O
,    O
MUC12    O
,    O
MUC13    O
,    O
MUC15    O
,    O
MUC16    B-Glycoprotein114888310
,    O
MUC17    B-Glycoprotein114888310
,    O
MUC19    O
,    O
and    O
MUC20    B-Glycoprotein114888310
.    O

Glycophorin    B-Glycoprotein114888310
C    I-Glycoprotein114888310
(    O
GYPC    B-Glycoprotein114888310
;    O
CD236    B-Glycoprotein114888310
CD236R    B-Glycoprotein114888310
;    O
glycoprotein    B-Glycoprotein114888310
beta    I-Glycoprotein114888310
;    O
glycoconnectin    B-Glycoprotein114888310
;    O
PAS-2    B-Glycoprotein114888310
)    O
plays    O
a    O
functionally    O
important    O
role    O
in    O
maintaining    O
erythrocyte    O
shape    O
and    O
regulating    O
membrane    O
material    O
properties    O
,    O
possibly    O
through    O
its    O
interaction    O
with    O
protein    O
4.1    O
.    O

About    O
600    O
genes    O
have    O
been    O
identified    O
that    O
may    O
have    O
been    O
undergoing    O
strong    O
positive    O
selection    O
in    O
the    O
human    O
and    O
chimp    O
lineages    O
;    O
many    O
of    O
these    O
genes    O
are    O
involved    O
in    O
immune    O
system    O
defense    O
against    O
microbial    O
disease    O
(    O
example    O
:    O
granulysin    O
is    O
protective    O
against    O
"    O
Mycobacterium    O
tuberculosis    O
"    O
)    O
or    O
are    O
targeted    O
receptors    O
of    O
pathogenic    O
microorganisms    O
(    O
example    O
:    O
Glycophorin    B-Glycoprotein114888310
C    I-Glycoprotein114888310
and    O
"    O
Plasmodium    O
falciparum    O
"    O
)    O
.    O

Wheat    B-Glycoprotein114888310
Germ    I-Glycoprotein114888310
Agglutinin    I-Glycoprotein114888310
,    O
a    O
protein    O
that    O
protects    O
wheat    O
from    O
insects    O
,    O
yeast    O
and    O
bacteria    O

Wheat    B-Glycoprotein114888310
germ    I-Glycoprotein114888310
agglutinin    I-Glycoprotein114888310
or    O
WGA    B-Glycoprotein114888310
is    O
a    O
lectin    O
that    O
protects    O
wheat    O
(    O
Triticum    O
vulgaris    O
)    O
from    O
insects    O
,    O
yeast    O
and    O
bacteria    O
.    O

Anti    O
-    O
gliadin    O
antibodies    O
are    O
produced    O
in    O
response    O
to    O
gliadin    B-Glycoprotein114888310
,    O
a    O
prolamin    B-Glycoprotein114888310
found    O
in    O
wheat    O
.    O

Some    O
of    O
these    O
antibodies    O
can    O
recognize    O
only    O
wheat    O
prolamin    B-Glycoprotein114888310
or    O
very    O
closely    O
related    O
grass    O
seeds    O
;    O
others    O
can    O
detect    O
antigens    O
over    O
broad    O
taxa    O
.    O

Zein    O
is    O
a    O
class    O
of    O
prolamine    B-Glycoprotein114888310
protein    O
found    O
in    O
maize    O
(    O
corn    O
)    O
.    O

This    O
is    O
also    O
the    O
part    O
of    O
the    O
tubule    O
that    O
generates    O
Tamm-Horsfall    B-Glycoprotein114888310
protein    I-Glycoprotein114888310
.    O

Its    O
protein    O
and/or    O
mRNA    O
is    O
expressed    O
in    O
kidney    O
(    O
i.e.    O
glomeruli    O
,    O
Tamm-Horsfall    B-Glycoprotein114888310
protein    I-Glycoprotein114888310
negative    O
late    O
distal    O
convoluted    O
tubules    O
,    O
connecting    O
segments    O
,    O
cortical    O
and    O
medullary    O
collecting    O
ducts    O
,    O
media    O
and    O
endothelial    O
cells    O
of    O
arteries    O
and    O
arterioles    O
)    O
;    O
stomach    O
(    O
vascular    O
smooth    O
muscle    O
and    O
gastric    O
fundus    O
mucosal    O
cells    O
)    O
;    O
thalamus    O
(    O
anterior    O
,    O
ventromedial    O
,    O
laterodorsal    O
,    O
paraventricular    O
and    O
central    O
medial    O
nuclei    O
)    O
;    O
intestinal    O
mucosal    O
epithelia    O
at    O
the    O
apex    O
of    O
crypts    O
;    O
myometrium    O
(    O
stromal    O
cells    O
,    O
endothelial    O
cells    O
,    O
and    O
,    O
in    O
pregnancy    O
,    O
placenta    O
,    O
chorion    O
,    O
and    O
amnion    O
)    O
;    O
mouth    O
gingival    O
fibroblasts    O
;    O
and    O
eye    O
(    O
corneal    O
endothelium    O
and    O
keratocytes    O
,    O
trabecular    O
cells    O
,    O
ciliary    O
epithelium    O
,    O
and    O
conjunctival    O
and    O
iridal    O
stroma    O
cells    O
,    O
and    O
retinal    O
Müller    O
cells    O
)    O
.    O

DCIR    B-Glycoprotein114888310
(    O
CLEC4A    O
)    O

The    O
chondroitin    O
sulfate    O
proteoglycans    O
phosphacan    O
and    O
neurocan    B-Glycoprotein114888310
have    O
also    O
been    O
shown    O
to    O
play    O
a    O
role    O
in    O
glial    O
scar    O
.    O

Versican    O
belongs    O
to    O
the    O
lectican    O
protein    O
family    O
,    O
with    O
aggrecan    B-Glycoprotein114888310
(    O
abundant    O
in    O
cartilage    O
)    O
,    O
brevican    B-Glycoprotein114888310
and    O
neurocan    B-Glycoprotein114888310
(    O
nervous    O
system    O
proteoglycans    O
)    O
as    O
other    O
members    O
.    O

15-HETE    O
-    O
PE    O
induces    O
expression    O
of    O
the    O
mucin    O
MUC5AC    B-Glycoprotein114888310
.    O

Galecto    O
Biotech    O
is    O
a    O
Swedish    O
private    O
biotechnology    O
company    O
that    O
has    O
developed    O
a    O
galectin-3    B-Glycoprotein114888310
inhibitor    O
that    O
would    O
prevent    O
fibrosis    O
.    O

The    O
galectin-3    B-Glycoprotein114888310
inhibitor    O
,    O
TD139    O
,    O
has    O
the    O
potential    O
to    O
treat    O
many    O
diseases    O
due    O
to    O
its    O
involvement    O
in    O
many    O
key    O
biological    O
pathways    O
such    O
as    O
cell    O
differentiation    O
,    O
cell    O
growth    O
,    O
and    O
apoptosis    O
.    O
Galecto    O
Biotech    O
is    O
using    O
this    O
inhibitor    O
to    O
treat    O
idiopathic    O
pulmonary    O
fibrosis    O
(    O
IPF    O
)    O
,    O
which    O
is    O
a    O
progressive    O
,    O
irreversible    O
and    O
ultimately    O
fatal    O
lung    O
disease    O
that    O
has    O
poor    O
prognosis    O
and    O
no    O
effective    O
therapies    O
.    O

MICL    B-Glycoprotein114888310
(    O
CLEC12A    O
)    O

Omalizumab    O
is    O
a    O
recombinant    O
DNA    O
-    O
derived    O
humanized    O
IgG1k    O
monoclonal    O
antibody    O
that    O
specifically    O
binds    O
to    O
free    O
human    O
immunoglobulin    B-Glycoprotein114888310
E    I-Glycoprotein114888310
(    O
IgE    O
)    O
in    O
the    O
blood    O
and    O
interstitial    O
fluid    O
and    O
to    O
membrane    O
-    O
bound    O
form    O
of    O
IgE    O
(    O
mIgE    O
)    O
on    O
the    O
surface    O
of    O
mIgE    O
-    O
expressing    O
B    O
lymphocytes    O
.    O

There    O
appears    O
to    O
be    O
a    O
correlation    O
with    O
both    O
total    O
IgE    B-Glycoprotein114888310
levels    O
and    O
asthma    O
and    O
mutations    O
in    O
the    O
Duffy    O
antigen    O
.    O

Food    O
allergies    O
are    O
immune    O
reactions    O
,    O
typically    O
an    O
IgE    B-Glycoprotein114888310
reaction    O
caused    O
by    O
the    O
release    O
of    O
histamine    O
but    O
also    O
encompassing    O
non    O
-    O
IgE    O
immune    O
responses    O
.    O

Hyperimmunoglobulin    O
E    O
syndrome    O
(    O
IgE    B-Glycoprotein114888310
)    O

Several    O
serological    O
tests    O
can    O
be    O
performed    O
to    O
assess    O
total    O
IgE    O
and    O
allergen    O
specific    O
IgE    B-Glycoprotein114888310
and    O
IgG    B-Glycoprotein114888310
:    O
ELISA    O
,    O
MAST    O
,    O
HIA    O
,    O
and    O
CAP    O
RAST    O
.    O

In    O
serum    O
-    O
based    O
allergy    O
diagnosis    O
,    O
antibodies    O
of    O
the    O
IgE    B-Glycoprotein114888310
class    O
directed    O
against    O
CCDs    O
therefore    O
give    O
the    O
impression    O
of    O
polysensitization    O
.    O

For    O
example    O
,    O
those    O
that    O
bind    O
the    O
most    O
common    O
class    O
of    O
antibody    O
,    O
IgG    B-Glycoprotein114888310
,    O
are    O
called    O
"    O
Fc    O
-    O
gamma    O
receptors    O
"    O
(    O
FcγR    O
)    O
,    O
those    O
that    O
bind    O
IgA    B-Glycoprotein114888310
are    O
called    O
"    O
Fc    O
-    O
alpha    O
receptors    O
"    O
(    O
FcαR    O
)    O
and    O
those    O
that    O
bind    O
IgE    B-Glycoprotein114888310
are    O
called    O
"    O
Fc    O
-    O
epsilon    O
receptors    O
"    O
(    O
FcεR    O
)    O
.    O

When    O
an    O
appropriate    O
allergic    O
antigen    O
or    O
parasite    O
is    O
present    O
,    O
the    O
cross    O
-    O
linking    O
of    O
a    O
least    O
two    O
of    O
IgE    B-Glycoprotein114888310
molecules    O
and    O
their    O
Fc    O
receptors    O
on    O
the    O
surface    O
of    O
a    O
granulocyte    O
will    O
trigger    O
the    O
cell    O
to    O
rapidly    O
release    O
preformed    O
mediators    O
from    O
its    O
granules    O
.    O

IgE    B-Glycoprotein114888310
antibodies    O
bind    O
to    O
antigens    O
of    O
allergens    O
.    O

Specific    O
allergen    O
exposure    O
(    O
e.g.    O
,    O
dust    O
mites    O
)    O
under    O
the    O
influence    O
of    O
helper    O
T2    O
lymphocytes    O
leads    O
to    O
B    O
-    O
lymphocyte    O
elaboration    O
of    O
immunoglobulin    B-Glycoprotein114888310
E    I-Glycoprotein114888310
(    O
IgE    O
)    O
antibodies    O
specific    O
to    O
that    O
allergen    O
.    O

Type    O
I    O
hypersensitivity    O
is    O
mediated    O
by    O
IgE    B-Glycoprotein114888310
,    O
which    O
triggers    O
degranulation    O
of    O
mast    O
cells    O
and    O
basophils    O
when    O
cross    O
-    O
linked    O
by    O
antigen    O
.    O

TH2-type    O
lymphocytes    O
are    O
activated    O
,    O
with    O
an    O
increase    O
in    O
T    O
cells    O
expressing    O
CD25    O
(    O
IL-2R    O
)    O
,    O
and    O
B    O
cells    O
expressing    O
CD    O
23    O
,    O
causing    O
increased    O
production    O
of    O
IgE    B-Glycoprotein114888310
After    O
exercise    O
,    O
the    O
conditions    O
will    O
fade    O
within    O
one    O
to    O
three    O
minutes    O
.    O

|    O
IgE    B-Glycoprotein114888310

Such    O
patients    O
often    O
give    O
family    O
history    O
of    O
other    O
atopic    O
diseases    O
such    O
as    O
hay    O
fever    O
,    O
asthma    O
or    O
eczema    O
,    O
and    O
their    O
peripheral    O
blood    O
shows    O
eosinophilia    O
and    O
increased    O
serum    O
IgE    B-Glycoprotein114888310
levels    O
.    O

The    O
combination    O
of    O
this    O
cytokine    O
and    O
IL12    O
has    O
been    O
shown    O
to    O
inhibit    O
IL-4    O
dependent    O
IgE    B-Glycoprotein114888310
and    O
IgG1    B-Glycoprotein114888310
production    O
,    O
and    O
enhance    O
IgG2a    O
production    O
in    O
B    O
cells    O
.    O

Rather    O
,    O
they    O
find    O
that    O
:    O
a    O
)    O
cells    O
expressing    O
both    O
CysLTR1    O
and    O
GPR17    O
receptors    O
exhibit    O
a    O
marked    O
reduction    O
in    O
binding    O
and    O
responding    O
to    O
LTD4    O
and    O
b    O
)    O
mice    O
lacking    O
GPR17    O
are    O
hyper    O
-    O
responsive    O
to    O
igE    B-Glycoprotein114888310
in    O
a    O
model    O
for    O
passive    O
cutaneous    O
anaphylaxis    O
.    O

It    O
dilates    O
airways    O
(    O
bronchodilation    O
)    O
contracted    O
by    O
the    O
allergic    O
mediator    O
,    O
histamine    O
;    O
inhibits    O
Immunoglobulin    B-Glycoprotein114888310
E    I-Glycoprotein114888310
-    O
activated    O
mast    O
cells    O
from    O
releasing    O
histamine    O
and    O
leukotrienes    O
(    O
viz    O
.    O

Model    O
studies    O
indicate    O
that    O
PG2    O
(    O
but    O
not    O
specific    O
antigens    O
or    O
IgE    B-Glycoprotein114888310
cross    O
-    O
linkage    O
)    O
stimulates    O
mouse    O
and    O
human    O
mast    O
cells    O
to    O
release    O
histamine    O
by    O
an    O
EP3-dependent    O
mechanism    O
.    O

Immunoglobulin    B-Glycoprotein114888310
E    I-Glycoprotein114888310
(    O
IgE    O
)    O
,    O
an    O
antibody    O

For    O
allergy    O
testing    O
,    O
Hycor    O
has    O
developed    O
specific    O
and    O
total    O
IgE    B-Glycoprotein114888310
,    O
specific    O
IgG    B-Glycoprotein114888310
,    O
specific    O
IgG4    B-Glycoprotein114888310
,    O
and    O
specific    O
IgE    O
EIA    O
tests    O
.    O

Both    O
provide    O
accurate    O
and    O
precise    O
specific    O
-    O
IgE    B-Glycoprotein114888310
results    O
(    O
kU    O
/    O
L    O
)    O
and    O
a    O
class    O
of    O
allergic    O
response    O
.    O

CD23    O
,    O
also    O
known    O
as    O
Fc    O
epsilon    O
RII    O
,    O
or    O
FcεRII    O
,    O
is    O
the    O
"    O
low    O
-    O
affinity    O
"    O
receptor    O
for    O
IgE    B-Glycoprotein114888310
,    O
an    O
antibody    O
isotype    O
involved    O
in    O
allergy    O
and    O
resistance    O
to    O
parasites    O
,    O
and    O
is    O
important    O
in    O
regulation    O
of    O
IgE    O
levels    O
.    O

For    O
example    O
,    O
IgE    B-Glycoprotein114888310
is    O
responsible    O
for    O
an    O
allergic    O
response    O
consisting    O
of    O
mast    O
cell    O
degranulation    O
and    O
histamine    O
release    O
.    O

While    O
most    O
of    O
these    O
early    O
studies    O
focused    O
on    O
IgM    O
and    O
IgG    O
,    O
other    O
immunoglobulin    O
isotypes    O
were    O
identified    O
in    O
the    O
1960s    O
:    O
Thomas    O
Tomasi    O
discovered    O
secretory    O
antibody    O
(    O
IgA    B-Glycoprotein114888310
)    O
;    O
David    O
S.    O
Rowe    O
and    O
John    O
L.    O
Fahey    O
discovered    O
IgD    O
;    O
and    O
Kimishige    O
Ishizaka    O
and    O
Teruko    O
Ishizaka    O
discovered    O
IgE    B-Glycoprotein114888310
and    O
showed    O
it    O
was    O
a    O
class    O
of    O
antibodies    O
involved    O
in    O
allergic    O
reactions    O
.    O

Tanaka    O
et    O
al    O
.    O
found    O
that    O
the    O
sweat    O
hyper    O
-    O
sensitivities    O
of    O
CU    O
and    O
atopic    O
dermatitis    O
seem    O
to    O
be    O
virtually    O
the    O
same    O
,    O
and    O
therefore    O
,    O
the    O
sweat    O
-    O
induced    O
histamine    O
release    O
from    O
basophils    O
may    O
also    O
be    O
mediated    O
by    O
a    O
specific    O
IgE    B-Glycoprotein114888310
for    O
sweat    O
in    O
atopic    O
dermatitis    O
as    O
well    O
as    O
CU    O
.    O

His    O
broader    O
interpretation    O
of    O
"    O
allergies    O
"    O
beyond    O
that    O
of    O
IgE    B-Glycoprotein114888310
antibodies    O
in    O
true    O
allergy    O
conflicted    O
with    O
traditional    O
allergists    O
of    O
his    O
time    O
.    O

Among    O
the    O
encoded    O
proteins    O
are    O
a    O
caspase    O
,    O
a    O
cathepsin    O
B    O
,    O
several    O
kinases    O
,    O
E3    O
ubiquitin    O
ligases    O
,    O
a    O
fatty    O
acid    O
elongase    O
,    O
a    O
sphingomyelinase    O
,    O
a    O
phosphate    O
acyltransferase    O
and    O
a    O
patatin    B-Glycoprotein114888310
-    O
like    O
phospholipase    O
.    O

A    O
clonal    O
chromosome    O
deletion    O
2p21    O
was    O
found    O
in    O
endomyometriosis    O
by    O
Verhest    O
et    O
al    O
.    O
while    O
Pai    O
evidenced    O
a    O
strict    O
relationship    O
among    O
ULM    O
,    O
breast    O
cancer    O
and    O
elevated    O
serum    O
CA125    B-Glycoprotein114888310
supporting    O
the    O
view    O
of    O
ULM    O
being    O
either    O
hormone    O
-    O
dependent    O
or    O
a    O
form    O
of    O
endometriosis    O
.    O

A    O
CA-125    B-Glycoprotein114888310
blood    O
test    O
is    O
a    O
nonspecific    O
test    O
that    O
tends    O
to    O
be    O
elevated    O
in    O
patients    O
with    O
tubal    O
cancer    O
.    O

Women    O
may    O
also    O
use    O
a    O
blood    O
test    O
for    O
CA-125    B-Glycoprotein114888310
and    O
clinical    O
pelvic    O
exams    O
.    O

Cholangiocarcinoma    O
can    O
be    O
detected    O
with    O
these    O
commonly    O
used    O
tumor    O
markers    O
:    O
carbohydrate    O
antigen    O
19    O
-    O
9    O
(    O
CA    O
19    O
-    O
9    O
)    O
,    O
carcinoembryonic    O
antigen    O
(    O
CEA    O
)    O
and    O
cancer    O
antigen    O
125    O
(    O
CA125    B-Glycoprotein114888310
)    O
.    O

CD22    B-Glycoprotein114888310
,    O

CD22    B-Glycoprotein114888310
,    O

It    O
down    O
-    O
regulates    O
B    O
lymphocyte    O
antigen    O
receptor    O
signaling    O
(    O
involving    O
CD22    B-Glycoprotein114888310
)    O
,    O
and    O
is    O
required    O
for    O
immunological    O
tolerance    O
e.g.    O
in    O
mice    O
.    O

These    O
patients    O
were    O
treated    O
with    O
the    O
recombinant    O
immunotoxin    O
,    O
BL22    O
,    O
which    O
targets    O
the    O
CD22    B-Glycoprotein114888310
cell    O
surface    O
receptor    O
,    O
which    O
is    O
highly    O
expressed    O
on    O
these    O
leukemic    O
cells    O
.    O

Alpha    B-Glycoprotein114888310
1-antichymotrypsin    I-Glycoprotein114888310

Alpha    B-Glycoprotein114888310
1-antichymotrypsin    I-Glycoprotein114888310

Minor    O
,    O
but    O
important    O
,    O
amounts    O
of    O
small    O
proteins    O
,    O
including    O
osteocalcin    O
and    O
osteopontin    B-Glycoprotein114888310
,    O
are    O
secreted    O
in    O
bone    O
's    O
organic    O
matrix    O
.    O

This    O
integrin    O
participates    O
in    O
cell    O
adhesion    O
with    O
various    O
ligands    O
in    O
the    O
extracellular    O
matrix    O
(    O
ECM    O
)    O
,    O
including    O
extra    O
domain    O
A    O
(    O
EDA    O
)    O
fibronectin    B-Glycoprotein114888310
,    O
tenascin    O
-    O
C    O
,    O
ADAMs    O
,    O
EMELIN1    O
,    O
osteopontin    B-Glycoprotein114888310
,    O
and    O
VEGF    O
.    O

The    O
bone    O
and    O
dentin    O
protein    O
osteopontin    B-Glycoprotein114888310
(    O
OPN    O
)    O
which    O
inhibits    O
mineralization    O
in    O
the    O
skeleton    O
and    O
in    O
teeth    O
is    O
a    O
substrate    O
for    O
PHEX    O
.    O

Some    O
of    O
the    O
regulatory    O
proteins    O
in    O
mineralized    O
tissues    O
are    O
osteonectin    B-Glycoprotein114888310
,    O
osteopontin    B-Glycoprotein114888310
,    O
osteocalcin    O
,    O
bone    O
sialoprotein    O
and    O
dentin    O
phosphophoryn    O
.    O

The    O
PH    O
-    O
E    O
form    O
of    O
phytohaemagglutinin    B-Glycoprotein114888310

Phytohaemagglutinin    B-Glycoprotein114888310
,    O
hemagglutinins    O
produced    O
by    O
plants    O

They    O
also    O
reported    O
stress    O
-    O
related    O
decreases    O
in    O
NK    O
and    O
T    O
cell    O
function    O
,    O
and    O
T    O
cell    O
proliferative    O
responses    O
to    O
phytohaemagglutinin    B-Glycoprotein114888310
[    O
PHA    O
]    O
and    O
concanavalin    B-Glycoprotein114888310
A    I-Glycoprotein114888310
[    O
Con    O
A    O
]    O
.    O

They    O
also    O
replicated    O
Herbert    O
and    O
Cohen    O
's    O
finding    O
of    O
stress    O
-    O
related    O
decreases    O
in    O
NKCC    O
and    O
T    O
cell    O
mitogen    O
proliferation    O
to    O
Phytohaemagglutinin    B-Glycoprotein114888310
(    O
PHA    O
)    O
and    O
Concanavalin    B-Glycoprotein114888310
A    I-Glycoprotein114888310
(    O
Con    O
A    O
)    O
.    O

Phytohaemagglutinin    B-Glycoprotein114888310
(    O
red    O
kidney    O
bean    O
poisoning    O
;    O
destroyed    O
by    O
boiling    O
)    O

Dectin    B-Glycoprotein114888310
1    I-Glycoprotein114888310
(    O
CLEC7A    O
)    O

At    O
least    O
20    O
human    O
mucin    O
genes    O
have    O
been    O
distinguished    O
by    O
cDNA    O
cloning    O
—    O
MUC1    B-Glycoprotein114888310
,    O
MUC2    B-Glycoprotein114888310
,    O
MUC3A    B-Glycoprotein114888310
,    O
MUC3B    O
,    O
MUC4    B-Glycoprotein114888310
,    O
MUC5AC    B-Glycoprotein114888310
,    O
MUC5B    B-Glycoprotein114888310
,    O
MUC6    B-Glycoprotein114888310
,    O
MUC7    B-Glycoprotein114888310
,    O
MUC8    O
,    O
MUC12    O
,    O
MUC13    O
,    O
MUC15    O
,    O
MUC16    B-Glycoprotein114888310
,    O
MUC17    B-Glycoprotein114888310
,    O
MUC19    O
,    O
and    O
MUC20    B-Glycoprotein114888310
.    O

Instead    O
of    O
having    O
the    O
usual    O
lipopolysaccharide    O
(    O
LPS    O
)    O
,    O
this    O
bacterium    O
,    O
whether    O
a    O
pathogenic    O
or    O
commensal    O
species    O
,    O
has    O
a    O
lipooligosaccharide    O
(    O
LOS    O
)    O
which    O
consists    O
of    O
a    O
core    O
polysaccharide    O
and    O
lipid    O
A.    O
It    O
functions    O
as    O
an    O
endotoxin    O
,    O
protects    O
against    O
antimicrobial    O
peptides    O
,    O
and    O
adheres    O
to    O
the    O
asialoglycoprotein    B-Glycoprotein114888310
receptor    I-Glycoprotein114888310
on    O
urethral    O
cells    O
.    O

Osteopontin    O
is    O
a    O
SIBLING    B-Glycoprotein114888310
(    O
glycoprotein    O
)    O
that    O
was    O
first    O
identified    O
in    O
1986    O
in    O
osteoblasts    O
.    O

However    O
,    O
the    O
other    O
major    O
anticoagulants    O
,    O
protein    B-Glycoprotein114888310
C    I-Glycoprotein114888310
and    O
antithrombin    B-Glycoprotein114888310
III    I-Glycoprotein114888310
,    O
remain    O
constant    O
.    O

Protein    B-Glycoprotein114888310
S    I-Glycoprotein114888310
or    O
protein    B-Glycoprotein114888310
C    I-Glycoprotein114888310
deficiency    O

To    O
rule    O
out    O
other    O
causes    O
for    O
hypercoagulation    O
,    O
it    O
may    O
be    O
appropriate    O
to    O
check    O
the    O
antithrombin    B-Glycoprotein114888310
,    O
protein    B-Glycoprotein114888310
C    I-Glycoprotein114888310
,    O
protein    B-Glycoprotein114888310
S    I-Glycoprotein114888310
,    O
factor    O
V    O
Leiden    O
,    O
and    O
prothrombin    O
G20210A.    O

It    O
is    O
not    O
related    O
to    O
C    O
-    O
peptide    O
(    O
insulin    O
)    O
or    O
protein    B-Glycoprotein114888310
C    I-Glycoprotein114888310
(    O
blood    O
coagulation    O
)    O
.    O

Protein    B-Glycoprotein114888310
C    I-Glycoprotein114888310
,    O
anticoagulant    O

Protein    B-Glycoprotein114888310
C    I-Glycoprotein114888310

Factor    O
Va    O
is    O
inactivated    O
following    O
cleavage    O
by    O
activated    O
protein    B-Glycoprotein114888310
C    I-Glycoprotein114888310
Activated    O
protein    O
C    O
cleaves    O
Factor    O
Va    O
in    O
both    O
its    O
light    O
and    O
heavy    O
chains    O
.    O

specific    O
factor    O
inhibitor    O
assays    O
,    O
like    O
Protein    B-Glycoprotein114888310
C    I-Glycoprotein114888310
,    O
TFPI    O
,    O
Antithrombin    B-Glycoprotein114888310
etc    O
.    O

"    O
Protein    B-Glycoprotein114888310
C    I-Glycoprotein114888310
"    O
is    O
active    O
in    O
anticoagulation    O
(    O
anti    O
-    O
clotting    O
)    O
and    O
breaking    O
down    O
blood    O
clots    O
.    O

Thrombophilia    O
,    O
a    O
tendency    O
to    O
develop    O
blood    O
clots    O
due    O
to    O
abnormalities    O
in    O
coagulation    O
,    O
e.g.    O
factor    O
V    O
Leiden    O
,    O
deficiency    O
of    O
protein    B-Glycoprotein114888310
C    I-Glycoprotein114888310
,    O
protein    B-Glycoprotein114888310
S    I-Glycoprotein114888310
or    O
antithrombin    B-Glycoprotein114888310
,    O
or    O
related    O
problems    O

This    O
gene    O
encodes    O
a    O
type    O
I    O
integral    O
ribophorin    B-Glycoprotein114888310
membrane    O
protein    O
found    O
only    O
in    O
the    O
rough    O
endoplasmic    O
reticulum    O
.    O

It    O
contains    O
fibronectin    B-Glycoprotein114888310
,    O
type    O
IV    O
collagen    O
,    O
perlecan    B-Glycoprotein114888310
,    O
and    O
laminin    B-Glycoprotein114888310
.    O

Specific    O
genes    O
have    O
also    O
had    O
reported    O
association    O
with    O
the    O
development    O
of    O
intracranial    O
aneurysms    O
,    O
including    O
perlecan    B-Glycoprotein114888310
,    O
elastin    O
,    O
collagen    O
type    O
1    O
A2    O
,    O
endothelial    O
nitric    O
oxide    O
synthase    O
,    O
endothelin    O
receptor    O
A    O
and    O
cyclin    O
dependent    O
kinase    O
inhibitor    O
.    O

Schwartz    O
–    O
Jampel    O
syndrome    O
(    O
SJS    O
)    O
is    O
a    O
rare    O
genetic    O
disease    O
caused    O
by    O
a    O
mutation    O
in    O
the    O
HSPG2    B-Glycoprotein114888310
gene    O
,    O
which    O
makes    O
the    O
protein    O
perlecan    B-Glycoprotein114888310
,    O
and    O
causing    O
osteochondrodysplasia    O
associated    O
with    O
myotonia    O
.    O

Relationships    O
between    O
the    O
disease    O
and    O
perlecan    B-Glycoprotein114888310
deficiency    O
have    O
been    O
studied    O
.    O

Langerin    B-Glycoprotein114888310
(    O
CD207    O
)    O

Immunoglobulin    B-Glycoprotein114888310
Y    I-Glycoprotein114888310
(    O
abbreviated    O
as    O
IgY    B-Glycoprotein114888310
)    O
is    O
a    O
type    O
of    O
immunoglobulin    O
which    O
is    O
the    O
major    O
antibody    O
in    O
bird    O
,    O
reptile    O
,    O
and    O
lungfish    O
blood    O
.    O

DC-SIGN    B-Glycoprotein114888310
(    O
CD209    O
)    O

Their    O
life    O
cycle    O
is    O
thought    O
to    O
begin    O
with    O
a    O
virion    O
attaching    O
to    O
specific    O
cell    O
-    O
surface    O
receptors    O
such    O
as    O
C-type    B-Glycoprotein114888310
lectin    I-Glycoprotein114888310
,    O
DC-SIGN    B-Glycoprotein114888310
,    O
or    O
integrin    B-Glycoprotein114888310
,    O
which    O
is    O
followed    O
by    O
fusion    O
of    O
the    O
viral    O
envelope    O
with    O
cellular    O
membranes    O
.    O

Prolamins    B-Glycoprotein114888310
are    O
a    O
group    O
of    O
plant    O
storage    O
proteins    O
having    O
a    O
high    O
proline    O
content    O
and    O
found    O
in    O
the    O
seeds    O
of    O
cereal    O
grains    O
:    O
wheat    O
(    O
gliadin    B-Glycoprotein114888310
)    O
,    O
barley    O
(    O
hordein    B-Glycoprotein114888310
)    O
,    O
rye    O
(    O
secalin    B-Glycoprotein114888310
)    O
,    O
corn    O
(    O
zein    O
)    O
,    O
sorghum    O
(    O
kafirin    O
)    O
and    O
as    O
a    O
minor    O
protein    O
,    O
avenin    O
in    O
oats    O
.    O

"    O
Hordeum    O
"    O
(    O
food    O
barleys    O
)    O
–    O
hordein    B-Glycoprotein114888310
(    O
B    O
-    O
hordein    O
is    O
homolous    O
to    O
LMW    O
-    O
glutenin    O
)    O

AM    O
fungi    O
enhance    O
soil    O
aggregate    O
stability    O
is    O
due    O
to    O
the    O
production    O
of    O
extraradical    O
hyphae    O
and    O
a    O
soil    O
protein    O
known    O
as    O
glomalin    B-Glycoprotein114888310
.    O

Biotic    O
materials    O
in    O
soil    O
include    O
glomalin    B-Glycoprotein114888310
,    O
Dopplerite    O
and    O
humic    O
acid    O
.    O

Spironolactone    O
is    O
bound    O
equivalently    O
to    O
albumin    O
and    O
α1-acid    B-Glycoprotein114888310
glycoprotein    I-Glycoprotein114888310
,    O
while    O
canrenone    O
is    O
bound    O
only    O
to    O
albumin    O
.    O

Orosomucoid    B-Glycoprotein114888310
(    O
acid    O
glycoprotein    O
)    O

Zileuton    O
is    O
93%    O
bound    O
to    O
plasma    O
proteins    O
,    O
primarily    O
to    O
albumin    O
,    O
with    O
minor    O
binding    O
to    O
alpha-1-acid    B-Glycoprotein114888310
glycoprotein    I-Glycoprotein114888310
.    O

Like    O
miraculin    B-Glycoprotein114888310
,    O
curculin    O
exhibits    O
taste    O
-    O
modifying    O
activity    O
;    O
however    O
,    O
unlike    O
miraculin    O
,    O
it    O
also    O
exhibits    O
a    O
sweet    O
taste    O
by    O
itself    O
.    O

Miraculin    B-Glycoprotein114888310

The    O
flamingo    O
subfamily    O
consists    O
of    O
nonclassic    O
-    O
type    O
cadherins    O
;    O
a    O
subpopulation    O
that    O
does    O
not    O
interact    O
with    O
catenin    B-Glycoprotein114888310
.    O

Catenin    B-Glycoprotein114888310

Once    O
the    O
cell    O
-    O
cell    O
adhesion    O
between    O
cadherins    O
present    O
in    O
the    O
cell    O
membranes    O
of    O
two    O
different    O
cells    O
has    O
formed    O
,    O
adherens    O
junctions    O
can    O
then    O
be    O
made    O
when    O
protein    O
complexes    O
,    O
usually    O
composed    O
of    O
α-,    B-Glycoprotein114888310
β-,    I-Glycoprotein114888310
and    I-Glycoprotein114888310
γ-catenins    I-Glycoprotein114888310
,    O
bind    O
to    O
the    O
actin    O
cytoskeleton    O
portion    O
of    O
the    O
cadherin    O
.    O

Catenin    B-Glycoprotein114888310

The    O
CL    O
-    O
K1    O
protein    O
is    O
a    O
C-type    B-Glycoprotein114888310
lectin    I-Glycoprotein114888310
,    O
and    O
belongs    O
to    O
the    O
collectin    B-Glycoprotein114888310
family    O
of    O
these    O
proteins    O
.    O

:    O
:*    O
Collectin    B-Glycoprotein114888310

Collectins    B-Glycoprotein114888310
(    O
collagen-containing    B-Glycoprotein114888310
C-type    I-Glycoprotein114888310
lectins    I-Glycoprotein114888310
)    O
are    O
a    O
part    O
of    O
the    O
innate    O
immune    O
system    O
.    O

Hyperimmune    B-Glycoprotein114888310
globulin    I-Glycoprotein114888310
is    O
similar    O
to    O
intravenous    B-Glycoprotein114888310
immunoglobulin    I-Glycoprotein114888310
(    O
IVIG    O
)    O
except    O
that    O
it    O
is    O
prepared    O
from    O
the    O
plasma    O
of    O
donors    O
with    O
high    O
titers    O
of    O
antibody    O
against    O
a    O
specific    O
organism    O
or    O
antigen    O
.    O

:    O
:*    O
Fibronectin    B-Glycoprotein114888310
receptor    O
:    O

Lipoprotein(a    O
)    O
has    O
been    O
shown    O
to    O
interact    O
with    O
Calnexin    B-Glycoprotein114888310
,    O
Fibronectin    B-Glycoprotein114888310
and    O
Fibrinogen    O
beta    O
chain    O
.    O

This    O
FN3    O
domain    O
contains    O
internal    O
repeats    O
that    O
are    O
present    O
in    O
the    O
plasma    O
protein    O
fibronectin    B-Glycoprotein114888310
.    O

GpIIb    O
/    O
IIIa    O
is    O
essential    O
to    O
blood    O
coagulation    O
since    O
the    O
activated    O
receptor    O
has    O
the    O
ability    O
to    O
bind    O
fibrinogen    O
(    O
as    O
well    O
as    O
von    B-Glycoprotein114888310
Willebrand    I-Glycoprotein114888310
factor    I-Glycoprotein114888310
,    O
fibronectin    B-Glycoprotein114888310
,    O
and    O
vitronectin    O
)    O
,    O
which    O
is    O
required    O
for    O
fibrinogen    O
-    O
dependent    O
platelet    O
-    O
platelet    O
interaction    O
(    O
aggregation    O
)    O
.    O

Fibronectin    B-Glycoprotein114888310

Invadopodia    O
can    O
be    O
visualized    O
by    O
the    O
holes    O
they    O
would    O
create    O
in    O
fibronectin    B-Glycoprotein114888310
-    O
coated    O
plates    O
or    O
by    O
using    O
immunohistochemistry    O
,    O
as    O
co    O
-    O
localizing    O
puncta    O
of    O
actin    O
with    O
Tks5    O
.    O

Laminin    B-Glycoprotein114888310
,    O
collagen    O
,    O
and    O
fibronectin    B-Glycoprotein114888310
,    O
which    O
are    O
all    O
ECM    O
components    O
,    O
guide    O
axonal    O
development    O
and    O
promote    O
neural    O
stimulation    O
and    O
activity    O
.    O

It    O
contains    O
fibronectin    B-Glycoprotein114888310
,    O
type    O
IV    O
collagen    O
,    O
perlecan    B-Glycoprotein114888310
,    O
and    O
laminin    B-Glycoprotein114888310
.    O

Using    O
ECM    O
microarrays    O
to    O
optimize    O
combinatorial    O
effects    O
of    O
collagen    O
,    O
laminin    B-Glycoprotein114888310
,    O
and    O
fibronectin    B-Glycoprotein114888310
on    O
stem    O
cells    O
is    O
more    O
advantageous    O
than    O
conventional    O
well    O
plates    O
due    O
to    O
its    O
higher    O
throughput    O
and    O
lower    O
requirement    O
of    O
expensive    O
reagents    O
.    O

A    O
)    O
Micropatterning    O
of    O
fibronectin    B-Glycoprotein114888310
on    O
PNIPAM    O
glass    O
surface    O
.    O

Fibronectin    O
binding    O
protein    O
A    O
(    O
FnBPA    O
)    O
is    O
a    O
"    O
Staphylococcus    O
aureus    O
"    O
MSCRAMM    O
cell    O
surface    O
-    O
bound    O
protein    O
that    O
binds    O
to    O
both    O
fibronectin    B-Glycoprotein114888310
and    O
fibrinogen    O
.    O

The    O
versican    B-Glycoprotein114888310
3’UTR    O
has    O
been    O
shown    O
to    O
regulate    O
expression    O
of    O
the    O
matrix    O
protein    O
fibronectin    B-Glycoprotein114888310
via    O
antagonizing    O
miR-199a    O
function    O
.    O

Ligands    O
for    O
integrins    O
include    O
fibronectin    B-Glycoprotein114888310
,    O
vitronectin    O
,    O
collagen    O
and    O
laminin    B-Glycoprotein114888310
.    O

Among    O
the    O
ligands    O
of    O
integrins    O
are    O
fibronectin    B-Glycoprotein114888310
,    O
vitronectin    O
,    O
collagen    O
,    O
and    O
laminin    B-Glycoprotein114888310
.    O

Histologically    O
,    O
keloids    O
are    O
fibrotic    O
tumors    O
characterized    O
by    O
a    O
collection    O
of    O
atypical    O
fibroblasts    O
with    O
excessive    O
deposition    O
of    O
extracellular    O
matrix    O
components    O
,    O
especially    O
collagen    O
,    O
fibronectin    B-Glycoprotein114888310
,    O
elastin    O
,    O
and    O
proteoglycan    B-Glycoprotein114888310
.    O

Under    O
stagnant    O
conditions    O
initial    O
protein    O
deposition    O
takes    O
place    O
in    O
the    O
sequence    O
:    O
albumin    O
;    O
globulin    O
;    O
fibrinogen    O
;    O
fibronectin    B-Glycoprotein114888310
;    O
factor    O
XII    O
,    O
and    O
HMWK    O
.    O

α    O
granules    O
(    O
alpha    O
granules    O
)    O
–    O
containing    O
P    O
-    O
selectin    O
,    O
platelet    O
factor    O
4    O
,    O
transforming    O
growth    O
factor-β1    O
,    O
platelet    O
-    O
derived    O
growth    O
factor    O
,    O
fibronectin    B-Glycoprotein114888310
,    O
B    O
-    O
thromboglobulin    O
,    O
vWF    B-Glycoprotein114888310
,    O
fibrinogen    O
,    O
and    O
coagulation    O
factors    O
V    B-Glycoprotein114888310
and    O
XIII    O
.    O

Fibronectin    B-Glycoprotein114888310
-    O
like    O
(    O
FN    O
-    O
like    O
)    O
repeats    O
of    O
Tenascin    B-Glycoprotein114888310
-    O
C    O
and    O
Tenascin    B-Glycoprotein114888310
-    O
R    O
bind    O
with    O
beta    O
2    O
in    O
contrast    O
to    O
the    O
Epidermal    O
growth    O
factor    O
-    O
like    O
(    O
EGF    O
-    O
like    O
)    O
repeats    O
that    O
repel    O
beta2    O
.    O

The    O
tenascins    O
have    O
anti    O
-    O
adhesive    O
effects    O
,    O
as    O
opposed    O
to    O
fibronectin    B-Glycoprotein114888310
which    O
is    O
adhesive    O
.    O

This    O
is    O
due    O
to    O
the    O
early    O
up    O
regulation    O
of    O
cell    O
adhesion    O
proteins    O
such    O
as    O
fibronectin    B-Glycoprotein114888310
and    O
tenascin    O
in    O
the    O
fetus    O
.    O

Fibronectin    B-Glycoprotein114888310

Structurally    O
,    O
gp130    O
is    O
composed    O
of    O
five    O
fibronectin    B-Glycoprotein114888310
type    O
-    O
III    O
domains    O
and    O
one    O
immunoglobulin    O
-    O
like    O
C2-type    O
(    O
immunoglobulin    O
-    O
like    O
)    O
domain    O
in    O
its    O
extracellular    O
portion    O
.    O

The    O
dog    B-Glycoprotein114888310
leukocyte    I-Glycoprotein114888310
antigen    I-Glycoprotein114888310
(    O
DLA    O
)    O
is    O
a    O
part    O
of    O
the    O
major    O
hisocompatability    O
complex    O
(    O
MHC    O
)    O
in    O
dogs    O
,    O
encoding    O
genes    O
in    O
the    O
MHC    O
.    O

Pesticide    O
producers    O
are    O
plants    O
that    O
can    O
kill    O
insects    O
with    O
an    O
introduced    O
toxin    B-Glycoprotein114888310
while    O
herbicide    O
resisters    O
are    O
immune    O
to    O
weed    O
killer    O
which    O
allows    O
farmers    O
to    O
use    O
herbicides    O
on    O
crops    O
leaving    O
the    O
plant    O
unharmed    O
.    O

The    O
study    O
showed    O
that    O
high    O
doses    O
of    O
strains    O
of    O
Btk    O
containing    O
δ-endotoxins    B-Glycoprotein114888310
were    O
acutely    O
toxic    O
to    O
the    O
wasps    O
,    O
while    O
Btk    O
without    O
these    O
toxins    O
had    O
no    O
adverse    O
effects    O
.    O

Galectin    B-Glycoprotein114888310
(    O
AGE    O
-    O
R3    O
)    O

the    O
three    O
major    O
classes    O
of    O
mammalian    O
glycan    B-Glycoprotein114888310
-    O
binding    O
proteins    O
(    O
GBPs    O
)    O
:    O
C-type    B-Glycoprotein114888310
lectin    I-Glycoprotein114888310
,    O
galectin    B-Glycoprotein114888310
,    O
and    O
SIGLEC    O

CD8    B-Glycoprotein114888310
+    O
memory    O
T    O
cell    O
number    O
is    O
controlled    O
by    O
a    O
balance    O
between    O
IL-15    O
and    O
IL-2    O
.    O

Arsenic    O
exposure    O
in    O
small    O
children    O
distorts    O
the    O
ratio    O
of    O
T    O
helper    O
cells    O
(    O
CD4    B-Glycoprotein114888310
)    O
to    O
cytotoxic    O
T    O
cells    O
(    O
CD8    B-Glycoprotein114888310
)    O
,    O
which    O
are    O
responsible    O
for    O
immunodepression    O
.    O

CD8+    B-Glycoprotein114888310
cytotoxic    O
T    O
cells    O
:    O
virus    O
-    O
infected    O
and    O
tumor    O
cells    O
.    O

CD8+    B-Glycoprotein114888310
cytotoxic    O
T    O
cells    O
:    O
T    O
cells    O
displaying    O
co    O
-    O
receptor    O
CD8    B-Glycoprotein114888310
are    O
known    O
as    O
CD8    O
+    O
T    O
cells    O
.    O

T    O
-    O
cell    O
changes    O
(    O
increased    O
CD4    B-Glycoprotein114888310
CD8    B-Glycoprotein114888310
ratio    O
)    O

Alloreactive    O
killer    O
T    O
cells    O
,    O
also    O
called    O
cytotoxic    O
T    O
lymphocytes    O
(    O
CTLs    O
)    O
,    O
have    O
CD8    B-Glycoprotein114888310
receptors    O
that    O
dock    O
to    O
the    O
transplanted    O
tissue    O
's    O
MHC    O
class    O
I    O
molecules    O
,    O
which    O
display    O
the    O
donor    O
's    O
self    O
peptides    O
.    O

It    O
is    O
described    O
as    O
CD4    B-Glycoprotein114888310
CD8    B-Glycoprotein114888310
+    O
,    O
with    O
CD30    O
and    O
CD56    O
usually    O
negative    O
.    O

Another    O
criticism    O
of    O
the    O
McDonald    O
criteria    O
is    O
that    O
the    O
definition    O
of    O
"    O
lesions    O
typical    O
of    O
MS    O
"    O
is    O
unclear    O
;    O
a    O
2013    O
review    O
identified    O
the    O
following    O
characteristics    O
:    O
specific    O
cell    O
morphology    O
shown    O
by    O
hematoxylin    O
,    O
demyelination    O
shown    O
by    O
Luxol    O
fast    O
blue    O
,    O
macrophage    O
appearance    O
by    O
KiM1P    O
or    O
CD68    O
,    O
damage    O
to    O
the    O
axons    O
shown    O
by    O
Bielschowsky    O
stain    O
,    O
astrocytopathy    O
shown    O
by    O
glial    O
fibrillary    O
acidic    O
protein    O
,    O
and    O
different    O
lymphocyte    O
subtypes    O
,    O
reacting    O
to    O
CD3    O
,    O
CD4    B-Glycoprotein114888310
,    O
CD8    B-Glycoprotein114888310
,    O
CD20    O
and    O
CD138    O
.    O

CD8    O
+    O
(    O
CD8    B-Glycoprotein114888310
positive    O
)    O
cell    O
commonly    O
refers    O
to    O
a    O
T    O
cell    O
that    O
expresses    O
CD8    B-Glycoprotein114888310
on    O
its    O
cells    O
surface    O
.    O

Cytotoxic    O
T    O
cells    O
(    O
also    O
known    O
as    O
Tc    O
,    O
killer    O
T    O
cell    O
,    O
or    O
cytotoxic    O
T    O
-    O
lymphocyte    O
(    O
CTL    O
)    O
)    O
express    O
CD8    B-Glycoprotein114888310
coreceptor    O
are    O
a    O
population    O
of    O
T    O
cells    O
that    O
are    O
specialised    O
for    O
inducing    O
programmed    O
cell    O
death    O
of    O
other    O
cells    O
.    O

CD137    O
can    O
be    O
expressed    O
by    O
activated    O
T    O
cells    O
,    O
but    O
to    O
a    O
larger    O
extent    O
on    O
CD8    B-Glycoprotein114888310
than    O
on    O
CD4    B-Glycoprotein114888310
T    O
cells    O
.    O

:    O
:*    O
FcγRIIB    B-Glycoprotein114888310
(    O
CD32B    O
)    O

MASCSG    O
can    O
be    O
distinguished    O
from    O
these    O
and    O
other    O
histologically    O
similar    O
tumors    O
by    O
either    O
tissue    O
identification    O
of    O
a    O
)    O
the    O
"    O
ETV6-NTRK3    O
"    O
fusion    O
gene    O
using    O
Fluorescence    O
in    O
situ    O
hybridization    O
or    O
reverse    O
transcription    O
polymerase    O
chain    O
reaction    O
gene    O
detection    O
methods    O
or    O
b    O
)    O
a    O
specific    O
pattern    O
of    O
marker    O
proteins    O
as    O
registered    O
using    O
specific    O
antibody    O
-    O
based    O
detection    O
methods    O
,    O
i.e.    O
MASCSG    O
tissue    O
should    O
have    O
detectable    O
S100    O
(    O
a    O
family    O
of    O
calcium    O
binding    O
proteins    O
)    O
,    O
Mammaglobin    B-Glycoprotein114888310
(    O
a    O
breast    O
cancer    O
marker    O
]    O
]    O
,    O
Keratin    O
7    O
(    O
an    O
intermediate    O
filament    O
found    O
in    O
epithelial    O
cells    O
)    O
,    O
GATA3    O
(    O
a    O
transcription    O
factor    O
and    O
breast    O
cancer    O
biomarker    O
)    O
,    O
SOX10    O
(    O
a    O
transcription    O
factor    O
important    O
in    O
neural    O
crest    O
origin    O
cells    O
and    O
development    O
of    O
the    O
peripheral    O
nervous    O
system    O
)    O
,    O
and    O
STAT5A    O
(    O
a    O
transcription    O
factor    O
)    O
but    O
lack    O
antibody    O
-    O
detectable    O
TP63    O
(    O
a    O
transcription    O
factor    O
in    O
the    O
same    O
family    O
as    O
p53    O
)    O
and    O
Anoctamin-1    O
(    O
a    O
voltage    O
sensitive    O
calcium    O
activated    O
chloride    O
channel    O
)    O
.    O

Addition    O
of    O
an    O
additional    O
galactose    O
monosaccharide    O
creates    O
a    O
disaccharide    O
antigen    O
:    O
the    O
Thomsen-Friedenreich    B-Glycoprotein114888310
antigen    I-Glycoprotein114888310
(    O
Gal(b1    O
-    O
3)GalNAc    O
)    O
.    O

The    O
virion    O
adheres    O
to    O
cell    O
surface    O
receptors    O
of    O
MHC    B-Glycoprotein114888310
class    I-Glycoprotein114888310
I    I-Glycoprotein114888310
by    O
the    O
virion    O
glycoprotein    O
VP1    O
.    O

Another    O
FcR    O
is    O
expressed    O
on    O
multiple    O
cell    O
types    O
and    O
is    O
similar    O
in    O
structure    O
to    O
MHC    B-Glycoprotein114888310
class    I-Glycoprotein114888310
I    I-Glycoprotein114888310
This    O
receptor    O
also    O
binds    O
IgG    O
and    O
is    O
involved    O
in    O
preservation    O
of    O
this    O
antibody    O
.    O

KIR    O
,    O
short    O
for    O
Killer    O
-    O
cell    O
Immunoglobulin    O
-    O
like    O
Receptor    O
,    O
is    O
a    O
receptor    O
for    O
MHC    B-Glycoprotein114888310
Class    I-Glycoprotein114888310
I    I-Glycoprotein114888310
molecules    O
on    O
Natural    O
Killer    O
cells    O
.    O

Another    O
function    O
of    O
interferons    O
is    O
to    O
upregulate    O
major    O
histocompatibility    O
complex    O
molecules    O
,    O
MHC    B-Glycoprotein114888310
I    I-Glycoprotein114888310
and    O
MHC    B-Glycoprotein114888310
II    I-Glycoprotein114888310
,    O
and    O
increase    O
immunoproteasome    O
activity    O
.    O

The    O
goal    O
of    O
these    O
proteins    O
is    O
threefold    O
:    O
to    O
alter    O
the    O
expression    O
of    O
host    O
proteins    O
that    O
are    O
necessary    O
for    O
DNA    O
synthesis    O
;    O
to    O
activate    O
other    O
virus    O
genes    O
(    O
such    O
as    O
the    O
virus    O
-    O
encoded    O
DNA    O
polymerase    O
)    O
;    O
and    O
to    O
avoid    O
premature    O
death    O
of    O
the    O
infected    O
cell    O
by    O
the    O
host    O
-    O
immune    O
defenses    O
(    O
blockage    O
of    O
apoptosis    O
,    O
blockage    O
of    O
interferon    O
activity    O
,    O
and    O
blockage    O
of    O
MHC    B-Glycoprotein114888310
class    I-Glycoprotein114888310
I    I-Glycoprotein114888310
translocation    O
and    O
expression    O
)    O
.    O

These    O
cells    O
bind    O
antigens    O
presented    O
on    O
MHC    B-Glycoprotein114888310
I    I-Glycoprotein114888310
complex    O
of    O
virus    O
-    O
infected    O
or    O
tumour    O
cells    O
and    O
kill    O
them    O
.    O

Natural    O
killer    O
cells    O
are    O
able    O
to    O
kill    O
cells    O
of    O
the    O
body    O
that    O
do    O
not    O
display    O
MHC    B-Glycoprotein114888310
class    I-Glycoprotein114888310
I    I-Glycoprotein114888310
molecules    O
,    O
or    O
display    O
stress    O
markers    O
such    O
as    O
MHC    O
class    O
I    O
polypeptide    O
-    O
related    O
sequence    O
A    O
(    O
MIC    O
-    O
A    O
)    O
.    O

However    O
,    O
γδ    O
T    O
cells    O
are    O
peculiar    O
in    O
that    O
they    O
do    O
not    O
seem    O
to    O
require    O
antigen    O
processing    O
and    O
major-histocompatibility-complex    B-Glycoprotein114888310
(    O
MHC    O
)    O
presentation    O
of    O
peptide    O
epitopes    O
,    O
although    O
some    O
recognize    O
MHC    B-Glycoprotein114888310
class    I-Glycoprotein114888310
Ib    I-Glycoprotein114888310
molecules    I-Glycoprotein114888310
.    O

PSME1    O
is    O
a    O
subunit    O
of    O
the    O
11S    O
regulator    O
which    O
is    O
a    O
part    O
of    O
the    O
immunoproteasome    O
responsible    O
for    O
cleaving    O
MHC    B-Glycoprotein114888310
class    I-Glycoprotein114888310
I    I-Glycoprotein114888310
peptides    O
.    O

CD1    O
(    O
cluster    O
of    O
differentiation    O
1    O
)    O
is    O
a    O
family    O
of    O
glycoproteins    O
expressed    O
on    O
the    O
surface    O
of    O
various    O
human    O
antigen    O
-    O
presenting    O
cells    O
.    O
They    O
are    O
related    O
to    O
the    O
class    B-Glycoprotein114888310
I    I-Glycoprotein114888310
MHC    I-Glycoprotein114888310
molecules    O
,    O
and    O
are    O
involved    O
in    O
the    O
presentation    O
of    O
lipid    O
antigens    O
to    O
T    O
cells    O
.    O

CD94/NKG2    O
recognize    O
nonclassical    O
MHC    B-Glycoprotein114888310
glycoproteins    I-Glycoprotein114888310
class    I-Glycoprotein114888310
I    I-Glycoprotein114888310
(    O
HLA    O
-    O
E    O
in    O
human    O
and    O
Qa-1    O
molecules    O
in    O
the    O
mouse    O
)    O
.    O

The    O
fragments    O
are    O
then    O
presented    O
on    O
the    O
cell    O
surface    O
in    O
the    O
complex    O
with    O
MHC    B-Glycoprotein114888310
class    I-Glycoprotein114888310
I    I-Glycoprotein114888310
molecules    O
.    O

"    O
Tumor    O
antigens    O
"    O
are    O
those    O
antigens    O
that    O
are    O
presented    O
by    O
MHC    B-Glycoprotein114888310
class    I-Glycoprotein114888310
I    I-Glycoprotein114888310
or    O
MHC    B-Glycoprotein114888310
class    I-Glycoprotein114888310
II    I-Glycoprotein114888310
molecules    O
on    O
the    O
surface    O
of    O
tumor    O
cells    O
.    O

There    O
are    O
two    O
types    O
of    O
MHC    O
molecules    O
which    O
differ    O
in    O
the    O
source    O
of    O
the    O
antigens    O
:    O
MHC    B-Glycoprotein114888310
class    I-Glycoprotein114888310
I    I-Glycoprotein114888310
molecules    O
(    O
MHC    O
-    O
I    O
)    O
bind    O
peptides    O
from    O
the    O
cell    O
cytosol    O
,    O
while    O
peptides    O
generated    O
in    O
the    O
endocytic    O
vesicles    O
after    O
internalisation    O
are    O
bound    O
to    O
MHC    B-Glycoprotein114888310
class    I-Glycoprotein114888310
II    I-Glycoprotein114888310
(    O
MHC    O
-    O
II    O
)    O
.    O

This    O
gene    O
encodes    O
a    O
transmembrane    O
glycoprotein    O
that    O
mediates    O
interaction    O
between    O
newly    O
assembled    O
major    O
histocompatibility    O
complex    O
(    O
MHC    B-Glycoprotein114888310
)    O
class    B-Glycoprotein114888310
I    I-Glycoprotein114888310
molecules    O
and    O
the    O
transporter    O
associated    O
with    O
antigen    O
processing    O
(    O
TAP    O
)    O
,    O
which    O
is    O
required    O
for    O
the    O
transport    O
of    O
antigenic    O
peptides    O
across    O
the    O
endoplasmic    O
reticulum    O
membrane    O
.    O

Tapasin    O
is    O
a    O
MHC    B-Glycoprotein114888310
class    I-Glycoprotein114888310
I    I-Glycoprotein114888310
antigen    O
-    O
processing    O
molecule    O
present    O
in    O
the    O
lumen    O
of    O
the    O
endoplasmic    O
reticulum    O
.    O

CRT    B-Glycoprotein114888310
,    O
and    O

Perforin    O
has    O
been    O
shown    O
to    O
interact    O
with    O
calreticulin    B-Glycoprotein114888310
.    O

N    O
-    O
linked    O
glycosylation    O
occurs    O
as    O
soon    O
as    O
the    O
protein    O
sequence    O
passes    O
into    O
the    O
ER    O
through    O
the    O
translocon    O
,    O
where    O
it    O
is    O
glycosylated    O
with    O
a    O
sugar    O
molecule    O
that    O
forms    O
the    O
key    O
ligand    O
for    O
the    O
lectin    O
molecules    O
calreticulin    B-Glycoprotein114888310
(    O
CRT    O
;    O
soluble    O
in    O
ER    O
lumen    O
)    O
and    O
calnexin    B-Glycoprotein114888310
(    O
CNX    O
;    O
membrane    O
bound)1    O
.    O

There    O
are    O
several    O
ER    O
chaperones    O
involved    O
in    O
MHC    O
-    O
I    O
assembly    O
,    O
such    O
as    O
calnexin    B-Glycoprotein114888310
,    O
clareticulin    B-Glycoprotein114888310
and    O
tapasin    O
.    O

The    O
peptide    O
-    O
loading    O
complex    O
consists    O
of    O
TAP    O
,    O
tapasin    O
,    O
MHC    O
class    O
I    O
,    O
calreticulin    B-Glycoprotein114888310
,    O
and    O
ERp57    O
.    O

Reduced    O
sex    B-Glycoprotein114888310
hormone-binding    I-Glycoprotein114888310
globulin    I-Glycoprotein114888310
(    O
SHBG    O
)    O

Prolonged    O
severe    O
CR    O
lowers    O
total    O
serum    O
and    O
free    O
testosterone    O
while    O
increasing    O
sex    B-Glycoprotein114888310
hormone    I-Glycoprotein114888310
binding    I-Glycoprotein114888310
globulin    I-Glycoprotein114888310
concentrations    O
in    O
humans    O
;    O
these    O
effects    O
are    O
independent    O
of    O
adiposity    O
.    O

Sex    B-Glycoprotein114888310
hormone-binding    I-Glycoprotein114888310
globulin    I-Glycoprotein114888310
levels    O
were    O
mildly    O
elevated    O
(    O
6.0–10.0    O
nmol    O
/    O
L    O
)    O
,    O
while    O
thyroxine    O
-    O
binding    O
globulin    O
,    O
corticosteroid-binding    B-Glycoprotein114888310
globulin    I-Glycoprotein114888310
,    O
and    O
prolactin    O
levels    O
were    O
all    O
normal    O
.    O

Sex    B-Glycoprotein114888310
hormone-binding    I-Glycoprotein114888310
globulin    I-Glycoprotein114888310
,    O
corticosteroid-binding    B-Glycoprotein114888310
globulin    I-Glycoprotein114888310
,    O
thyroxine    O
-    O
binding    O
globulin    O
,    O
prolactin    O
,    O
and    O
triglycerides    O
,    O
which    O
are    O
known    O
to    O
be    O
elevated    O
by    O
estrogen    O
,    O
were    O
all    O
within    O
normal    O
ranges    O
in    O
spite    O
of    O
the    O
extremely    O
high    O
levels    O
of    O
estrogen    O
,    O
and    O
inhibin    O
B    O
levels    O
were    O
also    O
normal    O
.    O

Levels    O
of    O
sex    B-Glycoprotein114888310
hormone-binding    I-Glycoprotein114888310
globulin    I-Glycoprotein114888310
(    O
SHBG    O
)    O
were    O
very    O
low    O
,    O
which    O
can    O
be    O
attributed    O
to    O
the    O
absence    O
of    O
hepatic    O
actions    O
of    O
estrogen    O
.    O

It    O
is    O
97.5    O
to    O
98%    O
protein    O
-    O
bound    O
,    O
to    O
albumin    O
,    O
and    O
does    O
not    O
bind    O
to    O
sex    B-Glycoprotein114888310
hormone-binding    I-Glycoprotein114888310
globulin    I-Glycoprotein114888310
or    O
corticosteroid-binding    B-Glycoprotein114888310
globulin    I-Glycoprotein114888310
.    O

Their    O
levels    O
of    O
Sex    B-Glycoprotein114888310
hormone-binding    I-Glycoprotein114888310
globulin    I-Glycoprotein114888310
(    O
SHBG    B-Glycoprotein114888310
)    O
increased    O
,    O
which    O
reduced    O
the    O
amount    O
of    O
free    O
testosterone    O
in    O
their    O
blood    O
.    O

SHBG    B-Glycoprotein114888310
:    O
Sex    O
hormone    O
binding    O
globulin    O
(    O
17p13.1    O
)    O

It    O
also    O
has    O
the    O
effect    O
of    O
decreasing    O
the    O
steroid    O
's    O
affinity    O
for    O
sex    B-Glycoprotein114888310
hormone-binding    I-Glycoprotein114888310
globulin    I-Glycoprotein114888310
,    O
a    O
protein    O
that    O
deactivates    O
steroid    O
molecules    O
and    O
prevents    O
them    O
from    O
further    O
reactions    O
with    O
the    O
body    O
.    O

sex    B-Glycoprotein114888310
hormone-binding    I-Glycoprotein114888310
globulin    I-Glycoprotein114888310

At    O
least    O
20    O
human    O
mucin    O
genes    O
have    O
been    O
distinguished    O
by    O
cDNA    O
cloning    O
—    O
MUC1    B-Glycoprotein114888310
,    O
MUC2    B-Glycoprotein114888310
,    O
MUC3A    B-Glycoprotein114888310
,    O
MUC3B    O
,    O
MUC4    B-Glycoprotein114888310
,    O
MUC5AC    B-Glycoprotein114888310
,    O
MUC5B    B-Glycoprotein114888310
,    O
MUC6    B-Glycoprotein114888310
,    O
MUC7    B-Glycoprotein114888310
,    O
MUC8    O
,    O
MUC12    O
,    O
MUC13    O
,    O
MUC15    O
,    O
MUC16    B-Glycoprotein114888310
,    O
MUC17    B-Glycoprotein114888310
,    O
MUC19    O
,    O
and    O
MUC20    B-Glycoprotein114888310
.    O

CLEC10A    B-Glycoprotein114888310
(    O
CD301    O
,    O
MGL    O
)    O

A    O
gastric    O
shield    O
is    O
an    O
organ    O
in    O
the    O
digestive    O
tract    O
of    O
bivalves    O
,    O
tusk    O
shells    O
,    O
and    O
some    O
gastropods    O
against    O
which    O
a    O
crystalline    B-Glycoprotein114888310
style    I-Glycoprotein114888310
typically    O
rotates    O
,    O
in    O
an    O
action    O
resembling    O
that    O
of    O
a    O
mortar    O
and    O
pestle    O
.    O

IgM    B-Glycoprotein114888310
,    O
pictured    O
,    O
is    O
an    O
example    O
of    O
a    O
macroglobulin    O
.    O

Other    O
studies    O
found    O
that    O
saliva    O
assay    O
for    O
anti    O
-    O
HAV    O
antibodies    O
(    O
IgM    B-Glycoprotein114888310
and    O
IgG    B-Glycoprotein114888310
)    O
was    O
an    O
effective    O
method    O
to    O
identify    O
HAV    O
-    O
infected    O
individuals    O
.    O
Hepatitis    O
C    O
has    O
also    O
been    O
identified    O
using    O
salivary    O
detection    O
methods    O
.    O

Ammann    O
,    O
Stiehm    O
and    O
James    O
D.    O
Cherry    O
identified    O
that    O
there    O
are    O
elevated    O
levels    O
of    O
Immunoglobulin    B-Glycoprotein114888310
M    I-Glycoprotein114888310
(    O
IgM    O
)    O
in    O
the    O
cord    O
blood    O
of    O
newborn    O
infants    O
born    O
with    O
the    O
congenital    O
rubella    O
syndrome    O
.    O

Colostrum    O
is    O
known    O
to    O
contain    O
immune    O
cells    O
(    O
as    O
lymphocytes    O
)    O
and    O
many    O
antibodies    O
such    O
as    O
IgA    B-Glycoprotein114888310
,    O
IgG    B-Glycoprotein114888310
,    O
and    O
IgM    B-Glycoprotein114888310
These    O
are    O
some    O
of    O
the    O
components    O
of    O
the    O
adaptive    O
immune    O
system    O
.    O

B    O
-    O
cell    O
anergy    O
can    O
be    O
induced    O
by    O
exposure    O
to    O
soluble    O
circulating    O
antigen    O
,    O
and    O
is    O
often    O
marked    O
by    O
a    O
downregulation    O
of    O
surface    O
IgM    B-Glycoprotein114888310
expression    O
and    O
partial    O
blockade    O
of    O
intracellular    O
signaling    O
pathways    O
.    O

Selective    O
deficiency    O
of    O
immunoglobulin    O
M    O
(    O
IgM    B-Glycoprotein114888310
)    O

Defective    O
T    O
and    O
B    O
cells    O
as    O
well    O
as    O
markedly    O
decreased    O
IgG1    B-Glycoprotein114888310
responses    O
were    O
observed    O
in    O
miR-155-deficient    O
mice    O
,    O
IgG1    O
is    O
reduced    O
whereas    O
the    O
expression    O
of    O
the    O
IgM    B-Glycoprotein114888310
immunoglobulin    O
remains    O
normal    O
in    O
these    O
mice    O
.    O

Another    O
receptor    O
can    O
also    O
bind    O
IgA    O
,    O
although    O
it    O
has    O
higher    O
affinity    O
for    O
another    O
antibody    O
called    O
IgM    B-Glycoprotein114888310
This    O
receptor    O
is    O
called    O
the    O
"    O
Fc    O
-    O
alpha    O
/    O
mu    O
receptor    O
"    O
(    O
Fcα/μR    O
)    O
and    O
is    O
a    O
type    O
I    O
transmembrane    O
protein    O
.    O

IgM    B-Glycoprotein114888310
antibodies    I-Glycoprotein114888310
are    O
detectable    O
two    O
days    O
after    O
symptom    O
onset    O
and    O
IgG    B-Glycoprotein114888310
antibodies    I-Glycoprotein114888310
can    O
be    O
detected    O
6    O
to    O
18    O
days    O
after    O
symptom    O
onset    O
.    O

This    O
is    O
also    O
called    O
antibody    O
-    O
dependent    O
(    O
or    O
cytotoxic    O
)    O
hypersensitivity    O
,    O
and    O
is    O
mediated    O
by    O
IgG    B-Glycoprotein114888310
and    O
IgM    B-Glycoprotein114888310
antibodies    O
.    O

Myocardial    O
inflammation    O
can    O
be    O
suspected    O
on    O
the    O
basis    O
of    O
electrocardiographic    O
(    O
ECG    O
)    O
results    O
,    O
elevated    O
C    O
-    O
reactive    O
protein    O
(    O
CRP    O
)    O
and/or    O
erythrocyte    O
sedimentation    O
rate    O
(    O
ESR    O
)    O
,    O
and    O
increased    O
IgM    B-Glycoprotein114888310
(    O
serology    O
)    O
against    O
viruses    O
known    O
to    O
affect    O
the    O
myocardium    O
.    O

|    O
IgM    B-Glycoprotein114888310

Ovine    O
uterine    O
serpin    O
also    O
binds    O
to    O
activin    O
,    O
IgM    B-Glycoprotein114888310
and    O
IgA    B-Glycoprotein114888310

These    O
include    O
deficiency    O
in    O
CD27    O
+    O
B    O
memory    O
cells    O
,    O
overrepresentation    O
of    O
CD10    O
+    O
transitional    O
B    O
cells    O
,    O
expanded    O
effector    O
(    O
CCR7-    O
)    O
T    O
cells    O
,    O
expanded    O
CD57    O
+    O
senescent    O
CD8    O
+    O
T    O
cells    O
,    O
and    O
alterations    O
in    O
serum    O
immunoglobulin    O
concentrations    O
,    O
most    O
with    O
normal    O
to    O
elevated    O
concentrations    O
of    O
IgM    B-Glycoprotein114888310
and    O
reduced    O
concentrations    O
of    O
IgA    B-Glycoprotein114888310

An    O
IgM    B-Glycoprotein114888310
-    O
positive    O
result    O
in    O
a    O
dengue    O
or    O
Zika    O
ELISA    O
test    O
can    O
only    O
be    O
considered    O
indicative    O
of    O
a    O
recent    O
flavivirus    O
infection    O
.    O

The    O
secreted    O
mammalian    O
IgM    B-Glycoprotein114888310
has    O
five    O
Ig    O
units    O
.    O

If    O
a    O
mother    O
is    O
exposed    O
to    O
a    O
foreign    O
antigen    O
and    O
produces    O
IgG    O
(    O
as    O
opposed    O
to    O
IgM    B-Glycoprotein114888310
which    O
does    O
not    O
cross    O
the    O
placenta    O
)    O
,    O
the    O
IgG    O
will    O
target    O
the    O
antigen    O
,    O
if    O
present    O
in    O
the    O
fetus    O
,    O
and    O
may    O
affect    O
it    O
"    O
in    O
utero    O
"    O
and    O
persist    O
after    O
delivery    O
.    O

The    O
classical    O
complement    O
pathway    O
is    O
initiated    O
by    O
antigen    O
-    O
antibody    O
complexes    O
with    O
the    O
antibody    O
isotypes    O
IgG    B-Glycoprotein114888310
and    O
IgM    B-Glycoprotein114888310

The    O
IFA    O
will    O
detect    O
an    O
increase    O
in    O
IgG    B-Glycoprotein114888310
or    O
IgM    B-Glycoprotein114888310
antibodies    O
in    O
the    O
bloodstream    O
.    O

Anti    O
-    O
M    O
and    O
anti    O
-    O
N    O
antibodies    O
are    O
usually    O
IgM    B-Glycoprotein114888310
and    O
are    O
rarely    O
associated    O
with    O
transfusion    O
reactions    O
.    O

For    O
example    O
the    O
total    O
levels    O
of    O
antibodies    O
isotypes    O
or    O
classes    O
:    O
Immunoglobulin    B-Glycoprotein114888310
M    I-Glycoprotein114888310
,    O
Immunoglobulin    B-Glycoprotein114888310
G    I-Glycoprotein114888310
,    O
and    O
Immunoglobulin    B-Glycoprotein114888310
A    I-Glycoprotein114888310
It    O
is    O
important    O
in    O
quantification    O
of    O
free    O
light    O
chains    O
in    O
diseases    O
such    O
as    O
multiple    O
myeloma    O
.    O

In    O
the    O
classical    O
pathway    O
,    O
the    O
microbial    O
pathogen    O
is    O
coated    O
in    O
antibodies    O
(    O
IgG    B-Glycoprotein114888310
and    O
IgM    B-Glycoprotein114888310
)    O
released    O
by    O
B    O
cells    O
.    O

Patients    O
may    O
have    O
low    O
serum    O
IgM    B-Glycoprotein114888310
and    O
mildly    O
anergic    O
T    O
cells    O
.    O

The    O
prothrombinase    O
complex    O
consists    O
of    O
the    O
serine    O
protein    O
,    O
Factor    O
Xa    O
,    O
and    O
the    O
protein    O
cofactor    O
,    O
Factor    B-Glycoprotein114888310
V    I-Glycoprotein114888310

Phosphatidylethanolamine    O
is    O
also    O
thought    O
to    O
play    O
a    O
role    O
in    O
blood    O
clotting    O
,    O
as    O
it    O
works    O
with    O
phosphatidylserine    O
to    O
increase    O
the    O
rate    O
of    O
thrombin    O
formation    O
by    O
promoting    O
binding    O
to    O
Factor    B-Glycoprotein114888310
V    I-Glycoprotein114888310
and    O
Factor    O
X    O
,    O
two    O
proteins    O
which    O
catalyze    O
the    O
formation    O
of    O
thrombin    O
from    O
prothrombin    O
.    O

Blood    O
coagulation    O
factors    O
V    B-Glycoprotein114888310
and    O
VIII    B-Glycoprotein114888310
contain    O
a    O
C    O
-    O
terminal    O
,    O
twice    O
repeated    O
,    O
domain    O
of    O
about    O
150    O
amino    O
acids    O
,    O
which    O
is    O
often    O
called    O
"    O
C2-like    O
domain    O
"    O
(    O
that    O
is    O
unrelated    O
to    O
C2    O
domain    O
)    O
.    O

F5    B-Glycoprotein114888310
;    O
F8    O
;    O
F8B    O
;    O
MFGE8    O
;    O
NRP1    O
;    O
NRP2    O
;    O
RS1    O
;    O
SSPO    O
;    O
UNC13A    O

Factor    B-Glycoprotein114888310
V    I-Glycoprotein114888310
,    O
a    O
protein    O
of    O
the    O
coagulation    O
system    O

Platelet    O
activation    O
in    O
turn    O
degranulates    O
and    O
releases    O
factor    B-Glycoprotein114888310
V    I-Glycoprotein114888310
and    O
fibrinogen    O
,    O
potentiating    O
the    O
coagulation    O
cascade    O
.    O

α    O
granules    O
(    O
alpha    O
granules    O
)    O
–    O
containing    O
P    O
-    O
selectin    O
,    O
platelet    O
factor    O
4    O
,    O
transforming    O
growth    O
factor-β1    O
,    O
platelet    O
-    O
derived    O
growth    O
factor    O
,    O
fibronectin    B-Glycoprotein114888310
,    O
B    O
-    O
thromboglobulin    O
,    O
vWF    B-Glycoprotein114888310
,    O
fibrinogen    O
,    O
and    O
coagulation    O
factors    O
V    B-Glycoprotein114888310
and    O
XIII    O
.    O

This    O
gene    O
is    O
a    O
member    O
of    O
ADAMTS    O
(    O
a    O
disintegrin    O
and    O
metalloproteinase    O
with    O
thrombospondin    B-Glycoprotein114888310
motifs)-like    O
gene    O
family    O
and    O
encodes    O
a    O
protein    O
with    O
seven    O
thrombospondin    O
type    O
1    O
repeats    O
.    O

Thrombospondin    B-Glycoprotein114888310

DBL    O
domains    O
can    O
bind    O
to    O
a    O
variety    O
of    O
cell    O
receptors    O
including    O
thrombospondin    B-Glycoprotein114888310
(    O
TSP    O
)    O
,    O
complement    O
receptor    O
1    O
(    O
CR1    O
)    O
,    O
chondroitin    O
sulfate    O
A    O
(    O
CSA    O
)    O
,    O
P    O
-    O
selectin    O
,    O
endothelial    O
protein    O
C    O
receptor    O
(    O
EPCR    O
)    O
,    O
and    O
heparan    O
sulfate    O
.    O

Aggrecanases    O
are    O
extracellular    O
proteolytic    O
enzymes    O
that    O
are    O
members    O
of    O
the    O
ADAMTS    O
(    O
A    O
Disintegrin    O
And    O
Metalloprotease    O
with    O
Thrombospondin    B-Glycoprotein114888310
Motifs    O
)    O
family    O
.    O

Both    O
proteins    O
contain    O
thrombospondin    B-Glycoprotein114888310
(    O
TS    O
)    O
motifs    O
required    O
for    O
proper    O
recognition    O
of    O
substrates    O
.    O

=    O
=    O
=    O
Thrombospondin    B-Glycoprotein114888310
superfamily===    O

These    O
bacteria    O
lack    O
peptidoglycan    B-Glycoprotein114888310
in    O
their    O
cell    O
wall    O
and    O
have    O
a    O
compartmentalized    O
cytoplasm    O
.    O

As    O
with    O
all    O
other    O
organisms    O
within    O
the    O
order    O
Planctomycetes    O
,    O
the    O
cell    O
wall    O
does    O
not    O
contain    O
peptidoglycan    B-Glycoprotein114888310
.    O

The    O
muralytic    O
(    O
peptidoglycan    B-Glycoprotein114888310
-    O
digesting    O
)    O
enzyme    O
,    O
P5    O
,    O
then    O
digests    O
a    O
portion    O
of    O
the    O
cell    O
wall    O
,    O
and    O
the    O
nucleocapsid    O
enters    O
the    O
cell    O
coated    O
with    O
the    O
bacterial    O
outer    O
membrane    O
.    O

OBPgp279    O
is    O
an    O
endolysin    O
that    O
hydrolyzes    O
peptidoglycan    B-Glycoprotein114888310
,    O
a    O
major    O
constituent    O
in    O
bacterial    O
membrane    O
.    O

It    O
is    O
bactericidal    O
and    O
acts    O
by    O
inhibiting    O
synthesis    O
of    O
the    O
peptidoglycan    B-Glycoprotein114888310
layer    O
of    O
the    O
bacterial    O
cell    O
wall    O
.    O

This    O
penetration    O
mechanism    O
can    O
involve    O
electrochemical    O
membrane    O
potential    O
,    O
ATP    O
molecules    O
,    O
enzymatic    O
splitting    O
of    O
peptidoglycan    B-Glycoprotein114888310
layer    O
,    O
or    O
all    O
three    O
of    O
these    O
factor    O
can    O
be    O
vital    O
for    O
the    O
penetration    O
of    O
the    O
nucleic    O
acid    O
inside    O
the    O
bacterial    O
cell    O
.    O

This    O
layered    O
structure    O
is    O
called    O
peptidoglycan    B-Glycoprotein114888310
.    O

D    O
-    O
glutamate    O
is    O
a    O
monomer    O
of    O
the    O
peptidoglycan    B-Glycoprotein114888310
layer    O
in    O
prokaryotic    O
cell    O
walls    O
.    O

Its    O
composition    O
is    O
distinct    O
from    O
that    O
of    O
the    O
inner    O
cytoplasmic    O
cell    O
membrane    O
-    O
among    O
other    O
things    O
,    O
the    O
outer    O
leaflet    O
of    O
the    O
outer    O
membrane    O
of    O
many    O
gram    O
-    O
negative    O
bacteria    O
includes    O
a    O
complex    O
lipopolysaccharide    O
whose    O
lipid    O
portion    O
acts    O
as    O
an    O
endotoxin    O
-    O
and    O
in    O
some    O
bacteria    O
such    O
as    O
"    O
E.    O
coli    O
"    O
it    O
is    O
linked    O
to    O
the    O
cell    O
's    O
peptidoglycan    B-Glycoprotein114888310
by    O
Braun    O
's    O
lipoprotein    O
.    O

Assignment    O
of    O
a    O
strain    O
to    O
the    O
genus    O
"    O
Staphylococcus    O
"    O
requires    O
it    O
to    O
be    O
a    O
Gram    O
-    O
positive    O
coccus    O
that    O
forms    O
clusters    O
,    O
produces    O
catalase    O
,    O
has    O
an    O
appropriate    O
cell    O
wall    O
structure    O
(    O
including    O
peptidoglycan    B-Glycoprotein114888310
type    O
and    O
teichoic    O
acid    O
presence    O
)    O
and    O
G    O
+    O
C    O
content    O
of    O
DNA    O
in    O
a    O
range    O
of    O
30–40    O
mol%    O
.    O

It    O
inhibits    O
cross    O
-    O
linkage    O
between    O
the    O
linear    O
peptidoglycan    B-Glycoprotein114888310
polymer    O
chains    O
that    O
make    O
up    O
a    O
major    O
component    O
of    O
the    O
cell    O
wall    O
of    O
Gram    O
-    O
positive    O
bacteria    O
.    O

The    O
holin    O
pores    O
are    O
generally    O
stable    O
and    O
nonspecific    O
,    O
allowing    O
endolysin    O
access    O
to    O
the    O
peptidoglycan    B-Glycoprotein114888310
.    O

[    O
A    O
]    O
Gram    O
-    O
negative    O
with    O
a    O
peptidoglycan    B-Glycoprotein114888310
cell    O
wall    O
like    O
Chlorosome    O
.    O

[    O
H    O
]    O
Gram    O
-    O
positive    O
Bacteria    O
:    O
hypertrophy    O
of    O
the    O
wall    O
peptidoglycan    B-Glycoprotein114888310
,    O
sortasa    O
enzyme    O
and    O
a    O
loss    O
of    O
the    O
outer    O
membrane    O
.    O

[    O
K    O
]    O
Neomura    O
revolution    O
:    O
Replacement    O
of    O
peptidoglycan    B-Glycoprotein114888310
by    O
glycoproteins    O
and    O
lipoproteins    O
.    O

It    O
has    O
the    O
ability    O
to    O
degrade    O
peptidoglycan    B-Glycoprotein114888310
.    O

As    O
a    O
cyclic    O
analogue    O
of    O
D    O
-    O
alanine    O
,    O
cycloserine    O
acts    O
against    O
two    O
crucial    O
enzymes    O
important    O
in    O
the    O
cytosolic    O
stages    O
of    O
peptidoglycan    B-Glycoprotein114888310
synthesis    O
:    O
alanine    O
racemase    O
(    O
Alr    O
)    O
and    O
D    O
-    O
alanine    O
:    O
D    O
-    O
alanine    O
ligase    O
(    O
Ddl    O
)    O
.    O

Holins    O
form    O
pores    O
in    O
the    O
host    O
's    O
cell    O
membrane    O
,    O
allowing    O
lysins    O
to    O
reach    O
and    O
degrade    O
peptidoglycan    B-Glycoprotein114888310
,    O
a    O
component    O
of    O
bacterial    O
cell    O
walls    O
.    O

The    O
conversion    O
of    O
prophenoloxidase    O
to    O
the    O
active    O
form    O
of    O
the    O
enzyme    O
can    O
be    O
brought    O
about    O
by    O
minuscule    O
amounts    O
of    O
molecules    O
such    O
as    O
lipopolysaccharide    O
,    O
peptidoglycan    B-Glycoprotein114888310
and    O
beta-1,3-glucans    O
from    O
microorganisms    O
.    O

In    O
these    O
microorganisms    O
,    O
D    O
-    O
amino    O
acids    O
are    O
part    O
of    O
peptidoglycan    B-Glycoprotein114888310
(    O
a    O
major    O
component    O
of    O
the    O
bacterial    O
cell    O
wall    O
)    O
.    O

This    O
enzyme    O
participates    O
in    O
peptidoglycan    B-Glycoprotein114888310
biosynthesis    O
.    O

The    O
peptidoglycan    B-Glycoprotein114888310
layer    O
gives    O
the    O
cell    O
wall    O
its    O
strength    O
,    O
and    O
helps    O
maintain    O
the    O
overall    O
shape    O
of    O
the    O
cell    O
.    O

Its    O
cell    O
wall    O
peptidoglycan    B-Glycoprotein114888310
is    O
similar    O
to    O
the    O
L    O
-    O
Lys    O
-    O
Gly3    O
-    O
5    O
L    O
-    O
Ser0.6    O
-    O
1.5    O
type    O
found    O
in    O
predominantly    O
human    O
species    O
.    O

Gram    O
-    O
positive    O
bacteria    O
have    O
a    O
thick    O
peptidoglycan    B-Glycoprotein114888310
layer    O
in    O
their    O
cell    O
wall    O
,    O
which    O
retains    O
the    O
crystal    O
violet    O
during    O
Gram    O
staining    O
,    O
resulting    O
in    O
a    O
purple    O
color    O
.    O

Ceftriaxone    O
selectively    O
and    O
irreversibly    O
inhibits    O
bacterial    O
cell    O
wall    O
synthesis    O
by    O
binding    O
to    O
transpeptidases    O
,    O
also    O
called    O
transamidases    O
,    O
which    O
are    O
penicillin    O
-    O
binding    O
proteins    O
(    O
PBPs    O
)    O
that    O
catalyze    O
the    O
cross    O
-    O
linking    O
of    O
the    O
peptidoglycan    B-Glycoprotein114888310
polymers    O
forming    O
the    O
bacterial    O
cell    O
wall    O
.    O

The    O
peptidoglycan    B-Glycoprotein114888310
cross    O
-    O
linking    O
activity    O
of    O
PBPs    O
is    O
a    O
construction    O
and    O
repair    O
mechanism    O
that    O
normally    O
helps    O
to    O
maintain    O
bacterial    O
cell    O
wall    O
integrity    O
,    O
so    O
the    O
inhibition    O
of    O
PBPs    O
leads    O
to    O
damage    O
and    O
destruction    O
of    O
the    O
cell    O
wall    O
and    O
eventually    O
to    O
cell    O
lysis    O
.    O

The    O
cyst    O
walls    O
of    O
bacteria    O
are    O
formed    O
by    O
the    O
thickening    O
of    O
the    O
normal    O
cell    O
wall    O
with    O
added    O
peptidoglycan    B-Glycoprotein114888310
layers    O
whereas    O
the    O
walls    O
of    O
protozoan    O
cysts    O
are    O
made    O
of    O
chitin    O
,    O
a    O
type    O
of    O
glycopolymer    O
.    O

Beta    O
glucans    O
are    O
carbohydrate    O
polymers    O
that    O
are    O
cross    O
-    O
linked    O
with    O
other    O
fungal    O
cell    O
wall    O
components    O
(    O
The    O
bacterial    O
equivalent    O
is    O
peptidoglycan    B-Glycoprotein114888310
)    O
.    O

Ticarcillin    O
's    O
antibiotic    O
properties    O
arise    O
from    O
its    O
ability    O
to    O
prevent    O
cross    O
-    O
linking    O
of    O
peptidoglycan    B-Glycoprotein114888310
during    O
cell    O
wall    O
synthesis    O
,    O
when    O
the    O
bacteria    O
try    O
to    O
divide    O
,    O
causing    O
cell    O
death    O
.    O

Activity    O
of    O
the    O
SIX3    O
gene    O
represses    O
Wnt1    B-Glycoprotein114888310
gene    O
activity    O
which    O
ensures    O
development    O
of    O
the    O
forebrain    O
and    O
establishes    O
the    O
proper    O
anterior    O
posterior    O
identity    O
in    O
the    O
mammalian    O
brain    O
.    O

Phosvitin    B-Glycoprotein114888310
is    O
one    O
of    O
the    O
egg    O
(    O
commonly    O
hen    O
’s    O
egg    O
)    O
yolk    O
phosphoproteins    O
known    O
for    O
being    O
the    O
most    O
phosphorylated    O
protein    O
found    O
in    O
nature    O
.    O

SialoPhoriN    B-Glycoprotein114888310
,    O
a    O
protein    O

CD43    B-Glycoprotein114888310
,    O

His    O
current    O
research    O
is    O
on    O
the    O
uptake    O
of    O
oxidized    O
low    O
density    O
lipoprotein    O
(    O
LDL    O
)    O
by    O
specialized    O
receptors    O
LOX-1    O
(    O
OLR1    B-Glycoprotein114888310
)    O
.    O

N    O
-    O
linked    O
glycosylation    O
occurs    O
as    O
soon    O
as    O
the    O
protein    O
sequence    O
passes    O
into    O
the    O
ER    O
through    O
the    O
translocon    O
,    O
where    O
it    O
is    O
glycosylated    O
with    O
a    O
sugar    O
molecule    O
that    O
forms    O
the    O
key    O
ligand    O
for    O
the    O
lectin    O
molecules    O
calreticulin    B-Glycoprotein114888310
(    O
CRT    O
;    O
soluble    O
in    O
ER    O
lumen    O
)    O
and    O
calnexin    B-Glycoprotein114888310
(    O
CNX    O
;    O
membrane    O
bound)1    O
.    O

VSG    O
then    O
undergoes    O
the    O
calreticulin    O
/    O
calnexin    B-Glycoprotein114888310
folding    O
cycle    O
(    O
calnexin    O
is    O
absent    O
in    O
"    O
Trypanosoma    O
brucei    O
"    O
)    O
,    O
where    O
it    O
is    O
transiently    O
monoglucosylated    O
and    O
deglucosylated    O
,    O
and    O
interacts    O
with    O
various    O
ER    O
chaperone    O
proteins    O
,    O
such    O
as    O
BiP    O
,    O
in    O
order    O
to    O
fold    O
correctly    O
.    O

There    O
are    O
several    O
ER    O
chaperones    O
involved    O
in    O
MHC    O
-    O
I    O
assembly    O
,    O
such    O
as    O
calnexin    B-Glycoprotein114888310
,    O
clareticulin    B-Glycoprotein114888310
and    O
tapasin    O
.    O

It    O
was    O
found    O
that    O
when    O
the    O
outer    O
core    O
was    O
removed    O
,    O
strong    O
binding    O
of    O
MBL    B-Glycoprotein114888310
to    O
N.    O
meningitidis    O
was    O
detected    O
,    O
even    O
when    O
physiologically    O
low    O
levels    O
of    O
MBL    O
had    O
been    O
used    O
.    O

MBL    O
=    O
mannan-binding    B-Glycoprotein114888310
lectin    I-Glycoprotein114888310
(    O
mannose    O
-    O
binding    O
lectin    O
)    O

Within    O
the    O
innate    O
immune    O
system    O
lectins    O
such    O
as    O
the    O
MBL,    B-Glycoprotein114888310
the    I-Glycoprotein114888310
mannose-binding    I-Glycoprotein114888310
lectin    I-Glycoprotein114888310
,    O
help    O
mediate    O
the    O
first    O
-    O
line    O
defense    O
against    O
invading    O
microorganisms    O
.    O

Mannan-binding    B-Glycoprotein114888310
lectin    I-Glycoprotein114888310
(    O
or    O
mannose    O
-    O
binding    O
lectin    O
)    O
,    O
a    O
protein    O
capable    O
of    O
binding    O
certain    O
sugars    O
and    O
polysaccharides    O


